<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE MedlineCitationSet PUBLIC "-//NLM//DTD Medline Citation, 1st January, 2014//EN"
                                    "http://www.nlm.nih.gov/databases/dtd/nlmmedlinecitationset_140101.dtd">
<MedlineCitationSet>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23930790</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1933-8244</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>69</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Archives of environmental &amp; occupational health</Title>
<ISOAbbreviation>Arch Environ Occup Health</ISOAbbreviation>
</Journal>
<ArticleTitle>From reactive "level of concern" to proactive on lead.</ArticleTitle>
<Pagination>
<MedlinePgn>1-2</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/19338244.2014.811994</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Guidotti</LastName>
<ForeName>Tee L</ForeName>
<Initials>TL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Editorial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Arch Environ Occup Health</MedlineTA>
<NlmUniqueID>101282564</NlmUniqueID>
<ISSNLinking>1933-8244</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>2P299V784P</RegistryNumber>
<NameOfSubstance>Lead</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Centers for Disease Control and Prevention (U.S.)</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Environmental Exposure</DescriptorName>
<QualifierName MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Lead</DescriptorName>
<QualifierName MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Lead Poisoning</DescriptorName>
<QualifierName MajorTopicYN="N">blood</QualifierName>
<QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Terminology as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
<QualifierName MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23930791</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>11</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1933-8244</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>69</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Archives of environmental &amp; occupational health</Title>
<ISOAbbreviation>Arch Environ Occup Health</ISOAbbreviation>
</Journal>
<ArticleTitle>Agricultural workers and urinary bladder cancer risk in Egypt.</ArticleTitle>
<Pagination>
<MedlinePgn>3-10</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/19338244.2012.719556</ELocationID>
<Abstract>
<AbstractText>The authors examined the associations between farming and the risk for squamous cell (SCC) or urothelial cell (UC) carcinoma of the urinary bladder among Egyptians. The authors used data from a multicenter case-control study (1,525 male and 315 female cases, and 2,069 male and 547 female age- and residence-matched, population-based controls) to calculate adjusted odds ratios (AORs) and 95% confidence intervals (CIs). Men in farming and who never smoked had increased risk for either SCC or UC (AOR [95% CI]: 4.65 [2.59-8.36] and 6.22 [3.82-10.15], respectively). If they ever smoked, their risks were 2.27 (1.75-2.95) and 1.93 (1.58-2.35), respectively. Women in farmer households were at increased risk for SCC (1.40 [0.93-2.09] and UC [1.25 (0.82-1.89]), although not statistically significant. Occupational and environmental exposures to farming increased the risk for bladder cancer among Egyptians.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Amr</LastName>
<ForeName>Sania</ForeName>
<Initials>S</Initials>
<Affiliation>Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA. samr@epi.umaryland.edu</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Dawson</LastName>
<ForeName>Rebecca</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Saleh</LastName>
<ForeName>Doa'a A</ForeName>
<Initials>DA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Magder</LastName>
<ForeName>Laurence S</ForeName>
<Initials>LS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mikhail</LastName>
<ForeName>Nabiel N</ForeName>
<Initials>NN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>St George</LastName>
<ForeName>Diane Marie</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Squibb</LastName>
<ForeName>Katherine</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Khaled</LastName>
<ForeName>Hussein</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Loffredo</LastName>
<ForeName>Christopher A</ForeName>
<Initials>CA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01-CA115618</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Multicenter Study</PublicationType>
<PublicationType>Research Support, N.I.H., Extramural</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Arch Environ Occup Health</MedlineTA>
<NlmUniqueID>101282564</NlmUniqueID>
<ISSNLinking>1933-8244</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Agricultural Workers' Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Carcinoma</DescriptorName>
<QualifierName MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chi-Square Distribution</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Egypt</DescriptorName>
<QualifierName MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Logistic Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neoplasms, Squamous Cell</DescriptorName>
<QualifierName MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Occupational Exposure</DescriptorName>
<QualifierName MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Odds Ratio</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Smoking</DescriptorName>
<QualifierName MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Urinary Bladder Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS509676 [Available on 01/01/15]</OtherID>
<OtherID Source="NLM">PMC3819117 [Available on 01/01/15]</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23930792</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1933-8244</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>69</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Archives of environmental &amp; occupational health</Title>
<ISOAbbreviation>Arch Environ Occup Health</ISOAbbreviation>
</Journal>
<ArticleTitle>Survey on radiation safety management (RSM) among Korean radiation workers who operate radiation generators or handle radioactive isotopes.</ArticleTitle>
<Pagination>
<MedlinePgn>11-22</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/19338244.2012.701250</ELocationID>
<Abstract>
<AbstractText>This study examined the knowledge, attitudes, and behaviors of radiation workers to radiation safety management (RSM) using survey questionnaires. Radiation workers are those who handle radiation generators, radioactive isotopes, and other radioactive materials for industrial uses. The survey was distributed to 861 radiation workers between 1 August to 5 September 2011. A knowledge of, awareness of, attitude toward, and behaviors related to RSM were analyzed by comparing the means and standard deviations. Both the knowledge and awareness of RSM among radiation workers were high. Although all questions about the awareness of RSM were answered correctly, there were also many negative responses. All questions regarding the attitude of radiation workers toward RSM were answered correctly, and their attitude toward and awareness of RSM were high. Overall, the results demonstrated that safety management is not taken seriously in many cases, highlighting the need for proper education in the future to raise awareness among radiation workers. Furthermore, it is important to establish a foundation for the efficient use of radiation based on the continuous management of radiation workers.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ryu</LastName>
<ForeName>Young-Hwan</ForeName>
<Initials>YH</Initials>
<Affiliation>Department of Radiology, Seoul Medical Center, Seoul, Republic of Korea.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Cho</LastName>
<ForeName>Jae-Hwan</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dong</LastName>
<ForeName>Kyung-Rae</ForeName>
<Initials>KR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chung</LastName>
<ForeName>Woon-Kwan</ForeName>
<Initials>WK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Jong-Woong</ForeName>
<Initials>JW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Choi</LastName>
<ForeName>Eun-Jin</ForeName>
<Initials>EJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Arch Environ Occup Health</MedlineTA>
<NlmUniqueID>101282564</NlmUniqueID>
<ISSNLinking>1933-8244</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Radioisotopes</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Data Collection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Educational Status</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Health Knowledge, Attitudes, Practice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Occupational Exposure</DescriptorName>
<QualifierName MajorTopicYN="Y">prevention &amp; control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radiation Protection</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radioisotopes</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Radionuclide Generators</DescriptorName>
<QualifierName MajorTopicYN="N">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Safety Management</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23930793</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1933-8244</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>69</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Archives of environmental &amp; occupational health</Title>
<ISOAbbreviation>Arch Environ Occup Health</ISOAbbreviation>
</Journal>
<ArticleTitle>Employment type, workplace interpersonal conflict, and insomnia: a cross-sectional study of 37,646 employees in Japan.</ArticleTitle>
<Pagination>
<MedlinePgn>23-32</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/19338244.2012.713040</ELocationID>
<Abstract>
<AbstractText>This study explored whether workplace interpersonal conflict (WIC) is associated with insomnia, and whether the relationship between WIC and insomnia differs across different employment groups. A total of 37,646 Japanese full-time employees participated in a cross-sectional survey. Employment types included permanent employment and 2 forms of temporary employment: direct-hire and temporary work agent (TWA). Insomnia symptoms, including difficulty initiating sleep, difficulty maintaining sleep, and early morning awakening were measured. Insomnia was defined as having experienced 1 or more of these symptoms on ≥3 nights per week over the past 12 months. Results showed that WIC was significantly associated with an increased risk of insomnia (odds ratio OR = 1.63; 95% confidence interval CI = 1.55-1.71), controlling for confounders. However, the relationship between WIC and the risk of insomnia was significantly stronger for TWAs than for permanent employees (OR = 1.97; 95% CI = 1.13-3.45). A frequent exposure to WIC may increase the risk of insomnia, particularly for TWAs.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sakurai</LastName>
<ForeName>Kenji</ForeName>
<Initials>K</Initials>
<Affiliation>School of Economics, Nihon University, Tokyo, Japan.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Nakata</LastName>
<ForeName>Aknori</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ikeda</LastName>
<ForeName>Tomoko</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Otsuka</LastName>
<ForeName>Yasumasa</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kawahito</LastName>
<ForeName>Junko</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Arch Environ Occup Health</MedlineTA>
<NlmUniqueID>101282564</NlmUniqueID>
<ISSNLinking>1933-8244</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Conflict (Psychology)</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Employment</DescriptorName>
<QualifierName MajorTopicYN="Y">psychology</QualifierName>
<QualifierName MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Interpersonal Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Japan</DescriptorName>
<QualifierName MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Logistic Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sleep Initiation and Maintenance Disorders</DescriptorName>
<QualifierName MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Workplace</DescriptorName>
<QualifierName MajorTopicYN="Y">psychology</QualifierName>
<QualifierName MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23930794</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1933-8244</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>69</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Archives of environmental &amp; occupational health</Title>
<ISOAbbreviation>Arch Environ Occup Health</ISOAbbreviation>
</Journal>
<ArticleTitle>Physical therapists versus nurses in a rehabilitation hospital: comparing prevalence of work-related musculoskeletal complaints and working conditions.</ArticleTitle>
<Pagination>
<MedlinePgn>33-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/19338244.2012.719555</ELocationID>
<Abstract>
<AbstractText>The objective of this study was to investigate the prevalence and work avoidance of work-related musculoskeletal complaints and to compare patient handling tasks and psychosocial factors of physical therapists (PTs) and nurses in a rehabilitation hospital. Cross-sectional observational study was carried out using questionnaires relating to basic demographics, prevalence of musculoskeletal morbidity, workload, and job satisfaction. Comparing 26 PTs and 54 nurses, all females, lower back pain was significantly more prevalent in PTs, even after adjusting for the confounding demographic factors; PTs performed full and partial manual patient transfer, as well as trunk bending and walking assistance more frequently than the nurses and were significantly more satisfied. Unique physical load could be the main factor for the high prevalence of lower back pain in PTs. They should urgently initiate a "no-lift policy" in treatment.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Alperovitch-Najenson</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<Affiliation>Department of Environmental and Occupational Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. deboraha@post.tau.ac.il</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Treger</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kalichman</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Comparative Study</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Arch Environ Occup Health</MedlineTA>
<NlmUniqueID>101282564</NlmUniqueID>
<ISSNLinking>1933-8244</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hospitals, Special</DescriptorName>
<QualifierName MajorTopicYN="N">manpower</QualifierName>
<QualifierName MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Job Satisfaction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Musculoskeletal Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Occupational Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Physical Therapists</DescriptorName>
<QualifierName MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prevalence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Psychology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rehabilitation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rehabilitation Nursing</DescriptorName>
<QualifierName MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Weight-Bearing</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Workload</DescriptorName>
<QualifierName MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Workplace</DescriptorName>
<QualifierName MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23930795</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1933-8244</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>69</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Archives of environmental &amp; occupational health</Title>
<ISOAbbreviation>Arch Environ Occup Health</ISOAbbreviation>
</Journal>
<ArticleTitle>The role of chemical interactions between thorium, cerium, and lanthanum in lymphocyte toxicity.</ArticleTitle>
<Pagination>
<MedlinePgn>40-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/19338244.2012.719557</ELocationID>
<Abstract>
<AbstractText>Thorium, cerium, and lanthanum are metals present in several types of minerals, the most common of which is monazite. Cerium and lanthanum are elements in the lanthanides series. Thorium, an actinide metal, is a hazardous element due to its radioactive characteristics. There is a lack of information describing the possible chemical interactions among these elements and the effects they may have on humans. Toxicological analyses were performed using cell viability, cell death, and DNA damage assays. Chemical interactions were evaluated based on the Loewe additivity model. The results indicate that thorium and cerium individually have no toxic effects on lymphocytes. However, thorium associated with lanthanum increases the toxicity of this element, thereby reducing the viability of lymphocytes at low concentrations of metals in the mixture.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Oliveira</LastName>
<ForeName>Monica S</ForeName>
<Initials>MS</Initials>
<Affiliation>Radioprotection and Dosimetry Institute, CNEN, Rio de Janeiro, Brazil. monica@ird.gov.br</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Duarte</LastName>
<ForeName>Isabelle M</ForeName>
<Initials>IM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Paiva</LastName>
<ForeName>Amanda V</ForeName>
<Initials>AV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yunes</LastName>
<ForeName>Samira N</ForeName>
<Initials>SN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Almeida</LastName>
<ForeName>Carlos E</ForeName>
<Initials>CE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mattos</LastName>
<ForeName>Rita C</ForeName>
<Initials>RC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sarcinelli</LastName>
<ForeName>Paula N</ForeName>
<Initials>PN</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Arch Environ Occup Health</MedlineTA>
<NlmUniqueID>101282564</NlmUniqueID>
<ISSNLinking>1933-8244</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Thorium Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>13823-29-5</RegistryNumber>
<NameOfSubstance>thorium nitrate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>30K4522N6T</RegistryNumber>
<NameOfSubstance>Cerium</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>33A856C3T7</RegistryNumber>
<NameOfSubstance>lanthanide nitrate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>60YU5MIG9W</RegistryNumber>
<NameOfSubstance>Thorium</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>6I3K30563S</RegistryNumber>
<NameOfSubstance>Lanthanum</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Apoptosis</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Survival</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cerium</DescriptorName>
<QualifierName MajorTopicYN="Y">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">DNA Damage</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Jurkat Cells</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Lanthanum</DescriptorName>
<QualifierName MajorTopicYN="Y">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Thorium</DescriptorName>
<QualifierName MajorTopicYN="Y">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Thorium Compounds</DescriptorName>
<QualifierName MajorTopicYN="N">toxicity</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23930796</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1933-8244</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>69</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Archives of environmental &amp; occupational health</Title>
<ISOAbbreviation>Arch Environ Occup Health</ISOAbbreviation>
</Journal>
<ArticleTitle>Associations between hair manganese levels and cognitive, language, and motor development in preschool children from Montevideo, Uruguay.</ArticleTitle>
<Pagination>
<MedlinePgn>46-54</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/19338244.2012.725229</ELocationID>
<Abstract>
<AbstractText>Environmental manganese (Mn) exposure in childhood has been associated with developmental deficits. This study investigated associations between low-level Mn exposure and developmental scores in children aged 14-45 months. Children's hair samples (n = 60) were analyzed for Mn and lead (Pb) using inductively coupled plasma mass spectrometry (ICP-MS). Children were assessed with the Bayley Scales of Infant Development III (BSID). Mean hair Mn and Pb concentrations were 0.98 ± 0.74 and 10.1 ± 10.5 μg/g, respectively. Unadjusted inverse associations were seen between Mn and BSID subscales, with girls having lower scores related to Mn than boys. No significant associations remained in covariate-adjusted models, although when stratified by sex boys had a positive association between hair Mn levels and language scores. This study does not show clear evidence of an association between hair Mn concentrations and children's developmental scores in a region of low-level Mn exposure.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Rink</LastName>
<ForeName>Stephanie M</ForeName>
<Initials>SM</Initials>
<Affiliation>Department of Nutritional Sciences, Pennsylvania State University, University Park, PA 16802, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Ardoino</LastName>
<ForeName>Graciela</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Queirolo</LastName>
<ForeName>Elena I</ForeName>
<Initials>EI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cicariello</LastName>
<ForeName>Daniela</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mañay</LastName>
<ForeName>Nelly</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kordas</LastName>
<ForeName>Katarzyna</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Arch Environ Occup Health</MedlineTA>
<NlmUniqueID>101282564</NlmUniqueID>
<ISSNLinking>1933-8244</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>42Z2K6ZL8P</RegistryNumber>
<NameOfSubstance>Manganese</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Child Development</DescriptorName>
<QualifierName MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cognition</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Environmental Exposure</DescriptorName>
<QualifierName MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hair</DescriptorName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Language Development</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Manganese</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
<QualifierName MajorTopicYN="N">toxicity</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neuropsychological Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Psychomotor Performance</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sex Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Uruguay</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23930797</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1933-8244</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>69</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Archives of environmental &amp; occupational health</Title>
<ISOAbbreviation>Arch Environ Occup Health</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect of shift work on the development of metabolic syndrome after 3 years in Japanese male workers.</ArticleTitle>
<Pagination>
<MedlinePgn>55-61</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/19338244.2012.732123</ELocationID>
<Abstract>
<AbstractText>A 3-year follow-up study of an occupational cohort was conducted to clarify the effect of the type of shift work on the risk of development of metabolic syndrome (MetS). The subjects were 1,677 Japanese male employees aged 36 to 57. Age, each component of MetS, serum uric acid, serum insulin, lifestyle factors, and occupational position were used for the analyses. The odds ratios (95% confidence intervals) of 2-shift work (n = 686) and 3-shift work (n = 99) against daytime work (n = 868) for the development of MetS, as defined by the National Cholesterol Education Program, were 1.43 (1.05, 1.95) and 0.72 (0.37, 1.41), respectively. When Japanese criteria were adopted for defining MetS, the corresponding odds ratios (95% confidence intervals) were 1.88 (1.29, 2.74) and 0.87 (0.39, 1.97), respectively. The results of the analyses suggested that 2-shift work was a risk factor for the development of metabolic syndrome.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kawada</LastName>
<ForeName>Tomoyuki</ForeName>
<Initials>T</Initials>
<Affiliation>Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan. kawada@nms.ac.jp</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Otsuka</LastName>
<ForeName>Toshiaki</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Arch Environ Occup Health</MedlineTA>
<NlmUniqueID>101282564</NlmUniqueID>
<ISSNLinking>1933-8244</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Insulin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>268B43MJ25</RegistryNumber>
<NameOfSubstance>Uric Acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Insulin</DescriptorName>
<QualifierName MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Japan</DescriptorName>
<QualifierName MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Life Style</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Metabolic Syndrome X</DescriptorName>
<QualifierName MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Occupational Diseases</DescriptorName>
<QualifierName MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Odds Ratio</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Uric Acid</DescriptorName>
<QualifierName MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Work Schedule Tolerance</DescriptorName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
<QualifierName MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23930799</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1933-8244</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>69</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Archives of environmental &amp; occupational health</Title>
<ISOAbbreviation>Arch Environ Occup Health</ISOAbbreviation>
</Journal>
<ArticleTitle>Toxicity and poisoning: the example of lead.</ArticleTitle>
<Pagination>
<MedlinePgn>64-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/19338244.2014.811995</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Guidotti</LastName>
<ForeName>Tee L</ForeName>
<Initials>TL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Editorial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Arch Environ Occup Health</MedlineTA>
<NlmUniqueID>101282564</NlmUniqueID>
<ISSNLinking>1933-8244</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>2P299V784P</RegistryNumber>
<NameOfSubstance>Lead</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
<QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Environmental Exposure</DescriptorName>
<QualifierName MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Lead</DescriptorName>
<QualifierName MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Lead Poisoning</DescriptorName>
<QualifierName MajorTopicYN="N">blood</QualifierName>
<QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Poisoning</DescriptorName>
<QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Public Health</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Terminology as Topic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23924634</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>Transmembrane protein 88: a Wnt regulatory protein that specifies cardiomyocyte development.</ArticleTitle>
<Pagination>
<MedlinePgn>3799-808</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.094789</ELocationID>
<Abstract>
<AbstractText>Genetic regulation of the cell fate transition from lateral plate mesoderm to the specification of cardiomyocytes requires suppression of Wnt/β-catenin signaling, but the mechanism for this is not well understood. By analyzing gene expression and chromatin dynamics during directed differentiation of human embryonic stem cells (hESCs), we identified a suppressor of Wnt/β-catenin signaling, transmembrane protein 88 (TMEM88), as a potential regulator of cardiovascular progenitor cell (CVP) specification. During the transition from mesoderm to the CVP, TMEM88 has a chromatin signature of genes that mediate cell fate decisions, and its expression is highly upregulated in advance of key cardiac transcription factors in vitro and in vivo. In early zebrafish embryos, tmem88a is expressed broadly in the lateral plate mesoderm, including the bilateral heart fields. Short hairpin RNA targeting of TMEM88 during hESC cardiac differentiation increases Wnt/β-catenin signaling, confirming its role as a suppressor of this pathway. TMEM88 knockdown has no effect on NKX2.5 or GATA4 expression, but 80% of genes most highly induced during CVP development have reduced expression, suggesting adoption of a new cell fate. In support of this, analysis of later stage cell differentiation showed that TMEM88 knockdown inhibits cardiomyocyte differentiation and promotes endothelial differentiation. Taken together, TMEM88 is crucial for heart development and acts downstream of GATA factors in the pre-cardiac mesoderm to specify lineage commitment of cardiomyocyte development through inhibition of Wnt/β-catenin signaling. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Palpant</LastName>
<ForeName>Nathan J</ForeName>
<Initials>NJ</Initials>
<Affiliation>Department of Pathology, University of Washington, Seattle, WA 98195-7470, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Pabon</LastName>
<ForeName>Lil</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rabinowitz</LastName>
<ForeName>Jeremy S</ForeName>
<Initials>JS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hadland</LastName>
<ForeName>Brandon K</ForeName>
<Initials>BK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stoick-Cooper</LastName>
<ForeName>Cristi L</ForeName>
<Initials>CL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Paige</LastName>
<ForeName>Sharon L</ForeName>
<Initials>SL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bernstein</LastName>
<ForeName>Irwin D</ForeName>
<Initials>ID</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moon</LastName>
<ForeName>Randall T</ForeName>
<Initials>RT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Murry</LastName>
<ForeName>Charles E</ForeName>
<Initials>CE</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>F30 HL095343</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01 GM081719</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P01 HL094374</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HL084642</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 HL007312</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 HL100405</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01HL100395</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<Agency>Howard Hughes Medical Institute</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, N.I.H., Extramural</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Membrane Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>TMEM88 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Tmem88a protein, zebrafish</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Wnt Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Zebrafish Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>beta Catenin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Lineage</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Down-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Embryo, Nonmammalian</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Endothelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Membrane Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myocytes, Cardiac</DescriptorName>
<QualifierName MajorTopicYN="Y">cytology</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Up-Regulation</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Wnt Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Zebrafish</DescriptorName>
<QualifierName MajorTopicYN="Y">embryology</QualifierName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Zebrafish Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">beta Catenin</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC3754478 [Available on 03/15/14]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Chromatin</Keyword>
<Keyword MajorTopicYN="N">Gene</Keyword>
<Keyword MajorTopicYN="N">Heart development</Keyword>
<Keyword MajorTopicYN="N">Human embryonic stem cell</Keyword>
<Keyword MajorTopicYN="N">Mesoderm</Keyword>
<Keyword MajorTopicYN="N">TMEM88</Keyword>
<Keyword MajorTopicYN="N">Wnt signaling</Keyword>
<Keyword MajorTopicYN="N">Zebrafish</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23924635</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>Distinct temporal requirements for Runx1 in hematopoietic progenitors and stem cells.</ArticleTitle>
<Pagination>
<MedlinePgn>3765-76</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.094961</ELocationID>
<Abstract>
<AbstractText>The transcription factor Runx1 is essential for the formation of yolk sac-derived erythroid/myeloid progenitors (EMPs) and hematopoietic stem cells (HSCs) from hemogenic endothelium during embryogenesis. However, long-term repopulating HSCs (LT-HSCs) persist when Runx1 is conditionally deleted in fetal liver cells, demonstrating that the requirement for Runx1 changes over time. To define more precisely when Runx1 transitions from an essential factor to a homeostatic regulator of EMPs and HSCs, and whether that transition requires fetal liver colonization, we performed conditional, timed deletions of Runx1 between E7.5 and E13.5. We determined that Runx1 loss reduces the formation or function of EMPs up through E10.5. The Runx1 requirement in HSCs ends later, as deletion up to E11.5 eliminates HSCs. At E11.5, there is an abrupt transition to Runx1 independence in at least a subset of HSCs that does not require fetal liver colonization. The transition to Runx1 independence in EMPs is not mediated by other core binding factors (Runx2 and/or Runx3); however, deleting the common non-DNA-binding β subunit (CBFβ) severely compromises LT-HSC function. Hence, the requirements for Runx1 in EMP and HSC formation are temporally distinct, and LT-HSC function is highly reliant on continued core binding factor activity. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tober</LastName>
<ForeName>Joanna</ForeName>
<Initials>J</Initials>
<Affiliation>Abramson Family Cancer Research Institute and Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Yzaguirre</LastName>
<ForeName>Amanda D</ForeName>
<Initials>AD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Piwarzyk</LastName>
<ForeName>Eileen</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Speck</LastName>
<ForeName>Nancy A</ForeName>
<Initials>NA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01HL091724</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32CA09140</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01HL100504</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, N.I.H., Extramural</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Core Binding Factor Alpha 2 Subunit</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Runx1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.7.-</RegistryNumber>
<NameOfSubstance>Cre recombinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.7.-</RegistryNumber>
<NameOfSubstance>Integrases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aorta</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">embryology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Differentiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chickens</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Colony-Forming Units Assay</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Core Binding Factor Alpha 2 Subunit</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Embryo, Mammalian</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Endothelium</DescriptorName>
<QualifierName MajorTopicYN="N">embryology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Epigenesis, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Erythroid Precursor Cells</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fetus</DescriptorName>
<QualifierName MajorTopicYN="N">embryology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Deletion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hematopoietic Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Integrases</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Liver</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">embryology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myeloid Progenitor Cells</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Yolk Sac</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC3754475 [Available on 09/15/14]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Embryo</Keyword>
<Keyword MajorTopicYN="N">Hematopoiesis</Keyword>
<Keyword MajorTopicYN="N">Hemogenic endothelium</Keyword>
<Keyword MajorTopicYN="N">Mouse</Keyword>
<Keyword MajorTopicYN="N">Runx1</Keyword>
<Keyword MajorTopicYN="N">Stem cells</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23924636</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>Transcriptional components of anteroposterior positional information during zebrafish fin regeneration.</ArticleTitle>
<Pagination>
<MedlinePgn>3754-64</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.098798</ELocationID>
<Abstract>
<AbstractText>Many fish and salamander species regenerate amputated fins or limbs, restoring the size and shape of the original appendage. Regeneration requires that spared cells retain or recall information encoding pattern, a phenomenon termed positional memory. Few factors have been implicated in positional memory during vertebrate appendage regeneration. Here, we investigated potential regulators of anteroposterior (AP) pattern during fin regeneration in adult zebrafish. Sequence-based profiling from tissues along the AP axis of uninjured pectoral fins identified many genes with region-specific expression, several of which encoded transcription factors with known AP-specific expression or function in developing embryonic pectoral appendages. Transgenic reporter strains revealed that regulatory sequences of the transcription factor gene alx4a activated expression in fibroblasts and osteoblasts within anterior fin rays, whereas hand2 regulatory sequences activated expression in these same cell types within posterior rays. Transgenic overexpression of hand2 in all pectoral fin rays did not affect formation of the proliferative regeneration blastema, yet modified the lengths and widths of regenerating bones. Hand2 influenced the character of regenerated rays in part by elevation of the vitamin D-inactivating enzyme encoded by cyp24a1, contributing to region-specific regulation of bone metabolism. Systemic administration of vitamin D during regeneration partially rescued bone defects resulting from hand2 overexpression. Thus, bone-forming cells in a regenerating appendage maintain expression throughout life of transcription factor genes that can influence AP pattern, and differ across the AP axis in their expression signatures of these and other genes. These findings have implications for mechanisms of positional memory in vertebrate tissues. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Nachtrab</LastName>
<ForeName>Gregory</ForeName>
<Initials>G</Initials>
<Affiliation>Department of Cell Biology and Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC 27710, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Kikuchi</LastName>
<ForeName>Kazu</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tornini</LastName>
<ForeName>Valerie A</ForeName>
<Initials>VA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Poss</LastName>
<ForeName>Kenneth D</ForeName>
<Initials>KD</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>GM074057</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<Agency>Howard Hughes Medical Institute</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, N.I.H., Extramural</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType>Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Basic Helix-Loop-Helix Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Zebrafish Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>hand2 protein, zebrafish</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>1406-16-2</RegistryNumber>
<NameOfSubstance>Vitamin D</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animal Fins</DescriptorName>
<QualifierName MajorTopicYN="Y">growth &amp; development</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Basic Helix-Loop-Helix Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Body Patterning</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bone and Bones</DescriptorName>
<QualifierName MajorTopicYN="N">anatomy &amp; histology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fibroblasts</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Organ Specificity</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Osteoblasts</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Regeneration</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Transcription, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vitamin D</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Zebrafish</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
<QualifierName MajorTopicYN="Y">growth &amp; development</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Zebrafish Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC3754474 [Available on 03/15/14]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Anteroposterior patterning</Keyword>
<Keyword MajorTopicYN="N">Blastema</Keyword>
<Keyword MajorTopicYN="N">Fin</Keyword>
<Keyword MajorTopicYN="N">Hand2</Keyword>
<Keyword MajorTopicYN="N">Positional memory</Keyword>
<Keyword MajorTopicYN="N">Regeneration</Keyword>
<Keyword MajorTopicYN="N">Vitamin D</Keyword>
<Keyword MajorTopicYN="N">Zebrafish</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23946438</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>Developmental stage-dependent transcriptional regulatory pathways control neuroblast lineage progression.</ArticleTitle>
<Pagination>
<MedlinePgn>3838-47</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.098723</ELocationID>
<Abstract>
<AbstractText>Neuroblasts generate neurons with different functions by asymmetric cell division, cell cycle exit and differentiation. The underlying transcriptional regulatory pathways remain elusive. Here, we performed genetic screens in C. elegans and identified three evolutionarily conserved transcription factors (TFs) essential for Q neuroblast lineage progression. Through live cell imaging and genetic analysis, we showed that the storkhead TF HAM-1 regulates spindle positioning and myosin polarization during asymmetric cell division and that the PAR-1-like kinase PIG-1 is a transcriptional regulatory target of HAM-1. The TEAD TF EGL-44, in a physical association with the zinc-finger TF EGL-46, instructs cell cycle exit after the terminal division. Finally, the Sox domain TF EGL-13 is necessary and sufficient to establish the correct neuronal fate. Genetic analysis further demonstrated that HAM-1, EGL-44/EGL-46 and EGL-13 form three transcriptional regulatory pathways. We have thus identified TFs that function at distinct developmental stages to ensure appropriate neuroblast lineage progression and suggest that their vertebrate homologs might similarly regulate neural development. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Feng</LastName>
<ForeName>Guoxin</ForeName>
<Initials>G</Initials>
<Affiliation>National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, 15 Datun Road, Chaoyang District, Beijing 100101, China.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Yi</LastName>
<ForeName>Peishan</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Yihong</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chai</LastName>
<ForeName>Yongping</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tian</LastName>
<ForeName>Dong</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>Zhiwen</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Jianhong</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Fanli</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cheng</LastName>
<ForeName>Ze</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Xiangming</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ou</LastName>
<ForeName>Guangshuo</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Caenorhabditis elegans Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.4.1</RegistryNumber>
<NameOfSubstance>Myosins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Asymmetric Cell Division</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Caenorhabditis elegans</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
<QualifierName MajorTopicYN="Y">growth &amp; development</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Caenorhabditis elegans Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Lineage</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Nucleus</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Polarity</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Conserved Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Evolution, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Regulatory Networks</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Genes, Helminth</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Life Cycle Stages</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mutation</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myosins</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neurons</DescriptorName>
<QualifierName MajorTopicYN="Y">cytology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Protein Binding</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Spindle Apparatus</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Transcription, Genetic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Asymmetric cell division</Keyword>
<Keyword MajorTopicYN="N">C. elegans</Keyword>
<Keyword MajorTopicYN="N">Neuroblast development</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23946439</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>Differential roles for 3-OSTs in the regulation of cilia length and motility.</ArticleTitle>
<Pagination>
<MedlinePgn>3892-902</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.096388</ELocationID>
<Abstract>
<AbstractText>As cells integrate molecular signals from their environment, cell surface receptors require modified proteoglycans for the robust activation of signaling pathways. Heparan sulfate proteoglycans (HSPGs) have long unbranched chains of repetitive disaccharide units that can be sulfated at specific positions by heparan sulfate O-sulfotransferase (OST) families. Here, we show that two members of the 3-OST family are required in distinct signaling pathways to control left-right (LR) patterning through control of Kupffer's vesicle (KV) cilia length and motility. 3-OST-5 functions in the fibroblast growth factor pathway to control cilia length via the ciliogenic transcription factors FoxJ1a and Rfx2. By contrast, a second 3-OST family member, 3-OST-6, does not regulate cilia length, but regulates cilia motility via kinesin motor molecule (Kif3b) expression and cilia arm dynein assembly. Thus, two 3-OST family members cell-autonomously control LR patterning through distinct pathways that regulate KV fluid flow. We propose that individual 3-OST isozymes create distinct modified domains or 'glycocodes' on cell surface proteoglycans, which in turn regulate the response to diverse cell signaling pathways. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Neugebauer</LastName>
<ForeName>Judith M</ForeName>
<Initials>JM</Initials>
<Affiliation>Department of Neurobiology and Anatomy, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Cadwallader</LastName>
<ForeName>Adam B</ForeName>
<Initials>AB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Amack</LastName>
<ForeName>Jeffrey D</ForeName>
<Initials>JD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bisgrove</LastName>
<ForeName>Brent W</ForeName>
<Initials>BW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yost</LastName>
<ForeName>H Joseph</ForeName>
<Initials>HJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>HL075472</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, N.I.H., Extramural</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Morpholinos</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Zebrafish Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>62031-54-3</RegistryNumber>
<NameOfSubstance>Fibroblast Growth Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.8.2.-</RegistryNumber>
<NameOfSubstance>Sulfotransferases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.1.-</RegistryNumber>
<NameOfSubstance>Kinesin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.6.4.2</RegistryNumber>
<NameOfSubstance>Dyneins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animal Structures</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Body Patterning</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cilia</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y">enzymology</QualifierName>
<QualifierName MajorTopicYN="N">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dyneins</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Embryo, Nonmammalian</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fibroblast Growth Factors</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Kinesin</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Morpholinos</DescriptorName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Movement</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sulfotransferases</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Zebrafish</DescriptorName>
<QualifierName MajorTopicYN="N">embryology</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Zebrafish Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC3754482 [Available on 09/15/14]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">3-OST</Keyword>
<Keyword MajorTopicYN="N">Cilia</Keyword>
<Keyword MajorTopicYN="N">FGF</Keyword>
<Keyword MajorTopicYN="N">Fibroblast growth factors</Keyword>
<Keyword MajorTopicYN="N">Fluid flow</Keyword>
<Keyword MajorTopicYN="N">Glycocode</Keyword>
<Keyword MajorTopicYN="N">Gut asymmetry</Keyword>
<Keyword MajorTopicYN="N">HSPG</Keyword>
<Keyword MajorTopicYN="N">Heart asymmetry</Keyword>
<Keyword MajorTopicYN="N">Heparan sulfate proteoglycans</Keyword>
<Keyword MajorTopicYN="N">Left-right development</Keyword>
<Keyword MajorTopicYN="N">O-Sulfotransferase</Keyword>
<Keyword MajorTopicYN="N">OST</Keyword>
<Keyword MajorTopicYN="N">Zebrafish</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23946440</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>Regulation of long-range planar cell polarity by Fat-Dachsous signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>3869-81</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.094730</ELocationID>
<Abstract>
<AbstractText>Fat (Ft) and Dachsous (Ds) are large cadherins that bind each other and have conserved roles in regulating planar cell polarity (PCP). We quantitatively analyzed Ft-Ds pathway mutant clones for their effects on ommatidial polarity in the Drosophila eye. Our findings suggest that the Ft-Ds pathway regulates PCP propagation independently of asymmetric cellular accumulation of Ft or Ds. We find that the Ft effector Atrophin has a position-specific role in regulating polarity in the eye, and that asymmetric accumulation of the atypical myosin Dachs is not essential for production and propagation of a long-range PCP signal. Our observations suggest that Ft and Ds interact to modulate a secondary signal that regulates long-range polarity, that signaling by the Ds intracellular domain is dependent on Ft, and that ommatidial fate specification is genetically separable from long-range signaling. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sharma</LastName>
<ForeName>Praveer</ForeName>
<Initials>P</Initials>
<Affiliation>Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>McNeill</LastName>
<ForeName>Helen</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>MOP102656</GrantID>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Cadherins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Cell Adhesion Molecules</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Drosophila Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>dachsous protein, Drosophila</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>fat protein, Drosophila</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cadherins</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Adhesion Molecules</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Cell Polarity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Clone Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Drosophila Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Drosophila melanogaster</DescriptorName>
<QualifierName MajorTopicYN="Y">cytology</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Eye</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mutation</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Protein Transport</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Atrophin</Keyword>
<Keyword MajorTopicYN="N">Dachsous</Keyword>
<Keyword MajorTopicYN="N">Drosophila</Keyword>
<Keyword MajorTopicYN="N">Fat</Keyword>
<Keyword MajorTopicYN="N">PCP</Keyword>
<Keyword MajorTopicYN="N">Polarity</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23946441</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>Foxp1 maintains hair follicle stem cell quiescence through regulation of Fgf18.</ArticleTitle>
<Pagination>
<MedlinePgn>3809-18</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.097477</ELocationID>
<Abstract>
<AbstractText>Hair follicles cyclically degenerate and regenerate throughout adult life and require regular stem cell activation to drive the cycle. In the resting phase of the hair cycle, hair follicle stem cells are maintained in a quiescent state until they receive signals to proliferate. We found that the forkhead transcription factor Foxp1 is crucial for maintaining the quiescence of hair follicle stem cells. Loss of Foxp1 in skin epithelial cells leads to precocious stem cell activation, resulting in drastic shortening of the quiescent phase of the hair cycle. Conversely, overexpression of Foxp1 in keratinocytes prevents cell proliferation by promoting cell cycle arrest. Finally, through both gain- and loss-of-function studies, we identify fibroblast growth factor 18 (Fgf18) as the key downstream target of Foxp1. We show that exogenously supplied FGF18 can prevent the hair follicle stem cells of Foxp1 null mice from being prematurely activated. As Fgf18 controls the length of the quiescent phase and is a key downstream target of Foxp1, our data strongly suggest that Foxp1 regulates the quiescent stem cell state in the hair follicle stem cell niche by controlling Fgf18 expression. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Leishman</LastName>
<ForeName>Erin</ForeName>
<Initials>E</Initials>
<Affiliation>Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, One Baylor Plaza, BCM 505, Houston, TX 77030, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Howard</LastName>
<ForeName>Jeffrey M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Garcia</LastName>
<ForeName>Gloria E</ForeName>
<Initials>GE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Miao</LastName>
<ForeName>Qi</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ku</LastName>
<ForeName>Amy T</ForeName>
<Initials>AT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dekker</LastName>
<ForeName>Joseph D</ForeName>
<Initials>JD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tucker</LastName>
<ForeName>Haley</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nguyen</LastName>
<ForeName>Hoang</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30AI036211</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30CA125123</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01-AR059122</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01-CA31534</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>S10RR024574</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, N.I.H., Extramural</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Cyclin-Dependent Kinase Inhibitor p57</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Forkhead Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Foxp1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Repressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>fibroblast growth factor 18</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>62031-54-3</RegistryNumber>
<NameOfSubstance>Fibroblast Growth Factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Count</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Cell Cycle</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Cycle Checkpoints</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cyclin-Dependent Kinase Inhibitor p57</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Embryo, Mammalian</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fibroblast Growth Factors</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Forkhead Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hair Follicle</DescriptorName>
<QualifierName MajorTopicYN="Y">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Repressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="Y">cytology</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC3754479 [Available on 09/15/14]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Fgf18</Keyword>
<Keyword MajorTopicYN="N">Foxp1</Keyword>
<Keyword MajorTopicYN="N">Mouse</Keyword>
<Keyword MajorTopicYN="N">Skin</Keyword>
<Keyword MajorTopicYN="N">Stem cells</Keyword>
<Keyword MajorTopicYN="N">hair follicle</Keyword>
<Keyword MajorTopicYN="N">p57KIP2</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23946442</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>Transgenic tools to characterize neuronal properties of discrete populations of zebrafish neurons.</ArticleTitle>
<Pagination>
<MedlinePgn>3927-31</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.099531</ELocationID>
<Abstract>
<AbstractText>The developing nervous system consists of a variety of cell types. Transgenic animals expressing reporter genes in specific classes of neuronal cells are powerful tools for the study of neuronal network formation. We generated a wide variety of transgenic zebrafish that expressed reporter genes in specific classes of neurons or neuronal progenitors. These include lines in which neurons of specific neurotransmitter phenotypes expressed fluorescent proteins or Gal4, and lines in which specific subsets of the dorsal progenitor domain in the spinal cord expressed fluorescent proteins. Using these, we examined domain organization in the developing dorsal spinal cord, and found that there are six progenitor domains in zebrafish, which is similar to the domain organization in mice. We also systematically characterized neurotransmitter properties of the neurons that are produced from each domain. Given that reporter gene expressions occurs in a wide area of the nervous system in the lines generated, these transgenic fish should serve as powerful tools for the investigation of not only the neurons in the dorsal spinal cord but also neuronal structures and functions in many other regions of the nervous system. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Satou</LastName>
<ForeName>Chie</ForeName>
<Initials>C</Initials>
<Affiliation>National Institutes of Natural Sciences, Okazaki Institute for Integrative Bioscience, National Institute for Physiological Sciences, Okazaki, Aichi 444-8787, Japan.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Kimura</LastName>
<ForeName>Yukiko</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hirata</LastName>
<ForeName>Hiromi</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Suster</LastName>
<ForeName>Maximiliano L</ForeName>
<Initials>ML</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kawakami</LastName>
<ForeName>Koichi</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Higashijima</LastName>
<ForeName>Shin-ichi</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Neurotransmitter Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals, Genetically Modified</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Gene Transfer Techniques</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neurons</DescriptorName>
<QualifierName MajorTopicYN="Y">cytology</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neurotransmitter Agents</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Spinal Cord</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Zebrafish</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Domain organization</Keyword>
<Keyword MajorTopicYN="N">Neurotransmitter phenotype</Keyword>
<Keyword MajorTopicYN="N">Spinal cord</Keyword>
<Keyword MajorTopicYN="N">Transcription factors</Keyword>
<Keyword MajorTopicYN="N">Transgenic zebrafish</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23946443</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>Control of tissue morphology by Fasciclin III-mediated intercellular adhesion.</ArticleTitle>
<Pagination>
<MedlinePgn>3858-68</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.096214</ELocationID>
<Abstract>
<AbstractText>Morphogenesis is dependent on the orchestration of multiple developmental processes to generate mature functional organs. However, the signalling pathways that coordinate morphogenesis and the mechanisms that translate these signals into tissue shape changes are not well understood. Here, we demonstrate that changes in intercellular adhesion mediated by the transmembrane protein Fasciclin III (FasIII) represent a key mediator of morphogenesis. Using the embryonic Drosophila hindgut as an in vivo model for organogenesis, we show that the tightening of hindgut curvature that normally occurs between embryonic stage 12 and 15 to generate the characteristic shepherd's crook shape is dependent on localised JAK/STAT pathway activation. This localised pathway activity drives the expression of FasIII leading to its subcellular lateralisation at a stage before formation of septate junctions. Additionally, we show that JAK/STAT- and FasIII-dependent morphogenesis also regulates folds within the third instar wing imaginal disc. We show that FasIII forms homophilic intercellular interactions that promote intercellular adhesion in vivo and in cultured cells. To explore these findings, we have developed a mathematical model of the developing hindgut, based on the differential interfacial tension hypothesis (DITH) linking intercellular adhesion and localised surface tension. Our model suggests that increased intercellular adhesion provided by FasIII can be sufficient to drive the tightening of tube curvature observed. Taken together, these results identify a conserved molecular mechanism that directly links JAK/STAT pathway signalling to intercellular adhesion and that sculpts both tubular and planar epithelial shape. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wells</LastName>
<ForeName>Richard E</ForeName>
<Initials>RE</Initials>
<Affiliation>MRC Centre for Developmental and Biomedical Genetics, The University of Sheffield, Firth Court, Sheffield S10 2TN, UK.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Barry</LastName>
<ForeName>Joseph D</ForeName>
<Initials>JD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Warrington</LastName>
<ForeName>Samantha J</ForeName>
<Initials>SJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cuhlmann</LastName>
<ForeName>Simon</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Evans</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Huber</LastName>
<ForeName>Wolfgang</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Strutt</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zeidler</LastName>
<ForeName>Martin P</ForeName>
<Initials>MP</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>BB/F017588/1</GrantID>
<Agency>Biotechnology and Biological Sciences Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>British Heart Foundation</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Cell Adhesion Molecules, Neuronal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Drosophila Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Fas3 (fasciclin 3) protein, Drosophila</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>STAT Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance>Janus Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Adhesion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Adhesion Molecules, Neuronal</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Drosophila Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Drosophila melanogaster</DescriptorName>
<QualifierName MajorTopicYN="Y">anatomy &amp; histology</QualifierName>
<QualifierName MajorTopicYN="Y">cytology</QualifierName>
<QualifierName MajorTopicYN="N">embryology</QualifierName>
<QualifierName MajorTopicYN="N">enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gastrointestinal Tract</DescriptorName>
<QualifierName MajorTopicYN="Y">anatomy &amp; histology</QualifierName>
<QualifierName MajorTopicYN="Y">cytology</QualifierName>
<QualifierName MajorTopicYN="N">embryology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Janus Kinases</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Protein Transport</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">STAT Transcription Factors</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Subcellular Fractions</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Wing</DescriptorName>
<QualifierName MajorTopicYN="N">anatomy &amp; histology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Adhesion</Keyword>
<Keyword MajorTopicYN="N">Drosophila</Keyword>
<Keyword MajorTopicYN="N">Modelling</Keyword>
<Keyword MajorTopicYN="N">Mouse</Keyword>
<Keyword MajorTopicYN="N">Organogenesis</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23946444</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>FGF signaling regulates Wnt ligand expression to control vulval cell lineage polarity in C. elegans.</ArticleTitle>
<Pagination>
<MedlinePgn>3882-91</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.095687</ELocationID>
<Abstract>
<AbstractText>The interpretation of extracellular cues leading to the polarization of intracellular components and asymmetric cell divisions is a fundamental part of metazoan organogenesis. The Caenorhabditis elegans vulva, with its invariant cell lineage and interaction of multiple cell signaling pathways, provides an excellent model for the study of cell polarity within an organized epithelial tissue. Here, we show that the fibroblast growth factor (FGF) pathway acts in concert with the Frizzled homolog LIN-17 to influence the localization of SYS-1, a component of the Wnt/β-catenin asymmetry pathway, indirectly through the regulation of cwn-1. The source of the FGF ligand is the primary vulval precursor cell (VPC) P6.p, which controls the orientation of the neighboring secondary VPC P7.p by signaling through the sex myoblasts (SMs), activating the FGF pathway. The Wnt CWN-1 is expressed in the posterior body wall muscle of the worm as well as in the SMs, making it the only Wnt expressed on the posterior and anterior sides of P7.p at the time of the polarity decision. Both sources of cwn-1 act instructively to influence P7.p polarity in the direction of the highest Wnt signal. Using single molecule fluorescence in situ hybridization, we show that the FGF pathway regulates the expression of cwn-1 in the SMs. These results demonstrate an interaction between FGF and Wnt in C. elegans development and vulval cell lineage polarity, and highlight the promiscuous nature of Wnts and the importance of Wnt gradient directionality within C. elegans. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Minor</LastName>
<ForeName>Paul J</ForeName>
<Initials>PJ</Initials>
<Affiliation>Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>He</LastName>
<ForeName>Ting-Fang</ForeName>
<Initials>TF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sohn</LastName>
<ForeName>Chang Ho</ForeName>
<Initials>CH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Asthagiri</LastName>
<ForeName>Anand R</ForeName>
<Initials>AR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sternberg</LastName>
<ForeName>Paul W</ForeName>
<Initials>PW</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 HD075605</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32GM07616</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<Agency>Howard Hughes Medical Institute</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, N.I.H., Extramural</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Caenorhabditis elegans Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Ligands</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Wnt Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>beta Catenin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>147336-22-9</RegistryNumber>
<NameOfSubstance>Green Fluorescent Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>62031-54-3</RegistryNumber>
<NameOfSubstance>Fibroblast Growth Factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Caenorhabditis elegans</DescriptorName>
<QualifierName MajorTopicYN="Y">cytology</QualifierName>
<QualifierName MajorTopicYN="N">growth &amp; development</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Caenorhabditis elegans Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Cell Lineage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Cell Polarity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fibroblast Growth Factors</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Ligands</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myoblasts</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Protein Transport</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Stem Cells</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Subcellular Fractions</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vulva</DescriptorName>
<QualifierName MajorTopicYN="Y">cytology</QualifierName>
<QualifierName MajorTopicYN="N">growth &amp; development</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Wnt Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">beta Catenin</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC3754481 [Available on 03/15/14]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">C. elegans</Keyword>
<Keyword MajorTopicYN="N">Cell polarity</Keyword>
<Keyword MajorTopicYN="N">FGF</Keyword>
<Keyword MajorTopicYN="N">Vulval development</Keyword>
<Keyword MajorTopicYN="N">Wnt</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23946445</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>Hedgehog signaling regulates prosensory cell properties during the basal-to-apical wave of hair cell differentiation in the mammalian cochlea.</ArticleTitle>
<Pagination>
<MedlinePgn>3848-57</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.095398</ELocationID>
<Abstract>
<AbstractText>Mechanosensory hair cells and supporting cells develop from common precursors located in the prosensory domain of the developing cochlear epithelium. Prosensory cell differentiation into hair cells or supporting cells proceeds from the basal to the apical region of the cochleae, but the mechanism and significance of this basal-to-apical wave of differentiation remain to be elucidated. Here, we investigated the role of Hedgehog (Hh) signaling in cochlear development by examining the effects of up- and downregulation of Hh signaling in vivo. The Hh effector smoothened (Smo) was genetically activated or inactivated specifically in the developing cochlear epithelium after prosensory domain formation. Cochleae expressing a constitutively active allele of Smo showed only one row of inner hair cells with no outer hair cells (OHCs); abnormal undifferentiated prosensory-like cells were present in the lateral compartment instead of OHCs and their adjacent supporting cells. This suggests that Hh signaling inhibits prosensory cell differentiation into hair cells or supporting cells and maintains their properties as prosensory cells. Conversely, in cochlea with the Smo conditional knockout (Smo CKO), hair cell differentiation was preferentially accelerated in the apical region. Smo CKO mice survived after birth, and exhibited hair cell disarrangement in the apical region, a decrease in hair cell number, and hearing impairment. These results indicate that Hh signaling delays hair cell and supporting cell differentiation in the apical region, which forms the basal-to-apical wave of development, and is required for the proper differentiation, arrangement and survival of hair cells and for hearing ability. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tateya</LastName>
<ForeName>Tomoko</ForeName>
<Initials>T</Initials>
<Affiliation>Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan. t_tateya@ent.kuhp.kyoto-u.ac.jp</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Imayoshi</LastName>
<ForeName>Itaru</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tateya</LastName>
<ForeName>Ichiro</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hamaguchi</LastName>
<ForeName>Kiyomi</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Torii</LastName>
<ForeName>Hiroko</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ito</LastName>
<ForeName>Juichi</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kageyama</LastName>
<ForeName>Ryoichiro</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Biological Markers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Hedgehog Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Receptors, G-Protein-Coupled</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Smo protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>62031-54-3</RegistryNumber>
<NameOfSubstance>Fibroblast Growth Factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Biological Markers</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Cell Differentiation</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Cell Polarity</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Epithelium</DescriptorName>
<QualifierName MajorTopicYN="N">embryology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Evoked Potentials, Auditory, Brain Stem</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fibroblast Growth Factors</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hair Cells, Auditory</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hearing Loss</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hedgehog Proteins</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mammals</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Morphogenesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">RNA, Messenger</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Receptors, G-Protein-Coupled</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cochlea</Keyword>
<Keyword MajorTopicYN="N">Hair cells</Keyword>
<Keyword MajorTopicYN="N">Hedgehog signaling</Keyword>
<Keyword MajorTopicYN="N">Mouse instigate</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23946446</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>Dual role of delta-like 1 homolog (DLK1) in skeletal muscle development and adult muscle regeneration.</ArticleTitle>
<Pagination>
<MedlinePgn>3743-53</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.095810</ELocationID>
<Abstract>
<AbstractText>Muscle development and regeneration is tightly orchestrated by a specific set of myogenic transcription factors. However, factors that regulate these essential myogenic inducers remain poorly described. Here, we show that delta-like 1 homolog (Dlk1), an imprinted gene best known for its ability to inhibit adipogenesis, is a crucial regulator of the myogenic program in skeletal muscle. Dlk1(-/-) mice were developmentally retarded in their muscle mass and function owing to inhibition of the myogenic program during embryogenesis. Surprisingly however, Dlk1 depletion improves in vitro and in vivo adult skeletal muscle regeneration by substantial enhancement of the myogenic program and muscle function, possibly by means of an increased number of available myogenic precursor cells. By contrast, Dlk1 fails to alter the adipogenic commitment of muscle-derived progenitors in vitro, as well as intramuscular fat deposition during in vivo regeneration. Collectively, our results suggest a novel and surprising dual biological function of DLK1 as an enhancer of muscle development, but as an inhibitor of adult muscle regeneration. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Andersen</LastName>
<ForeName>Ditte Caroline</ForeName>
<Initials>DC</Initials>
<Affiliation>Laboratory of Molecular and Cellular Cardiology, Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Winsloewparken 21 3rd, 5000 Odense C, Denmark.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Laborda</LastName>
<ForeName>Jorge</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Baladron</LastName>
<ForeName>Victoriano</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kassem</LastName>
<ForeName>Moustapha</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sheikh</LastName>
<ForeName>Søren Paludan</ForeName>
<Initials>SP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jensen</LastName>
<ForeName>Charlotte Harken</ForeName>
<Initials>CH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Adiponectin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Dlk1 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Intercellular Signaling Peptides and Proteins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adipogenesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adiponectin</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aging</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Size</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cells, Cultured</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Intercellular Signaling Peptides and Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice, Knockout</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Muscle Development</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Muscle Fibers, Skeletal</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Organ Size</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Regeneration</DescriptorName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Delta-like 1 homolog</Keyword>
<Keyword MajorTopicYN="N">Mouse</Keyword>
<Keyword MajorTopicYN="N">Muscle development</Keyword>
<Keyword MajorTopicYN="N">Muscle regeneration</Keyword>
<Keyword MajorTopicYN="N">Muscle stem cells</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23946447</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>TGFβ signaling is required for sprouting lymphangiogenesis during lymphatic network development in the skin.</ArticleTitle>
<Pagination>
<MedlinePgn>3903-14</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.095026</ELocationID>
<Abstract>
<AbstractText>Dermal lymphatic endothelial cells (LECs) emerge from the dorsolateral region of the cardinal veins within the anterior trunk to form an intricate, branched network of lymphatic vessels during embryogenesis. Multiple growth factors and receptors are required for specification and maintenance of LECs, but the mechanisms coordinating LEC movements and morphogenesis to develop three-dimensional lymphatic network architecture are not well understood. Here, we demonstrate in mice that precise LEC sprouting is a key process leading to stereotypical lymphatic network coverage throughout the developing skin, and that transforming growth factor β (TGFβ) signaling is required for LEC sprouting and proper lymphatic network patterning in vivo. We utilized a series of conditional mutants to ablate the TGFβ receptors Tgfbr1 (Alk5) and Tgfbr2 in LECs. To analyze lymphatic defects, we developed a novel, whole-mount embryonic skin imaging technique to visualize sprouting lymphangiogenesis and patterning at the lymphatic network level. Loss of TGFβ signaling in LECs leads to a severe reduction in local lymphangiogenic sprouting, resulting in a significant decrease in global lymphatic network branching complexity within the skin. Our results also demonstrate that TGFβ signaling negatively regulates LEC proliferation during lymphatic network formation. These data suggest a dual role for TGFβ signaling during lymphatic network morphogenesis in the skin, such that it enhances LEC sprouting and branching complexity while attenuating LEC proliferation. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>James</LastName>
<ForeName>Jennifer M</ForeName>
<Initials>JM</Initials>
<Affiliation>Laboratory of Stem Cell and Neuro-Vascular Biology, Genetics and Developmental Biology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Building 10/6C103, 10 Center Drive, Bethesda, MD 20892, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Nalbandian</LastName>
<ForeName>Ani</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mukouyama</LastName>
<ForeName>Yoh-suke</ForeName>
<Initials>YS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>HL005702-07</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, N.I.H., Intramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Neuropilin-2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Receptors, Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>neuropilin-2, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance>Vascular Endothelial Growth Factor Receptor-3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.7.-</RegistryNumber>
<NameOfSubstance>Cre recombinase</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.7.-</RegistryNumber>
<NameOfSubstance>Integrases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Proliferation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Shape</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Embryo, Mammalian</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Endothelial Cells</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gene Deletion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Integrases</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Lymphangiogenesis</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Lymphatic Vessels</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y">embryology</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mutation</DescriptorName>
<QualifierName MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neuropilin-2</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Organ Specificity</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Receptors, Transforming Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Signal Transduction</DescriptorName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Skin</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
<QualifierName MajorTopicYN="Y">embryology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vascular Endothelial Growth Factor Receptor-3</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC3754483 [Available on 09/15/14]</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Dermal lymphangiogenesis</Keyword>
<Keyword MajorTopicYN="N">LEC sprouting</Keyword>
<Keyword MajorTopicYN="N">TGFβ</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23981654</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>Cohesin in development and disease.</ArticleTitle>
<Pagination>
<MedlinePgn>3715-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.090605</ELocationID>
<Abstract>
<AbstractText>Cohesin is a ring-shaped complex, conserved from yeast to human, that was named for its ability to mediate sister chromatid cohesion. This function is essential for chromosome segregation in both mitosis and meiosis, and also for DNA repair. In addition, more recent studies have shown that cohesin influences gene expression during development through mechanisms that likely involve DNA looping and interactions with several transcriptional regulators. Here, we provide an overview of how cohesin functions, highlighting its role both in development and in disease. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Remeseiro</LastName>
<ForeName>Silvia</ForeName>
<Initials>S</Initials>
<Affiliation>Chromosome Dynamics Group, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Cuadrado</LastName>
<ForeName>Ana</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Losada</LastName>
<ForeName>Ana</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Cell Cycle Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Chromosomal Proteins, Non-Histone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Multiprotein Complexes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>cohesins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Cycle</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Cycle Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chromosomal Proteins, Non-Histone</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Disease</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Embryonic Development</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Multiprotein Complexes</DescriptorName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Transcription, Genetic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Chromatin loops</Keyword>
<Keyword MajorTopicYN="N">Cohesinopathies</Keyword>
<Keyword MajorTopicYN="N">Cohesion</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23981655</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>Molecular causes of aneuploidy in mammalian eggs.</ArticleTitle>
<Pagination>
<MedlinePgn>3719-30</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.090589</ELocationID>
<Abstract>
<AbstractText>Mammalian oocytes are particularly error prone in segregating their chromosomes during their two meiotic divisions. This results in the creation of an embryo that has inherited the wrong number of chromosomes: it is aneuploid. The incidence of aneuploidy rises significantly with maternal age and so there is much interest in understanding this association and the underlying causes of aneuploidy. The spindle assembly checkpoint, a surveillance mechanism that operates in all cells to prevent chromosome mis-segregation, and the cohesive ties that hold those chromosomes together, have thus both been the subject of intensive investigation in oocytes. It is possible that a lowered sensitivity of the spindle assembly checkpoint to certain types of chromosome attachment error may endow oocytes with an innate susceptibility to aneuploidy, which is made worse by an age-related loss in the factors that hold the chromosomes together. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jones</LastName>
<ForeName>Keith T</ForeName>
<Initials>KT</Initials>
<Affiliation>Centre for Biological Sciences, University of Southampton, Southampton SO17 1BJ, UK. k.t.jones@soton.ac.uk</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Lane</LastName>
<ForeName>Simon I R</ForeName>
<Initials>SI</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Aneuploidy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chromosome Segregation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mammals</DescriptorName>
<QualifierName MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Meiosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Ovum</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Aneuploidy</Keyword>
<Keyword MajorTopicYN="N">Cell cycle</Keyword>
<Keyword MajorTopicYN="N">Chromosomes</Keyword>
<Keyword MajorTopicYN="N">Meiosis</Keyword>
<Keyword MajorTopicYN="N">Oocyte</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23981656</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>04</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1477-9129</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>18</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Development (Cambridge, England)</Title>
<ISOAbbreviation>Development</ISOAbbreviation>
</Journal>
<ArticleTitle>Female-biased dimorphism underlies a female-specific role for post-embryonic Ilp7 neurons in Drosophila fertility.</ArticleTitle>
<Pagination>
<MedlinePgn>3915-26</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1242/dev.094714</ELocationID>
<Abstract>
<AbstractText>In Drosophila melanogaster, much of our understanding of sexually dimorphic neuronal development and function comes from the study of male behavior, leaving female behavior less well understood. Here, we identify a post-embryonic population of Insulin-like peptide 7 (Ilp7)-expressing neurons in the posterior ventral nerve cord that innervate the reproductive tracts and exhibit a female bias in their function. They form two distinct dorsal and ventral subsets in females, but only a single dorsal subset in males, signifying a rare example of a female-specific neuronal subset. Female post-embryonic Ilp7 neurons are glutamatergic motoneurons innervating the oviduct and are required for female fertility. In males, they are serotonergic/glutamatergic neuromodulatory neurons innervating the seminal vesicle but are not required for male fertility. In both sexes, these neurons express the sex-differentially spliced fruitless-P1 transcript but not doublesex. The male fruitless-P1 isoform (fruM) was necessary and sufficient for serotonin expression in the shared dorsal Ilp7 subset, but although it was necessary for eliminating female-specific Ilp7 neurons in males, it was not sufficient for their elimination in females. By contrast, sex-specific RNA-splicing by female-specific transformer is necessary for female-type Ilp7 neurons in females and is sufficient for their induction in males. Thus, the emergence of female-biased post-embryonic Ilp7 neurons is mediated in a subset-specific manner by a tra- and fru-dependent mechanism in the shared dorsal subset, and a tra-dependent, fru-independent mechanism in the female-specific subset. These studies provide an important counterpoint to studies of the development and function of male-biased neuronal dimorphism in Drosophila. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Castellanos</LastName>
<ForeName>Monica C</ForeName>
<Initials>MC</Initials>
<Affiliation>Department of Cellular and Physiological Sciences, 2401 Life Sciences Centre, 2350 Health Sciences Mall, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Tang</LastName>
<ForeName>Jonathan C Y</ForeName>
<Initials>JC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Allan</LastName>
<ForeName>Douglas W</ForeName>
<Initials>DW</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Development</MedlineTA>
<NlmUniqueID>8701744</NlmUniqueID>
<ISSNLinking>0950-1991</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Drosophila Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Neuropeptides</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>insulin-like peptide 7, Drosophila</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Drosophila Proteins</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Drosophila melanogaster</DescriptorName>
<QualifierName MajorTopicYN="Y">cytology</QualifierName>
<QualifierName MajorTopicYN="Y">embryology</QualifierName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Embryo, Nonmammalian</DescriptorName>
<QualifierName MajorTopicYN="Y">cytology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fertility</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Motor Neurons</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neurons</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neuropeptides</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Seminal Vesicles</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Serotonergic Neurons</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Sex Characteristics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Urogenital System</DescriptorName>
<QualifierName MajorTopicYN="N">cytology</QualifierName>
<QualifierName MajorTopicYN="N">innervation</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Female behavior</Keyword>
<Keyword MajorTopicYN="N">Motoneuron</Keyword>
<Keyword MajorTopicYN="N">Neuronal identity</Keyword>
<Keyword MajorTopicYN="N">Neuronal lineage</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983480</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1178-7007</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>6</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Diabetes, metabolic syndrome and obesity : targets and therapy</Title>
<ISOAbbreviation>Diabetes Metab Syndr Obes</ISOAbbreviation>
</Journal>
<ArticleTitle>Treatment outcome and prognostic indices in patients with hyperglycemic emergencies.</ArticleTitle>
<Pagination>
<MedlinePgn>303-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2147/DMSO.S44477</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this study is to assess the treatment outcomes in patients with hyperglycemic emergencies and to ascertain the factors associated with outcome, with emphasis on the determinants of outcome.</AbstractText>
<AbstractText Label="METHOD" NlmCategory="METHODS">A total of 105 patients admitted to the Accident and Emergency unit, who fulfilled the criteria for hyperglycemic emergencies, were selected. The information extracted included sociodemographic, clinical, and laboratory data, as well as hospitalization outcome.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 105 subjects that participated in the study, hyperosmolar hyperglycemic nonketotic state (HHNK) was seen in 50% (53) of the subjects, while diabetic ketoacidosis (DKA) was seen in 31% (29), normo-osmolar nonketotic hyperglycemic state (NNHS) in 12% (13), and mixed hyperglycemic emergency in 7% (10) of the subjects. The overall mortality rate in this study was 4.8%. Three deaths were recorded in patients with HHNK, while DKA and NNHS each had one death. Three of the deaths occurred within the first 24 hours of admission while the other two were more than 24 hours after admission. The mean (standard deviation) total duration of hospital stay was 24.2 days (SD), and the range of stay was 0.5-88 days.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The most common type of hyperglycemic emergency seen in this study was HHNK. Also, the presence of infection, and sex of the study subject, were significant determinants of outcome in this study.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ezeani</LastName>
<ForeName>Iu</ForeName>
<Initials>Iu</Initials>
<Affiliation>Department of Medicine, Federal Medical centre, Umuahia, Abia State, Nigeria.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Eregie</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ogedengbe</LastName>
<ForeName>Os</ForeName>
<Initials>O</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>New Zealand</Country>
<MedlineTA>Diabetes Metab Syndr Obes</MedlineTA>
<NlmUniqueID>101515585</NlmUniqueID>
<ISSNLinking>1178-7007</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3749816</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">diabetes mellitus</Keyword>
<Keyword MajorTopicYN="N">emergency</Keyword>
<Keyword MajorTopicYN="N">hyperglycemia</Keyword>
<Keyword MajorTopicYN="N">insulin</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983448</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1070-3608</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Diagnostic and therapeutic endoscopy</Title>
<ISOAbbreviation>Diagn Ther Endosc</ISOAbbreviation>
</Journal>
<ArticleTitle>Narrow band imaging with magnification endoscopy for celiac disease: results from a prospective, single-center study.</ArticleTitle>
<Pagination>
<MedlinePgn>580526</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/580526</ELocationID>
<Abstract>
<AbstractText>In celiac disease (CD), the intestinal lesions can be patchy and partial villous atrophy may elude detection at standard endoscopy (SE). Narrow Band Imaging (NBI) system in combination with a magnifying endoscope (ME) is a simple tool able to obtain targeted biopsy specimens. The aim of the study was to assess the correlation between NBI-ME and histology in CD diagnosis and to compare diagnostic accuracy between NBI-ME and SE in detecting villous abnormalities in CD. Forty-four consecutive patients with suspected CD undergoing upper gastrointestinal endoscopy have been prospectively evaluated. Utilizing both SE and NBI-ME, observed surface patterns were compared with histological results obtained from biopsy specimens using the k-Cohen agreement coefficient. NBI-ME identified partial villous atrophy in 12 patients in whom SE was normal, with sensitivity, specificity, and accuracy of 100%, 92.6%, and 95%, respectively. The overall agreement between NBI-ME and histology was significantly higher when compared with SE and histology (kappa score: 0.90 versus 0.46; P = 0.001) in diagnosing CD. NBI-ME could help identify partial mucosal atrophy in the routine endoscopic practice, potentially reducing the need for blind biopsies. NBI-ME was superior to SE and can reliably predict in vivo the villous changes of CD. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>De Luca</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<Affiliation>Gastroenterology and Digestive Endoscopy Unit, "San Salvatore" Hospital, Piazzale Cinelli, 1-61121 Pesaro, Italy.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Ricciardiello</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rocchi</LastName>
<ForeName>M B L</ForeName>
<Initials>MB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fabi</LastName>
<ForeName>M T</ForeName>
<Initials>MT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bianchi</LastName>
<ForeName>M L</ForeName>
<Initials>ML</Initials>
</Author>
<Author ValidYN="Y">
<LastName>de Leone</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fiori</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Baroncini</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>06</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Diagn Ther Endosc</MedlineTA>
<NlmUniqueID>9502019</NlmUniqueID>
<ISSNLinking>1026-714X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3748412</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983491</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1179-1365</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>5</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Drug, healthcare and patient safety</Title>
<ISOAbbreviation>Drug Healthc Patient Saf</ISOAbbreviation>
</Journal>
<ArticleTitle>Attrition of Canadian Internet pharmacy websites: what are the implications?</ArticleTitle>
<Pagination>
<MedlinePgn>171-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2147/DHPS.S46232</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The unavailability of Internet pharmacy websites may impact a consumer's drug purchases and health care.</AbstractText>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To address the issue of attrition, a defined set of Canadian Internet pharmacy websites was examined at three separate time intervals.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">In February to March 2006, 117 distinct, fully functional "Canadian Internet pharmacy" websites were located using the advanced search options of Google and the uniform resource locator (URL) for each website was recorded. To determine website attrition, each of the 117 websites obtained and recorded from the previous study was revisited at two later periods of time within a 4-year period.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">After approximately 4 years and 5 months, only 59 (50.4%) sites were found in the original state. Thirty-four sites (29.1%) had moved to a new URL address and were not functioning as the original Internet pharmacy. For 24 sites (20.5%) the viewer was redirected to another Canadian Internet pharmacy site.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Of concern for patients if Internet pharmacy sites were suddenly inaccessible would be the disruption of continuity of care.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Veronin</LastName>
<ForeName>Michael A</ForeName>
<Initials>MA</Initials>
<Affiliation>Rangel College of Pharmacy, Texas A&amp;M Health Science Center, Texas, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Clancy</LastName>
<ForeName>Kristen M</ForeName>
<Initials>KM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>New Zealand</Country>
<MedlineTA>Drug Healthc Patient Saf</MedlineTA>
<NlmUniqueID>101544775</NlmUniqueID>
<ISSNLinking>1179-1365</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747814</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Canadian Internet pharmacy</Keyword>
<Keyword MajorTopicYN="N">continuity of care</Keyword>
<Keyword MajorTopicYN="N">online pharmacy</Keyword>
<Keyword MajorTopicYN="N">website attrition</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983814</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1754-6605</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>7</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Ecancermedicalscience</Title>
<ISOAbbreviation>Ecancermedicalscience</ISOAbbreviation>
</Journal>
<ArticleTitle>Risk strata-based therapy and outcome in stage Ib-IIa carcinoma cervix: single-centre ten-year experience.</ArticleTitle>
<Pagination>
<MedlinePgn>341</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3332/ecancer.2013.341</ELocationID>
<Abstract>
<AbstractText Label="AIM" NlmCategory="OBJECTIVE">To review the outcome of stage (Ib, IIa), cervical cancer patients were primarily treated with radical hysterectomy and risk-based postoperative therapy.</AbstractText>
<AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Between January 2001 and December 2011, 601 cases underwent surgery followed by tailored therapy. Patients were classified into low risk (pelvic lymph node negative, tumour less than 4 cm, no evidence of lympho-vascular invasion, less than one-third of thickness of surgical stoma involved), intermediate risk (positive lympho-vascular space invasion, tumour size more than 4 cm, and deep invasion of cervical stroma), and high risk (pelvic lymph node involved, positive parametrial, or vaginal margins) groups. Postoperative adju-vant therapy in the form of radiotherapy alone to those with intermediate risk and chemo-radiotherapy to those with high risk was given to patients. The median follow-up was 60 months.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The majority of patients had intermediate risk. The overall event-free survival (EFS) at five years was 74.37%, with EFS of 86.5% in those from the low-risk group, 73% in those from the intermediate-risk group, and 64% in those from the high-risk group. In conclusion, risk strata-based adjuvant postoperative therapy is able to provide a favourable outcome in patients with stage Ib-IIa cervical cancer with a nearly 11% improvement in survival compared with historical control.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kundargi</LastName>
<ForeName>Rajshekar S</ForeName>
<Initials>RS</Initials>
<Affiliation>Department of Gynaec-oncology, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka 560029, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Guruprasad</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rathod</LastName>
<ForeName>Praveen Shankar</ForeName>
<Initials>PS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shakuntala</LastName>
<ForeName>Pn</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shobha</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pallavi</LastName>
<ForeName>Vr</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Uma Devi</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bafna</LastName>
<ForeName>Ud</ForeName>
<Initials>U</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Ecancermedicalscience</MedlineTA>
<NlmUniqueID>101392236</NlmUniqueID>
<ISSNLinking>1754-6605</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3749044</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">carcinoma cervix Ib–IIa</Keyword>
<Keyword MajorTopicYN="N">chemotherapy</Keyword>
<Keyword MajorTopicYN="N">radiotherapy</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983815</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1754-6605</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>7</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Ecancermedicalscience</Title>
<ISOAbbreviation>Ecancermedicalscience</ISOAbbreviation>
</Journal>
<ArticleTitle>Heterogeneity of circulating epithelial tumour cells from individual patients with respect to expression profiles and clonal growth (sphere formation) in breast cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>343</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3332/ecancer.2013.343</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The detection of tumour cells circulating in the peripheral blood of patients with breast cancer is a sign that cells have been able to leave the primary tumour and survive in the circulation. However, in order to form metastases, they require additional properties such as the ability to adhere, self-renew, and grow. Here we present data that a variable fraction among the circulating tumour cells detected by the Maintrac(®) approach expresses mRNA of the stem cell gene NANOG and of the adhesion molecule vimentin and is capable of forming tumour spheres, a property ascribed to tumour-initiating cells (TICs).</AbstractText>
<AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Between ten and 50 circulating epithelial antigen-positive cells detected by the Maintrac approach were selected randomly from each of 20 patients with breast cancer before and after surgery and were isolated using automated capillary aspiration and deposited individually onto slides for expression profiling. In addition, the circulating tumour cells were cultured without isolation among the white blood cells from 39 patients with breast cancer in different stages of disease using culture methods favouring growth of epithelial cells.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Although no epithelial cell adhesion molecule (EpCAM)-positive cells expressing stem cell genes or the adhesion molecule vimentin was detected before surgery, 10%-20% of the cells were found to be positive for mRNA of these genes after surgery. Tumour spheres from circulating cells of 39 patients with different stages of breast cancer were grown without previous isolation in a fraction increasing with the aggressivity of the tumour.</AbstractText>
<AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Here we show that among the peripherally circulating tumour cells, a variable fraction is able to express stem cell and adhesion properties and can be grown into tumour spheres, a property ascribed to cells capable of initiating tumours and metastases.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pizon</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<Affiliation>Transfusion Center Bayreuth D-95448, Germany.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Zimon</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Carl</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pachmann</LastName>
<ForeName>U</ForeName>
<Initials>U</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pachmann</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Camara</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Ecancermedicalscience</MedlineTA>
<NlmUniqueID>101392236</NlmUniqueID>
<ISSNLinking>1754-6605</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3750196</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">breast cancer</Keyword>
<Keyword MajorTopicYN="N">circulating epithelial tumour cells</Keyword>
<Keyword MajorTopicYN="N">tumour spheres</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984073</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">2090-2840</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Emergency medicine international</Title>
<ISOAbbreviation>Emerg Med Int</ISOAbbreviation>
</Journal>
<ArticleTitle>Image and imaging an emergency department: expense and benefit of different quality assessment methods.</ArticleTitle>
<Pagination>
<MedlinePgn>213263</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/213263</ELocationID>
<Abstract>
<AbstractText>Introduction. In this era of high-tech medicine, it is becoming increasingly important to assess patient satisfaction. There are several methods to do so, but these differ greatly in terms of cost, time, and labour and external validity. The aim of this study is to describe and compare the structure and implementation of different methods to assess the satisfaction of patients in an emergency department. Methods. The structure and implementation of the different methods to assess patient satisfaction were evaluated on the basis of a 90-minute standardised interview. Results. We identified a total of six different methods in six different hospitals. The average number of patients assessed was 5012, with a range from 230 (M5) to 20 000 patients (M2). In four methods (M1, M3, M5, and M6), the questionnaire was composed by a specialised external institute. In two methods, the questionnaire was created by the hospital itself (M2, M4).The median response rate was 58.4% (range 9-97.8%). With a reminder, the response rate increased by 60% (M3). Conclusion. The ideal method to assess patient satisfaction in the emergency department setting is to use a patient-based, in-emergency department-based assessment of patient satisfaction, planned and guided by expert personnel. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pfortmueller</LastName>
<ForeName>Carmen Andrea</ForeName>
<Initials>CA</Initials>
<Affiliation>Department of General Internal Medicine, Bern University Hospital, 3010 Bern, Switzerland ; Emergency Department, Bern University Hospital, 3010 Bern, Switzerland.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Keller</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mueller</LastName>
<ForeName>Urs</ForeName>
<Initials>U</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zimmermann</LastName>
<ForeName>Heinz</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Exadaktylos</LastName>
<ForeName>Aristomenis Konstantinos</ForeName>
<Initials>AK</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>Emerg Med Int</MedlineTA>
<NlmUniqueID>101567070</NlmUniqueID>
<ISSNLinking>2090-2840</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745856</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982899</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1098-2280</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>54 Suppl 1</Volume>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Environmental and molecular mutagenesis</Title>
<ISOAbbreviation>Environ. Mol. Mutagen.</ISOAbbreviation>
</Journal>
<ArticleTitle>Abstracts of the Environmental Mutagen Society 44th Annual Meeting. September 21-25, 2013. Monterey, California, USA.</ArticleTitle>
<Pagination>
<MedlinePgn>S13-59</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/em.21814</ELocationID>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Congresses</PublicationType>
<PublicationType>Overall</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Environ Mol Mutagen</MedlineTA>
<NlmUniqueID>8800109</NlmUniqueID>
<ISSNLinking>0893-6692</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Mutagens</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Environmental Exposure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Mutagenesis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Mutagens</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984056</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">2090-1348</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Epilepsy research and treatment</Title>
<ISOAbbreviation>Epilepsy Res Treat</ISOAbbreviation>
</Journal>
<ArticleTitle>Vitamin-responsive epileptic encephalopathies in children.</ArticleTitle>
<Pagination>
<MedlinePgn>510529</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/510529</ELocationID>
<Abstract>
<AbstractText>Untreated epileptic encephalopathies in children may potentially have disastrous outcomes. Treatment with antiepileptic drugs (AEDs) often may not control the seizures, and even if they do, this measure is only symptomatic and not specific. It is especially valuable to identify potential underlying conditions that have specific treatments. Only a few conditions have definitive treatments that can potentially modify the natural course of disease. In this paper, we discuss the few such conditions that are responsive to vitamin or vitamin derivatives. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Agadi</LastName>
<ForeName>Satish</ForeName>
<Initials>S</Initials>
<Affiliation>Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA ; Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA ; Texas Children's Hospital, 6621 Fannin Street, CCC 1250.03, 12th Floor, Houston, TX 77030, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Quach</LastName>
<ForeName>Michael M</ForeName>
<Initials>MM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Haneef</LastName>
<ForeName>Zulfi</ForeName>
<Initials>Z</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Epilepsy Res Treat</MedlineTA>
<NlmUniqueID>101576602</NlmUniqueID>
<ISSNLinking>2090-1348</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745849</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23925715</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1433-8491</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>263 Suppl 1</Volume>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>European archives of psychiatry and clinical neuroscience</Title>
<ISOAbbreviation>Eur Arch Psychiatry Clin Neurosci</ISOAbbreviation>
</Journal>
<ArticleTitle>Together for better treatment and care. Abstracts of the 4th European Conference on Schizophrenia Research. September 26-28, 2013. Berlin, Germany.</ArticleTitle>
<Pagination>
<MedlinePgn>5-119</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00406-013-0432-1</ELocationID>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Congresses</PublicationType>
<PublicationType>Overall</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Eur Arch Psychiatry Clin Neurosci</MedlineTA>
<NlmUniqueID>9103030</NlmUniqueID>
<ISSNLinking>0940-1334</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Schizophrenia</DescriptorName>
<QualifierName MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983919</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">2000-8066</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>European journal of psychotraumatology</Title>
<ISOAbbreviation>Eur J Psychotraumatol</ISOAbbreviation>
</Journal>
<ArticleTitle>Five essential principles of post-disaster psychosocial care: looking back and forward with Stevan Hobfoll.</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.3402/ejpt.v4i0.21914</ELocationID>
<Abstract>
<AbstractText>In 2007, a leading article was published by Stevan Hobfoll and a team of international experts. The authors synthesized available scientific evidence and distinguished five essential principles of psychosocial care to people confronted with disaster, tragedy, and loss. Care givers should promote: (1) a sense of safety, (2) calming, (3) self- and community efficacy, (4) social connectedness, and (5) hope. After their publication, the "essential principles" influenced the thoughts of policy makers, care providers, and scholars from all over the world. They have been embedded in several guidelines. In this interview, Professor Hobfoll is invited to revisit the principles and to look forward: "The next step is to create passageways and mutual partnerships." </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dückers</LastName>
<ForeName>Michel L A</ForeName>
<Initials>ML</Initials>
<Affiliation>Impact, National Knowledge and Advice Centre for Psychosocial Care Concerning Critical Incidents, Partner in Arq, Psychotrauma Expert Group, Diemen, The Netherlands.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Sweden</Country>
<MedlineTA>Eur J Psychotraumatol</MedlineTA>
<NlmUniqueID>101559025</NlmUniqueID>
<ISSNLinking>2000-8066</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752040</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Psychosocial care</Keyword>
<Keyword MajorTopicYN="N">community intervention</Keyword>
<Keyword MajorTopicYN="N">disaster</Keyword>
<Keyword MajorTopicYN="N">interview</Keyword>
<Keyword MajorTopicYN="N">social change</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983920</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">2000-8066</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>European journal of psychotraumatology</Title>
<ISOAbbreviation>Eur J Psychotraumatol</ISOAbbreviation>
</Journal>
<ArticleTitle>Validation of the Davidson Trauma Scale in its original and a new shorter version in people exposed to the F-27 earthquake in Chile.</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.3402/ejpt.v4i0.21239</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">On February 27, 2010 (F-27), an earthquake and tsunami occurred having a significant impact on the mental health of the Chilean population, leading to an increase in cases of post-traumatic stress disorder (PTSD).</AbstractText>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Within this context, validated for the first time in Chile was the Davidson Trauma Scale (DTS) using three samples (each one consisting of 200 participants), two of them random from the Chilean population.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Reliability analyses (i.e., α=0.933), concurrent validity (63% of the items are significantly correlated with the criteria variable "degree of damage to home") and construct validity (i.e., CMIN = 3.754, RMSEA = 0.118, NFI = 0.808, CFI = 0.850 and PNFI = 0.689) indicate validity between regular and good for DTS. However, a new short version of the scale (DTS-SF) created using the items with heavier factor weights, presented better fits (CMIN = 2.170, RMSEA = 0.077, NFI = 0.935, CFI = 0.963, PNFI = 0.697).</AbstractText>
<AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Finally, the usefulness of DTS and DTS-SF is discussed, the latter being briefer, valid and having better psychometric characteristics.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Leiva-Bianchi</LastName>
<ForeName>Marcelo C</ForeName>
<Initials>MC</Initials>
<Affiliation>Faculty of Psychology, University of Talca, Talca, Chile.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Araneda</LastName>
<ForeName>Andrea C</ForeName>
<Initials>AC</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Sweden</Country>
<MedlineTA>Eur J Psychotraumatol</MedlineTA>
<NlmUniqueID>101559025</NlmUniqueID>
<ISSNLinking>2000-8066</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752042</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Post-traumatic stress disorder</Keyword>
<Keyword MajorTopicYN="N">confirmatory factor analysis</Keyword>
<Keyword MajorTopicYN="N">earthquake</Keyword>
<Keyword MajorTopicYN="N">exploratory factor analysis</Keyword>
<Keyword MajorTopicYN="N">psychosocial impact</Keyword>
<Keyword MajorTopicYN="N">screening scale</Keyword>
<Keyword MajorTopicYN="N">tsunami</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983772</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>The Relationship between Traditional Chinese Medicine and Modern Medicine.</ArticleTitle>
<Pagination>
<MedlinePgn>153148</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/153148</ELocationID>
<Abstract>
<AbstractText>The essence of the traditional Chinese medicine has always been the most advanced and experienced therapeutic approach in the world. It has knowledge that can impact the direction of future modern medical development; still, it is easy to find simple knowledge with mark of times and special cultures. The basic structure of traditional Chinese medicine is composed of three parts: one consistent with modern medicine, one involuntarily beyond modern medicine, and one that needs to be further evaluated. The part that is consistent with modern medicine includes consensus on several theories and concepts of traditional Chinese medicine, and usage of several treatments and prescriptions of traditional Chinese medicine including commonly used Chinese herbs. The part that is involuntarily beyond modern medicine contains several advanced theories and important concepts of traditional Chinese medicine, relatively advanced treatments, formula and modern prescriptions, leading herbs, acupuncture treatment and acupuncture anesthesia of traditional Chinese medicine that affect modern medicine and incorporates massage treatment that has been gradually acknowledged by modern therapy. The part that needs to be further evaluated consists not only the knowledge of pulse diagnosis, prescription, and herbs, but also many other aspects of traditional Chinese medicine. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dong</LastName>
<ForeName>Jingcheng</ForeName>
<Initials>J</Initials>
<Affiliation>Institute of Integrated Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China ; Department of Integrated Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745867</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983773</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Analysis on outcome of 3537 patients with coronary artery disease: integrative medicine for cardiovascular events.</ArticleTitle>
<Pagination>
<MedlinePgn>162501</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/162501</ELocationID>
<Abstract>
<AbstractText>Aims. To investigate the treatment of hospitalized patients with coronary artery disease (CAD) and the prognostic factors in Beijing, China. Materials and Methods. A multicenter prospective study was conducted through an integrative platform of clinical and research at 12 hospitals in Beijing, China. The clinical information of 3537 hospitalized patients with CAD was collected from September 2009 to May 2011, and the efficacy of secondary prevention during one-year followup was evaluated. In addition, a logistic regression analysis was performed to identify some factors which will have independent impact on the prognosis. Results. The average age of all patients was 64.88 ± 11.97. Of them, 65.42% are males. The medicines for patients were as follows: antiplatelet drugs accounting for 91.97%, statins accounting for 83.66%, β -receptor blockers accounting for 72.55%, ACEI/ARB accounting for 58.92%, and revascularization (including PCI and CABG) accounting for 40.29%. The overall incidence of cardiovascular events was 13.26% (469/3537). The logistic stepwise regression analysis showed that heart failure (OR, 3.707, 95% CI = 2.756-4.986), age ≥ 65 years old (OR, 2.007, 95% CI = 1.587-2.53), and myocardial infarction (OR, 1.649, 95% CI = 1.322-2.057) were the independent risk factors of others factors for cardiovascular events that occurred during followup of one-year period. Integrative medicine (IM) therapy showed the beneficial tendency for decreasing incidence of cardiovascular events, although no statistical significance was found (OR, 0.797, 95% CI = 0.613~1.036). Conclusions. Heart failure, age ≥ 65 years old, and myocardial infarction were associated with an increase in incidence of cardiovascular events, and treatment with IM showed a tendency for decreasing incidence of cardiovascular events. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>Zhu-Ye</ForeName>
<Initials>ZY</Initials>
<Affiliation>Department of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Qiu</LastName>
<ForeName>Yu</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jiao</LastName>
<ForeName>Yang</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shang</LastName>
<ForeName>Qing-Hua</ForeName>
<Initials>QH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Hao</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shi</LastName>
<ForeName>Da-Zhuo</ForeName>
<Initials>DZ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747377</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983774</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Growth and Survival of Bagged Lucilia sericata Maggots in Wounds of Patients Undergoing Maggot Debridement Therapy.</ArticleTitle>
<Pagination>
<MedlinePgn>192149</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/192149</ELocationID>
<Abstract>
<AbstractText>Maggot debridement therapy (MDT) is an established method of debridement of nonhealing wounds. Despite intense clinical research about its efficacy and effects of substances produced by the larvae, growth and development of maggots in the wounds remain largely unexplored. In the present study, the bags with larvae (n = 52), which had been used to debride traumatic, ischemic, diabetic and venous ulcers, were collected and examined. Survival, length, width and larval instar of the maggots within each bag were recorded and analyzed with respect to the wound type and duration of the treatment. Survival of maggots after a 48-h cycle of MDT ranged between 63.6 and 82.7%. Maggots in venous ulcers had on average 9-19% higher mortality than maggots within traumatic, ischemic, and diabetic ulcers. Length of larvae after 48 h cycle of MDT reached on average 7.09-9.68 mm, and average width varied between 1.77 and 2.26 mm. Larvae in venous ulcers were significantly smaller after 48 h, but not after 72 h treatment compared to the other wound types. Further studies should be aimed to identify other patient-associated factors which might influence growth and survival of the larvae during maggot debridement therapy. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Cičková</LastName>
<ForeName>Helena</ForeName>
<Initials>H</Initials>
<Affiliation>Institute of Zoology, Slovak Academy of Sciences, Dúbravská cesta 9, 845 06 Bratislava, Slovakia ; Scientica s. r. o., Hybešova 33, 831 06 Bratislava, Slovakia.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Cambal</LastName>
<ForeName>Marek</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kozánek</LastName>
<ForeName>Milan</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takáč</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745885</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983775</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Validity of the "streitberger" needle in a chinese population with acupuncture: a randomized, single-blinded, and crossover pilot study.</ArticleTitle>
<Pagination>
<MedlinePgn>251603</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/251603</ELocationID>
<Abstract>
<AbstractText>We studied the validity of a "Streitberger" needle as a valid approach in a Chinese population with experience of acupuncture. Volunteers were recruited from students of the School of Acupuncture and Moxibustion, Guangzhou University of Chinese Medicine. Sixty students receiving education in acupuncture theory and experience in practical acupuncture were tested in study determining whether needling with the placebo needle felt any different from conventional acupuncture. Outcomes included measures of penetration sensation, VAS ratings, and Deqi sensation questionnaire. As a result, needle penetration, VAS ratings for either needle and Deqi sensation were not significantly different between two kinds of needles. Our findings show that the use of "Streitberger" needle is credible in a Chinese population with acupuncture experience. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Xie</LastName>
<ForeName>Chang-Cai</ForeName>
<Initials>CC</Initials>
<Affiliation>Department of Acupuncture and Moxibustion, Guangdong Provincial Hospital of TCM, Guangzhou 510120, China.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Wen</LastName>
<ForeName>Xiu-Yun</ForeName>
<Initials>XY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jiang</LastName>
<ForeName>Li</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xie</LastName>
<ForeName>Min-Jun</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fu</LastName>
<ForeName>Wen Bin</ForeName>
<Initials>WB</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747414</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983776</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>CAM in Psychiatry.</ArticleTitle>
<Pagination>
<MedlinePgn>293248</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/293248</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Melzer</LastName>
<ForeName>Jörg</ForeName>
<Initials>J</Initials>
<Affiliation>Institute of Complementary Medicine and Clinic for Psychiatry and Psychotherapy, University Hospital Zurich, Raemistraße 100, 8091 Zurich, Switzerland.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Deter</LastName>
<ForeName>Hans-Christian</ForeName>
<Initials>HC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Uehleke</LastName>
<ForeName>Bernhard</ForeName>
<Initials>B</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745881</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983777</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Can medical herbs stimulate regeneration or neuroprotection and treat neuropathic pain in chemotherapy-induced peripheral neuropathy?</ArticleTitle>
<Pagination>
<MedlinePgn>423713</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/423713</ELocationID>
<Abstract>
<AbstractText>Chemotherapy-induced neuropathy (CIPN) has a relevant impact on the quality of life of cancer patients. There are no curative conventional treatments, so further options have to be investigated. We conducted a systematic review in English and Chinese language databases to illuminate the role of medical herbs. 26 relevant studies on 5 single herbs, one extract, one receptor-agonist, and 8 combinations of herbs were identified focusing on the single herbs Acorus calamus rhizoma, Cannabis sativa fructus, Chamomilla matricaria, Ginkgo biloba, Salvia officinalis, Sweet bee venom, Fritillaria cirrhosae bulbus, and the herbal combinations Bu Yang Huan Wu, modified Bu Yang Huan Wu plus Liuwei Di Huang, modified Chai Hu Long Gu Mu Li Wan, Geranii herba plus Aconiti lateralis praeparata radix , Niu Che Sen Qi Wan (Goshajinkigan), Gui Zhi Jia Shu Fu Tang (Keishikajutsubuto), Huang Qi Wu Wu Tang (Ogikeishigomotsuto), and Shao Yao Gan Cao Tang (Shakuyakukanzoto). The knowledge of mechanism of action is still limited, the quality of clinical trials needs further improvement, and studies have not yielded enough evidence to establish a standard practice, but a lot of promising substances have been identified. While CIPN has multiple mechanisms of neuronal degeneration, a combination of herbs or substances might deal with multiple targets for the aim of neuroprotection or neuroregeneration in CIPN. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Schröder</LastName>
<ForeName>Sven</ForeName>
<Initials>S</Initials>
<Affiliation>HanseMerkur Center for Traditional Chinese Medicine at the University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany ; ICBAS, University of Porto, Rua de Jorge Viterbo Ferreira No. 228, 4050-313 Porto, Portugal.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Beckmann</LastName>
<ForeName>Kathrin</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Franconi</LastName>
<ForeName>Giovanna</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Meyer-Hamme</LastName>
<ForeName>Gesa</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Friedemann</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Greten</LastName>
<ForeName>Henry Johannes</ForeName>
<Initials>HJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rostock</LastName>
<ForeName>Matthias</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Efferth</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747437</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983778</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect of facial cosmetic acupuncture on facial elasticity: an open-label, single-arm pilot study.</ArticleTitle>
<Pagination>
<MedlinePgn>424313</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/424313</ELocationID>
<Abstract>
<AbstractText>Background. The use of acupuncture for cosmetic purposes has gained popularity worldwide. Facial cosmetic acupuncture (FCA) is applied to the head, face, and neck. However, little evidence supports the efficacy and safety of FCA. We hypothesized that FCA affects facial elasticity by restoring resting mimetic muscle tone through the insertion of needles into the muscles of the head, face, and neck. Methods. This open-label, single-arm pilot study was implemented at Kyung Hee University Hospital at Gangdong from August through September 2011. Participants were women aged 40 to 59 years with a Glogau photoaging scale III. Participants received five treatment sessions over three weeks. Participants were measured before and after FCA. The primary outcome was the Moire topography criteria. The secondary outcome was a patient-oriented self-assessment scale of facial elasticity. Results. Among 50 women screened, 28 were eligible and 27 completed the five FCA treatment sessions. A significant improvement after FCA treatment was evident according to mean change in Moire topography criteria (from 1.70 ± 0.724 to 2.26 ± 1.059, P &lt; 0.0001). The most common adverse event was mild bruising at the needle site. Conclusions. In this pilot study, FCA showed promising results as a therapy for facial elasticity. However, further large-scale trials with a controlled design and objective measurements are needed. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yun</LastName>
<ForeName>Younghee</ForeName>
<Initials>Y</Initials>
<Affiliation>Department of Dermatology of Korean Medicine, College of Korean Medicine, Kyung Hee University, No. 149 Sangil-dong, Gangdong-gu, Seoul 134-727, Republic of Korea.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Sehyun</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Minhee</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Kyuseok</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Jeong-Su</ForeName>
<Initials>JS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Choi</LastName>
<ForeName>Inhwa</ForeName>
<Initials>I</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745857</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983779</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Mechanisms of electroacupuncture-induced analgesia on neuropathic pain in animal model.</ArticleTitle>
<Pagination>
<MedlinePgn>436913</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/436913</ELocationID>
<Abstract>
<AbstractText>Neuropathic pain remains as one of the most difficult clinical pain syndromes to treat. Electroacupuncture (EA), involving endogenous opioids and neurotransmitters in the central nervous system (CNS), is reported to be clinically efficacious in various fields of pain. Although multiple experimental articles were conducted to assess the effect of EA-induced analgesia, no review has been published to assess the efficacy and clarify the mechanism of EA on neuropathic pain. To this aim, this study was firstly designed to evaluate the EA-induced analgesic effect on neuropathic pain and secondly to guide and help future efforts to advance the neuropathic pain treatment. For this purpose, articles referring to the analgesic effect of acupuncture on neuropathic pain and particularly the work performed in our own laboratory were analyzed. Based on the articles reviewed, the role of spinal opioidergic, adrenergic, serotonergic, cholinergic, and GABAergic receptors in the mechanism of EA-induced analgesia was studied. The results of this research demonstrate that μ and δ opioid receptors, α 2-adrenoreceptors, 5-HT1A and 5-HT3 serotonergic receptors, M1 muscarinic receptors, and GABAA and GABAB GABAergic receptors are involved in the mechanisms of EA-induced analgesia on neuropathic pain. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Woojin</ForeName>
<Initials>W</Initials>
<Affiliation>Department of East-West Medicine, Graduate School, Kyung Hee University, Seoul 130-701, Republic of Korea.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Sun Kwang</ForeName>
<Initials>SK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Min</LastName>
<ForeName>Byung-Il</ForeName>
<Initials>BI</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747484</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983780</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Expression of stem cell markers in primo vessel of rat.</ArticleTitle>
<Pagination>
<MedlinePgn>438079</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/438079</ELocationID>
<Abstract>
<AbstractText>Accumulating line of evidence support that adult tissues contain a rare population of pluripotent stem cells (PSCs), which differentiate into all types of cells in our body. Bonghan microcell (primo microcells (PMCs)) discovered in 1960s was reported to have a pluripotency like a stem cell in vivo as well as in vitro condition. Here, we describe the detailed morphology and molecular features of PMCs. PMCs reside in Bonghan duct (primo vessel (PV)) reported as a corresponding structure of acupuncture points and meridian system. We found that PMCs were frequently observed in the liver surface of the rat between 300 g and 400 g from April to June, suggesting that the their detection frequency depends on the weight, the season, and the organ of rat. As reported, PMCs freshly isolated from PVs were spherical ~1-2  μ m microsized cells. In contrast, a unique bithread or budding-shaped PMCs emerged during tissue culture around 8 days. RT-PCR analysis demonstrated that PVs-derived cells express the Oct4, the most important PSCs gene, in addition to several PSCs markers (Sox2, Stella, Rex1, and Klf4). Thus, we for the first time provide the evidence about Oct4-expressing stem-like characteristics for cells resident in PVs, a possible novel stem cell enriched niche. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Eun Seok</ForeName>
<Initials>ES</Initials>
<Affiliation>Department of Physiology, University of Ulsan College of Medicine, 88 43-Gil Olympic-Ro, Songpa-gu, Seoul 138-736, Republic of Korea.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Jeong Hoon</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Won Jin</ForeName>
<Initials>WJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Heo</LastName>
<ForeName>Jinbeom</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shin</LastName>
<ForeName>Dong Myung</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Leem</LastName>
<ForeName>Chae Hun</ForeName>
<Initials>CH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747494</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983781</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Mechanisms Underlying the Antiproliferative and Prodifferentiative Effects of Psoralen on Adult Neural Stem Cells via DNA Microarray.</ArticleTitle>
<Pagination>
<MedlinePgn>452948</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/452948</ELocationID>
<Abstract>
<AbstractText>Adult neural stem cells (NSCs) persist throughout life to replace mature cells that are lost during turnover, disease, or injury. The investigation of NSC creates novel treatments for central nervous system (CNS) injuries and neurodegenerative disorders. The plasticity and reparative potential of NSC are regulated by different factors, which are critical for neurological regenerative medicine research. We investigated the effects of Psoralen, which is the mature fruit of Psoralea corylifolia L., on NSC behaviors and the underlying mechanisms. The self-renewal and proliferation of NSC were examined. We detected neuron- and/or astrocyte-specific markers using immunofluorescence and Western blotting, which could evaluate NSC differentiation. Psoralen treatment significantly inhibited neurosphere formation in a dose-dependent manner. Psoralen treatment increased the expression of the astrocyte-specific marker but decreased neuron-specific marker expression. These results suggested that Psoralen was a differentiation inducer in astrocyte. Differential gene expression following Psoralen treatment was screened using DNA microarray and confirmed by quantitative real-time PCR. Our microarray study demonstrated that Psoralen could effectively regulate the specific gene expression profile of NSC. The genes involved in the classification of cellular differentiation, proliferation, and metabolism, the transcription factors belonging to Ets family, and the hedgehog pathway may be closely related to the regulation. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ning</LastName>
<ForeName>You</ForeName>
<Initials>Y</Initials>
<Affiliation>Institute of Integrated Traditional Chinese Medicine and Western Medicine, Huashan Hospital, Fudan University, Shanghai 200031, China.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Jian-Hua</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xia</LastName>
<ForeName>Shi-Jin</ForeName>
<Initials>SJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bian</LastName>
<ForeName>Qin</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Yang</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Xin-Min</ForeName>
<Initials>XM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dong</LastName>
<ForeName>Jing-Cheng</ForeName>
<Initials>JC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shen</LastName>
<ForeName>Zi-Yin</ForeName>
<Initials>ZY</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745865</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983782</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Hyperglycemia induces altered expressions of angiogenesis associated molecules in the trophoblast.</ArticleTitle>
<Pagination>
<MedlinePgn>457971</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/457971</ELocationID>
<Abstract>
<AbstractText>We previously reported that the increased level of perlecan with altered glycosaminoglycan (GAG) substitution was present in the placenta with gestational diabetes mellitus (GDM) and in the trophoblasts cultured under hyperglycemic condition. Trophoblast is the first cell lineage to differentiate, invasive, and migrate into the vessel tissues of placenta and fetal membrane during pregnancy. Therefore, active matrix remodeling and vessel formation must occur during placentation. In this study, we further investigated whether hyperglycemia-induced alterations of perlecan in the extracellular matrix (ECM) affect the proliferation and the expressions of angiogenesis-related growth factors and cytokines in the trophoblasts. 3A-Sub-E trophoblastic cells cultured in high glucose medium were conducted to mimic the hyperglycemic condition. Results showed that the hyperglycemia-induced GAG alterations in the cell surface perlecan as well as in the ECM indeed upregulated the expressions of IL-6, IL-8, and MCP-1 and the activities of MMP-2 and MMP-9 and downregulated the expressions of TIMP-2. A regulatory molecular mechanism of hyperglycemia-induced alterations of the cell surface proteoglycans and the ECM remodeling on the expressions of angiogenesis-related cytokines and growth factors in trophoblasts was proposed. This mechanism may contribute to the aberrant placental structure and the maternal and fetal complications during development. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chang</LastName>
<ForeName>Shu-Chun</ForeName>
<Initials>SC</Initials>
<Affiliation>Graduate Institute of Biomedical Materials and Tissue Engineering, College of Oral Medicine, Taipei Medical University, 250 Wu-Hsin Street, Taipei 110, Taiwan.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Vivian Yang</LastName>
<ForeName>Wei-Chung</ForeName>
<Initials>WC</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745874</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983783</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Antileishmanial Phenylpropanoids from the Leaves of Hyptis pectinata (L.) Poit.</ArticleTitle>
<Pagination>
<MedlinePgn>460613</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/460613</ELocationID>
<Abstract>
<AbstractText>Hyptis pectinata, popularly known in Brazil as "sambacaitá" or "canudinho," is an aromatic shrub largely grown in the northeast of Brazil. The leaves and bark are used in an infusion for the treatment of throat and skin inflammations, bacterial infections, pain, and cancer. Analogues of rosmarinic acid and flavonoids were obtained from the leaves of Hyptis pectinata and consisted of two new compounds, sambacaitaric acid (1) and 3-O-methyl-sambacaitaric acid (2), and nine known compounds, rosmarinic acid (3), 3-O-methyl-rosmarinic acid (4), ethyl caffeate (5), nepetoidin A (6), nepetoidin B (7), cirsiliol (8), circimaritin (9), 7-O-methylluteolin (10), and genkwanin (11). The structures of these compounds were determined by spectroscopic methods. Compounds 1-5, and 7 were evaluated in vitro against the promastigote form of L. braziliensis, and the ethanol extract. The hexane, ethyl acetate, and methanol-water fractions were also evaluated. The EtOH extract, the hexane extract, EtOAc, MeOH:H2O fractions; and compounds 1, 2 and 4 exhibited antileishmanial activity, and compound 1 was as potent as pentamidine. In contrast, compounds 3, 5, and 7 did not present activity against the promastigote form of L. braziliensis below 100 µM. To our knowledge, compounds 1 and 2 are being described for the first time. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Falcao</LastName>
<ForeName>Rosangela A</ForeName>
<Initials>RA</Initials>
<Affiliation>Laboratório de Bioprospecção Fitoquímica, Departamento de Ciências Moleculares, Universidade Federal Rural de Pernambuco, 52171-900 Recife, Pernambuco, Brazil.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>do Nascimento</LastName>
<ForeName>Patricia L A</ForeName>
<Initials>PL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>de Souza</LastName>
<ForeName>Silvana A</ForeName>
<Initials>SA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>da Silva</LastName>
<ForeName>Telma M G</ForeName>
<Initials>TM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>de Queiroz</LastName>
<ForeName>Aline C</ForeName>
<Initials>AC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>da Matta</LastName>
<ForeName>Carolina B B</ForeName>
<Initials>CB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moreira</LastName>
<ForeName>Magna S A</ForeName>
<Initials>MS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Camara</LastName>
<ForeName>Celso A</ForeName>
<Initials>CA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Silva</LastName>
<ForeName>Tania M S</ForeName>
<Initials>TM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745876</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983784</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>The Protective Effects of Cobra Venom from Naja naja atra on Acute and Chronic Nephropathy.</ArticleTitle>
<Pagination>
<MedlinePgn>478049</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/478049</ELocationID>
<Abstract>
<AbstractText>This study investigated the effects of Naja naja atra venom (NNAV) on acute and chronic nephropathy in rats. Rats received 6 mg/kg adriamycin (ADR) once to evoke the chronic nephropathy or 8 ml/kg 50% v/v glycerol to produce acute renal failure (ARF). The NNAV was given orally once a day starting five days prior to ADR or glycerol injection and continued to the end of experiments. The animals were placed in metabolic cages for 24 h for urine collection for urinary protein determination. The kidney function-related biochemical changes and index of oxidative stress were determined with automatic biochemistry analyzer or colorimetric enzyme assay kits. The pathomorphological changes were observed using light and transmission electron microcopies. The levels of inflammatory cytokines and NF- κ B activation were determined using ELISA kits, Western blot analysis, or immunofluorescence. The results showed that NNAV relieved ADR-induced chronic nephropathy and glycerol-triggered acute renal failure syndromes including proteinuria, hypoalbuminemia, hyperlipidemia, serum electrolyte unbalance, renal oxidative stress, and pathological damages. NNAV reduced kidney levels of TNF- α and IL-1 β , but it increased the levels of I κ B- α and inhibited NF- κ B p65 nuclear localization. These findings suggest that NNAV may be a valuable therapeutic drug for acute and chronic kidney diseases. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Shu-Zhi</ForeName>
<Initials>SZ</Initials>
<Affiliation>Department of Pharmacology and Laboratory of Aging and Nervous Diseases, Soochow University School of Pharmaceutical Science, 199 Ren Ai Road, Suzhou 215123, China.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>He</LastName>
<ForeName>He</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Han</LastName>
<ForeName>Rong</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>Jia-Li</ForeName>
<Initials>JL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kou</LastName>
<ForeName>Jian-Qun</ForeName>
<Initials>JQ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ding</LastName>
<ForeName>Xiao-Lan</ForeName>
<Initials>XL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Qin</LastName>
<ForeName>Zheng-Hong</ForeName>
<Initials>ZH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745861</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983785</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Effects of qigong exercise on fatigue, anxiety, and depressive symptoms of patients with chronic fatigue syndrome-like illness: a randomized controlled trial.</ArticleTitle>
<Pagination>
<MedlinePgn>485341</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/485341</ELocationID>
<Abstract>
<AbstractText>Background. Anxiety/depressive symptoms are common in patients with chronic fatigue syndrome- (CFS-) like illness. Qigong as a modality of complementary and alternative therapy has been increasingly applied by patients with chronic illnesses, but little is known about the effect of Qigong on anxiety/depressive symptoms of the patients with CFS-like illness. Purpose. To investigate the effects of Qigong on fatigue, anxiety, and depressive symptoms in patients with CFS-illness. Methods. One hundred and thirty-seven participants who met the diagnostic criteria for CFS-like illness were randomly assigned to either an intervention group or a waitlist control group. Participants in the intervention group received 10 sessions of Qigong training twice a week for 5 consecutive weeks, followed by home-based practice for 12 weeks. Fatigue, anxiety, and depressive symptoms were assessed at baseline and postintervention. Results. Total fatigue score [F(1,135) = 13.888, P &lt; 0.001], physical fatigue score [F(1,135) = 20.852, P &lt; 0.001] and depression score [F(1,135) = 9.918, P = 0.002] were significantly improved and mental fatigue score [F(1,135) = 3.902, P = 0.050] was marginally significantly improved in the Qigong group compared to controls. The anxiety score was not significantly improved in the Qigong group. Conclusion. Qigong may not only reduce the fatigue symptoms, but also has antidepressive effect for patients with CFS-like illness. Trial registration HKCTR-1200. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Chan</LastName>
<ForeName>Jessie S M</ForeName>
<Initials>JS</Initials>
<Affiliation>Centre on Behavioral Health, The University of Hong Kong, Hong Kong.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Ho</LastName>
<ForeName>Rainbow T H</ForeName>
<Initials>RT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Chong-Wen</ForeName>
<Initials>CW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yuen</LastName>
<ForeName>Lai Ping</ForeName>
<Initials>LP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sham</LastName>
<ForeName>Jonathan S T</ForeName>
<Initials>JS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chan</LastName>
<ForeName>Cecilia L W</ForeName>
<Initials>CL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747479</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983786</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Mindful walking in psychologically distressed individuals: a randomized controlled trial.</ArticleTitle>
<Pagination>
<MedlinePgn>489856</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/489856</ELocationID>
<Abstract>
<AbstractText>Background. The aim of this randomized, controlled study was to investigate the effectiveness of a mindful walking program in patients with high levels of perceived psychological distress. Methods. Participants aged between 18 and 65 years with moderate to high levels of perceived psychological distress were randomized to 8 sessions of mindful walking in 4 weeks (each 40 minutes walking, 10 minutes mindful walking, 10 minutes discussion) or to no study intervention (waiting group). Primary outcome parameter was the difference to baseline on Cohen's Perceived Stress Scale (CPSS) after 4 weeks between intervention and control. Results. Seventy-four participants were randomized in the study; 36 (32 female, 52.3 ± 8.6 years) were allocated to the intervention and 38 (35 female, 49.5 ± 8.8 years) to the control group. Adjusted CPSS differences after 4 weeks were -8.8 [95% CI: -10.8; -6.8] (mean 24.2 [22.2; 26.2]) in the intervention group and -1.0 [-2.9; 0.9] (mean 32.0 [30.1; 33.9]) in the control group, resulting in a highly significant group difference (P &lt; 0.001). Conclusion. Patients participating in a mindful walking program showed reduced psychological stress symptoms and improved quality of life compared to no study intervention. Further studies should include an active treatment group and a long-term follow-up. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Teut</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<Affiliation>Institute for Social Medicine, Epidemiology and Health Economics, Charité-Universtitätsmedizin Berlin, Luisenst ra β e 57, 10117 Berlin, Germany.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Roesner</LastName>
<ForeName>E J</ForeName>
<Initials>EJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ortiz</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Reese</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Binting</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Roll</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fischer</LastName>
<ForeName>H F</ForeName>
<Initials>HF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Michalsen</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Willich</LastName>
<ForeName>S N</ForeName>
<Initials>SN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brinkhaus</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747483</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983787</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Antiapoptotic Effects of EGb 761.</ArticleTitle>
<Pagination>
<MedlinePgn>495703</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/495703</ELocationID>
<Abstract>
<AbstractText>Ginkgo biloba extracts have long been used in Chinese traditional medicine for hundreds of years. The most significant extract obtained from Ginkgo biloba leaves has been EGb 761, a widely used phytopharmaceutical product in Europe. EGb 761 is a well-defined mixture of active compounds, which contains two main active substances: flavonoid glycosides (24-26%) and terpene lactones (6-8%). These compounds have shown antiapoptotic effects through the protection of mitochondrial membrane integrity, inhibition of mitochondrial cytochrome c release, enhancement of antiapoptotic protein transcription, and reduction of caspase transcription and DNA fragmentation. Other effects include the reduction of oxidative stress (which has been related to the occurrence of vascular, degenerative, and proliferative diseases), coupled to strong induction of phase II-detoxifying and cellular defense enzymes by Nrf2/ARE activation, in addition to the modulation of transcription factors, such as CREB, HIF-1 α , NF- κ B, AP-1, and p53, involved in the apoptosis process. This work reviews experimental results about the antiapoptotic effects induced by the standardized extract of Ginkgo biloba leaves (EGb 761). </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Serrano-García</LastName>
<ForeName>Norma</ForeName>
<Initials>N</Initials>
<Affiliation>Laboratorio de Neurobiología Molecular y Celular, INNN-UNAM, Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suárez", 14269 México, DF, Mexico.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Pedraza-Chaverri</LastName>
<ForeName>José</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mares-Sámano</LastName>
<ForeName>José Juan</ForeName>
<Initials>JJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Orozco-Ibarra</LastName>
<ForeName>Marisol</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cruz-Salgado</LastName>
<ForeName>Arturo</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jiménez-Anguiano</LastName>
<ForeName>Anabel</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sotelo</LastName>
<ForeName>Julio</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Trejo-Solís</LastName>
<ForeName>Cristina</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745884</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983788</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>A systematic review of experimental and clinical acupuncture in chemotherapy-induced peripheral neuropathy.</ArticleTitle>
<Pagination>
<MedlinePgn>516916</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/516916</ELocationID>
<Abstract>
<AbstractText>Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect that can be very disabling and can limit or delay the dose of chemotherapy that can be administered. Acupuncture may be effective for treating peripheral neuropathy. The aim of this study was to review the available literature on the use of acupuncture for CIPN. The systematic literature search was performed using MEDLINE, Google Scholar, Cochrane Database, CINHAL, and ISI Proceedings. Hand searching was conducted, and consensus was reached on all extracted data. Only papers in the English language were included, irrespective of study design. From 3989 retrieved papers, 8 relevant papers were identified. One was an experimental study which showed that electroacupuncture suppressed CIPN pain in rats. In addition, there were 7 very heterogeneous clinical studies, 1 controlled randomised study using auricular acupuncture, 2 randomized controlled studies using somatic acupuncture, and 3 case series/case reports which suggested a positive effect of acupuncture in CIPN. Conclusions. Only one controlled randomised study demonstrated that acupuncture may be beneficial for CIPN. All the clinical studies reviewed had important methodological limitations. Further studies with robust methodology are needed to demonstrate the role of acupuncture for treating CIPN resulting from cancer treatment. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Franconi</LastName>
<ForeName>Giovanna</ForeName>
<Initials>G</Initials>
<Affiliation>Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Manni</LastName>
<ForeName>Luigi</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schröder</LastName>
<ForeName>Sven</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Marchetti</LastName>
<ForeName>Paolo</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Robinson</LastName>
<ForeName>Nicola</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3741953</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983789</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Microarray analysis reveals the molecular basis of antiarthritic activity of huo-luo-xiao-ling dan.</ArticleTitle>
<Pagination>
<MedlinePgn>524746</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/524746</ELocationID>
<Abstract>
<AbstractText>Rheumatoid arthritis (RA) is a chronic inflammatory disease of autoimmune origin. Huo-luo-xiao-ling dan (HLXL) is an herbal mixture that has been used in traditional Chinese medicine over several decades to treat chronic inflammatory diseases including RA. However, the mechanism of the anti-arthritic action of this herbal remedy is poorly understood at the molecular level. In this study, we determined by microarray analysis the effects of HLXL on the global gene expression profile of the draining lymph node cells (LNC) in the rat adjuvant arthritis (AA) model of human RA. In LNC restimulated in vitro with the disease-related antigen mycobacterial heat-shock protein 65 (Bhsp65), 84 differentially expressed genes (DEG) (64 upregulated and 20 downregulated) versus 120 DEG (94 upregulated and 26 downregulated) were identified in HLXL-treated versus vehicle (Water)-treated rats, respectively, and 62 DEG (45 upregulated and 17 downregulated) were shared between the two groups. The most affected pathways in response to HLXL treatment included immune response, inflammation, cellular proliferation and apoptosis, and metabolic processes, many of which are directly relevant to arthritis pathogenesis. These results would advance our understanding of the mechanisms underlying the anti-arthritic activity of HLXL. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Hua</ForeName>
<Initials>H</Initials>
<Affiliation>Department of Microbiology and Immunology, University of Maryland School of Medicine, HSF-1, Suite 380, 685 West Baltimore Street, Baltimore, MD 21201, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>David Y-W</ForeName>
<Initials>DY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nanjundaiah</LastName>
<ForeName>Siddaraju M</ForeName>
<Initials>SM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Venkatesha</LastName>
<ForeName>Shivaprasad H</ForeName>
<Initials>SH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Berman</LastName>
<ForeName>Brian M</ForeName>
<Initials>BM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moudgil</LastName>
<ForeName>Kamal D</ForeName>
<Initials>KD</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745855</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983790</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Cartilage Protective and Chondrogenic Capacity of WIN-34B, a New Herbal Agent, in the Collagenase-Induced Osteoarthritis Rabbit Model and in Progenitor Cells from Subchondral Bone.</ArticleTitle>
<Pagination>
<MedlinePgn>527561</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/527561</ELocationID>
<Abstract>
<AbstractText>We sought to determine the cartilage repair capacity of WIN-34B in the collagenase-induced osteoarthritis rabbit model and in progenitor cells from subchondral bone. The cartilage protective effect of WIN-34B was measured by clinical and histological scores, cartilage area, and proteoglycan and collagen contents in the collagenase-induced osteoarthritis rabbit model. The efficacy of chondrogenic differentiation of WIN-34B was assessed by expression of CD105, CD73, type II collagen, and aggrecan in vivo and was analyzed by the surface markers of progenitor cells, the mRNA levels of chondrogenic marker genes, and the level of proteoglycan, GAG, and type II collagen in vitro. Oral administration of WIN-34B significantly increased cartilage area, and this was associated with the recovery of proteoglycan and collagen content. Moreover, WIN-34B at 200 mg/kg significantly increased the expression of CD105, CD73, type II collagen, and aggrecan compared to the vehicle group. WIN-34B markedly enhanced the chondrogenic differentiation of CD105 and type II collagen in the progenitor cells from subchondral bone. Also, we confirmed that treatment with WIN-34B strongly increased the number of SH-2(CD105) cells and expression type II collagen in subchondral progenitor cells. Moreover, WIN-34B significantly increased proteoglycan, as measured by alcian blue staining; the mRNA level of type II α 1 collagen, cartilage link protein, and aggrecan; and the inhibition of cartilage matrix molecules, such as GAG and type II collagen, in IL-1 β -treated progenitor cells. These findings suggest that WIN-34B could be a potential candidate for effective anti-osteoarthritic therapy with cartilage repair as well as cartilage protection via enhancement of chondrogenic differentiation in the collagenase-induced osteoarthritis rabbit model and progenitor cells from subchondral bone. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Huh</LastName>
<ForeName>Jeong-Eun</ForeName>
<Initials>JE</Initials>
<Affiliation>East-West Bone &amp; Joint Research Institute, Kyung Hee University, 149 Sangil-dong, Gangdong-gu, Seoul 134-727, Republic of Korea.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Yeon-Cheol</ForeName>
<Initials>YC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Seo</LastName>
<ForeName>Byung-Kwan</ForeName>
<Initials>BK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Jae-Dong</ForeName>
<Initials>JD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Baek</LastName>
<ForeName>Yong-Hyeon</ForeName>
<Initials>YH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Choi</LastName>
<ForeName>Do-Young</ForeName>
<Initials>DY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Dong-Suk</ForeName>
<Initials>DS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747396</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983791</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Naringenin inhibits adipogenesis and reduces insulin sensitivity and adiponectin expression in adipocytes.</ArticleTitle>
<Pagination>
<MedlinePgn>549750</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/549750</ELocationID>
<Abstract>
<AbstractText>Adipose tissue development and function are widely studied to examine the relationship between obesity and the metabolic syndrome. It is well documented that the inability of adipose tissue to properly increase its lipid storage capacity during the obese state can lead to metabolic dysfunction. In a blind screen of 425 botanicals, we identified naringenin as an inhibitor of adipocyte differentiation. Naringenin is one of the most abundant citrus flavonoids, and recent studies have demonstrated antihyperlipidemic capabilities. These studies have largely focused on the effects of naringenin on the liver. Our biochemical studies clearly demonstrate that naringenin inhibits adipogenesis and impairs mature fat cell function. Naringenin specifically inhibited adipogenesis in a dose-dependent fashion as judged by examining lipid accumulation and induction of adipocyte marker protein expression. In mature 3T3-L1 adipocytes, naringenin reduced the ability of insulin to induce IRS-1 tyrosine phosphorylation and substantially inhibited insulin-stimulated glucose uptake in a dose-dependent manner and over a time frame of 1.5 to 24 hours. Exposure to naringenin also inhibited adiponectin protein expression in mature murine and human adipocytes. Our studies have revealed that naringenin may have a negative impact on adipocyte-related diseases by limiting differentiation of preadipocytes, by significantly inducing insulin resistance, and by decreasing adiponectin expression in mature fat cells. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Richard</LastName>
<ForeName>Allison J</ForeName>
<Initials>AJ</Initials>
<Affiliation>Pennington Biomedical Research Center, Louisiana State University, 6400 Perkins Road, Baton Rouge, LA 70808, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Amini-Vaughan</LastName>
<ForeName>Zhaleh</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ribnicky</LastName>
<ForeName>David M</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stephens</LastName>
<ForeName>Jacqueline M</ForeName>
<Initials>JM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P50 AT002776</GrantID>
<Acronym>AT</Acronym>
<Agency>NCCAM NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745873</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983792</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Aconiti Lateralis Preparata Radix Activates the Proliferation of Mouse Bone Marrow Mesenchymal Stem Cells and Induces Osteogenic Lineage Differentiation through the Bone Morphogenetic Protein-2/Smad-Dependent Runx2 Pathway.</ArticleTitle>
<Pagination>
<MedlinePgn>586741</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/586741</ELocationID>
<Abstract>
<AbstractText>Mesenchymal stem cells have the capacity for self-renewal and under appropriate stimulation give rise to osteogenic, adipogenic, and chondrogenic lineages. To advance the clinical use of stem cell therapy, such as stem cell transplantation, it is important to find substances that promote endogenous stem cell proliferation and differentiation. We investigated whether medicinal herbs have the potential to promote stem cell proliferation and differentiation, using a cell cycle analysis and differentiation assay. We found that Aconiti Lateralis Preparata Radix (ALR) promoted the proliferation rate of mouse bone marrow mesenchymal stem cells (mBMMSCs) up to 122.24% compared to untreated cells. Fluorescence-activated cell sorter analysis showed that the percentage of cells in the G2/M phase increased to 17.33% in ALR-treated cells compared to 5.65% in normal cells. Signaling pathway analysis indicated that this was mediated through the extracellular signal-regulated kinase 1/2 pathway. A differentiation assay showed that ALR induced differentiation of mBMMSCs into an osteogenic lineage 2 weeks after treatment, whereas traditional osteogenic induction medium treatment did not promote differentiation for 3 weeks. This osteogenic differentiation was signaled by the bone morphogenetic protein-2/Smad-dependent Runx2 pathway. We found that ALR could promote mBMMSC proliferation and differentiation into the osteogenic lineage. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Do Rim</ForeName>
<Initials>do R</Initials>
<Affiliation>Department of Prescriptionology, College of Korean Medicine, Kyung Hee University, 26 Kyunghee Dae-ro, Dongdaemun-gu, Seoul 130-701, Republic of Korea.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Ha Young</ForeName>
<Initials>HY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Jae Kwang</ForeName>
<Initials>JK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Seong Kyu</ForeName>
<Initials>SK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chang</LastName>
<ForeName>Mun Seog</ForeName>
<Initials>MS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745886</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983793</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>50 years of bong-han theory and 10 years of primo vascular system.</ArticleTitle>
<Pagination>
<MedlinePgn>587827</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/587827</ELocationID>
<Abstract>
<AbstractText>The primo vascular system (PVS) was first introduced by Bong-Han Kim via his five research reports. Among these the third report was most extensive and conclusive in terms of the PVS anatomy and physiology relating to the acupuncture meridians. His study results, unfortunately, were not reproduced by other scientists because he did not describe the materials and methods in detail. In 2002, a research team in Seoul National University reinitiated the PVS research, confirmed the existence of PVS in various organs, and discovered new characteristics of PVS. Two important examples are as follows: PVS was found in the adipose tissue and around cancer tissues. In parallel to these new findings, new methods for observing and identifying PVS were developed. Studies on the cell and material content inside the PVS, including the immune function cells and stem cells, are being progressed. In this review, Bong-Han Kim's study results in his third report are summarized, and the new results after him are briefly reviewed. In the last section, the obstacles in finding the PVS in the skin as an anatomical structure of acupuncture meridian are discussed. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Soh</LastName>
<ForeName>Kwang-Sup</ForeName>
<Initials>KS</Initials>
<Affiliation>Nano Primo Research Center, Advanced Institute of Convergence Technology, Seoul National University, Suwon 443-270, Republic of Korea.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Kang</LastName>
<ForeName>Kyung A</ForeName>
<Initials>KA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ryu</LastName>
<ForeName>Yeon Hee</ForeName>
<Initials>YH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747427</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983794</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Deqi sensation in placebo acupuncture: a crossover study on chinese medicine students.</ArticleTitle>
<Pagination>
<MedlinePgn>620671</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/620671</ELocationID>
<Abstract>
<AbstractText>Objective. To evaluate the similarity of deqi sensation of real and noninvasive placebo acupuncture in healthy people with knowledge of Chinese medicine. Methods. In a crossover design, volunteers recruited from Chinese medicine college students were randomized to two groups to receive two phases of intervention with a one-week washout interval. In Group A, the participants were firstly treated by real acupuncture and then by sham needle, and the treatment sequence was reversed in Group B. VAS for pain intensity and deqi sensation was evaluated as outcomes. Results. Sixty-three volunteers were recruited and 60 were included and finished the study. In Group A, VAS was higher in Phase I than in Phase II (P = 0.017). Only treatment methods were selected as factor to VAS difference (P = 0.046) in ANOVA test. More positive deqi was reported in Group A in Phase I when treated by real acupuncture (P = 0.039), but the difference was not significant in Phase II (P = 0.301). Conclusion. The noninvasive placebo acupuncture device can effetely simulate the deqi sensation as real acupuncture, but it is less likely to evoke the active effect of deqi in real practice. This trial is registered with Chinese Clinical Trial Registry: ChiCTR-ORC-09000505. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Liang</LastName>
<ForeName>Zhao-Hui</ForeName>
<Initials>ZH</Initials>
<Affiliation>The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Xie</LastName>
<ForeName>Chang-Cai</ForeName>
<Initials>CC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Zi-Ping</ForeName>
<Initials>ZP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>Xiao-Ping</ForeName>
<Initials>XP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>Ai-Ping</ForeName>
<Initials>AP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fu</LastName>
<ForeName>Wen-Bin</ForeName>
<Initials>WB</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745883</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983795</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Spa treatment (balneotherapy) for fibromyalgia-a qualitative-narrative review and a historical perspective.</ArticleTitle>
<Pagination>
<MedlinePgn>638050</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/638050</ELocationID>
<Abstract>
<AbstractText>Aim. To perform a narrative review of spa therapy for management of the fibromyalgia syndrome (FMS), evaluating this traditional time-honored form of therapy in a historical perspective. Methods. Medline was searched using the terms "Spa therapy," "Balneotherapy," and "Fibromyalgia" between 1990 (year of ACR fibromyalgia criteria publication) and April 2013. The Cochrane database was also searched. Publications relating to the implementation of spa therapy and related practices over the centuries were identified through references, searched, and reviewed. Results. Reports of balneotherapy were described from diverse locations throughout Europe and Asia, and various forms of water-related therapy have been incorporated for many musculoskeletal indications. In the management of FMS, spa therapy has generally been shown to be well accepted and moderately effective for symptom reduction. Conclusion. While achieving high-quality evidence-based conclusions is difficult for complex natural therapies such as spa therapy, the existing evidence indicates a positive effect in management of FMS. In view of the long history of this modality in the management of rheumatic pain as well as the inherent difficulties related to pharmacological treatment, the role of spa therapy should currently be recognized as part of a therapeutic program for FMS. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ablin</LastName>
<ForeName>Jacob N</ForeName>
<Initials>JN</Initials>
<Affiliation>Institute of Rheumatology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, 6 Weizman Street, 64239 Tel Aviv, Israel.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Häuser</LastName>
<ForeName>Winfried</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Buskila</LastName>
<ForeName>Dan</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747489</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983796</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Add-on effect of chinese herbal medicine bath to phototherapy for psoriasis vulgaris: a systematic review.</ArticleTitle>
<Pagination>
<MedlinePgn>673078</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/673078</ELocationID>
<Abstract>
<AbstractText>Psoriasis vulgaris is the most common form of psoriasis. Phototherapy has been proven effective for psoriasis, but side effects have become a concern. Chinese herbal medicine (CHM) bath combined with phototherapy has been used in clinical settings, but the additional benefit requires evaluation. This review aims to evaluate the additional benefit and safety of adding CHM bath to phototherapy for psoriasis vulgaris. Cochrane library, PubMed, Embase, CNKI, and CQVIP were searched from their inceptions to 6 August 2012. Randomized controlled trials (RCTs) comparing CHM bath plus phototherapy to phototherapy alone for psoriasis vulgaris were included. Data was analyzed using Review Manager 5.1.0. Thirteen RCTs were included in the review, and eight were included in the meta-analysis. Meta-analysis showed higher efficacy of CHM bath plus phototherapy when compared with phototherapy alone in terms of PASI 60 (RR 1.25; 95% CI: 1.18-1.32). Mild adverse events were reported in ten studies, but these could be alleviated by reducing UV dosage or applying emollient. In conclusion, CHM bath appears to be a beneficial and safe adjunctive therapy to phototherapy for psoriasis vulgaris. However, these results should be interpreted with caution due to the low methodological quality of the included studies. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Jason Jingjie</ForeName>
<Initials>JJ</Initials>
<Affiliation>Department of Dermatology, The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou 510120, China.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Claire Shuiqing</ForeName>
<Initials>CS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Anthony Lin</ForeName>
<Initials>AL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>May</LastName>
<ForeName>Brian</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xue</LastName>
<ForeName>Charlie Changli</ForeName>
<Initials>CC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>Chuanjian</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745880</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983797</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Effects of hydrogen-rich saline on taurocholate-induced acute pancreatitis in rat.</ArticleTitle>
<Pagination>
<MedlinePgn>731932</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/731932</ELocationID>
<Abstract>
<AbstractText>Oxidative stress plays an important role in the pathogenesis of acute pancreatitis (AP). As an ideal exterminator of poisonous free radicals, hydrogen can clearly reduce the degree of oxidative damage caused by severe acute pancreatitis (SAP) and lessen the presence of inflammatory cytokines. The aim of this study was to investigate the effects and mechanism of hydrogen-rich saline on SAP in rats. Serum TNF- α , IL-6, and IL-18 and histopathological score in the pancreas were reduced after hydrogen-rich saline treatment. Malondialdehyde (MDA) and myeloperoxidase (MPO) contents were obviously reduced, while superoxide dismutase (SOD) and glutathione (GSH) contents were increased after hydrogen-rich saline treatment. The expression of mRNA of tumor necrosis factor- α (TNF- α ) and intercellular adhesion molecule-1 (ICAM-1) in the pancreas was reduced in hydrogen-rich saline treated group. In conclusion, intravenous hydrogen-rich saline injections could attenuate the severity of AP, probably via inhibiting the oxidative stress and reducing the presence of inflammatory mediators. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>De-Qing</ForeName>
<Initials>DQ</Initials>
<Affiliation>Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Feng</LastName>
<ForeName>Huang</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Wei-Chang</ForeName>
<Initials>WC</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745843</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983798</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Navigating traditional chinese medicine network pharmacology and computational tools.</ArticleTitle>
<Pagination>
<MedlinePgn>731969</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/731969</ELocationID>
<Abstract>
<AbstractText>The concept of "network target" has ushered in a new era in the field of traditional Chinese medicine (TCM). As a new research approach, network pharmacology is based on the analysis of network models and systems biology. Taking advantage of advancements in systems biology, a high degree of integration data analysis strategy and interpretable visualization provides deeper insights into the underlying mechanisms of TCM theories, including the principles of herb combination, biological foundations of herb or herbal formulae action, and molecular basis of TCM syndromes. In this study, we review several recent developments in TCM network pharmacology research and discuss their potential for bridging the gap between traditional and modern medicine. We briefly summarize the two main functional applications of TCM network models: understanding/uncovering and predicting/discovering. In particular, we focus on how TCM network pharmacology research is conducted and highlight different computational tools, such as network-based and machine learning algorithms, and sources that have been proposed and applied to the different steps involved in the research process. To make network pharmacology research commonplace, some basic network definitions and analysis methods are presented. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Ming</ForeName>
<Initials>M</Initials>
<Affiliation>Longhua Hospital Affiliated to Shanghai University of TCM, Shanghai 200032, China ; Institute of Digestive Disease, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Jia-Lei</ForeName>
<Initials>JL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Li-Wen</ForeName>
<Initials>LW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ji</LastName>
<ForeName>Guang</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747450</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983799</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>JNK1/2 Activation by an Extract from the Roots of Morus alba L. Reduces the Viability of Multidrug-Resistant MCF-7/Dox Cells by Inhibiting YB-1-Dependent MDR1 Expression.</ArticleTitle>
<Pagination>
<MedlinePgn>741985</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/741985</ELocationID>
<Abstract>
<AbstractText>Cancer cells acquire anticancer drug resistance during chemotherapy, which aggravates cancer disease. MDR1 encoded from multidrug resistance gene 1 mainly causes multidrug resistance phenotypes of different cancer cells. In this study, we demonstrate that JNK1/2 activation by an extract from the root of Morus alba L. (White mulberry) reduces doxorubicin-resistant MCF-7/Dox cell viability by inhibiting YB-1 regulation of MDR1 gene expression. When MCF-7 or MCF-7/Dox cells, where MDR1 is highly expressed were treated with an extract from roots or leaves of Morus alba L., respectively, the root extract from the mulberry (REM) but not the leaf extract (LEM) reduced cell viabilities of both MCF-7 and MCF-7/Dox cells, which was enhanced by cotreatment with doxorubicin. REM but not LEM further inhibited YB-1 nuclear translocation and its regulation of MDR1 gene expression. Moreover, REM promoted phosphorylation of c-Jun NH2-terminal kinase 1/2 (JNK1/2) and JNK1/2 inhibitor, SP600125 and rescued REM inhibition of both MDR1 expression and viabilities in MCF-7/Dox cells. Consistently, overexpression of JNK1, c-Jun, or c-Fos inhibited YB-1-dependent MDR1 expression and reduced viabilities in MCF-7/Dox cells. In conclusion, our data indicate that REM-activated JNK-cJun/c-Fos pathway decreases the viability of MCF-7/Dox cells by inhibiting YB-1-dependent MDR1 gene expression. Thus, we suggest that REM may be useful for treating multidrug-resistant cancer cells. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Choi</LastName>
<ForeName>Youn Kyung</ForeName>
<Initials>YK</Initials>
<Affiliation>Laboratory of Clinical Biology and Pharmacogenomics, Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, 1 Hoegi, Dongdaemun, Seoul 130-701, Republic of Korea.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Cho</LastName>
<ForeName>Sung-Gook</ForeName>
<Initials>SG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Choi</LastName>
<ForeName>Hyeong Sim</ForeName>
<Initials>HS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Woo</LastName>
<ForeName>Sang-Mi</ForeName>
<Initials>SM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yun</LastName>
<ForeName>Yee Jin</ForeName>
<Initials>YJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shin</LastName>
<ForeName>Yong Cheol</ForeName>
<Initials>YC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ko</LastName>
<ForeName>Seong-Gyu</ForeName>
<Initials>SG</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3741934</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983800</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Antimalarial Activity of Cocos nucifera Husk Fibre: Further Studies.</ArticleTitle>
<Pagination>
<MedlinePgn>742476</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/742476</ELocationID>
<Abstract>
<AbstractText>In this study, the antimalarial and toxicity potentials of husk fibre extracts of five Nigerian varieties of Cocos nucifera were evaluated in vitro. The only active extract fraction, West African Tall (WAT) ethyl acetate extract fraction, was then evaluated for its phytochemical constituents, antimalarial and toxicity potentials at varying doses (31.25-500 mg/kg body weight) using various organ function indices. The results revealed that WAT ethyl acetate extract fraction (WATEAEF) contained alkaloids, tannins, and flavonoids and was active against Plasmodium falciparum W2 strain maintained in continuous culture, with a selectivity index of 30.3. The same extract fraction was active in vivo against Plasmodium berghei NK65, causing more than 50% reduction in parasitaemia on days 4 and 6 after inoculation at various doses administered. WATEAEF did not significantly alter (P &gt; 0.05) function indices of the liver and cardiovascular system at all doses administered but significantly increased (P &lt; 0.05) plasma creatinine concentration at 250 and 500 mg/Kg body weight compared to controls. The results of this study suggest that WATEAEF possesses antimalarial activity and may not adversely affect normal liver function nor predispose subjects to cardiovascular diseases but may impair normal kidney function at higher doses. Further studies are underway to isolate the active principles. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Adebayo</LastName>
<ForeName>J O</ForeName>
<Initials>JO</Initials>
<Affiliation>Department of Biochemistry, University of Ilorin, Ilorin, Nigeria.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Balogun</LastName>
<ForeName>E A</ForeName>
<Initials>EA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Malomo</LastName>
<ForeName>S O</ForeName>
<Initials>SO</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Soladoye</LastName>
<ForeName>A O</ForeName>
<Initials>AO</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Olatunji</LastName>
<ForeName>L A</ForeName>
<Initials>LA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kolawole</LastName>
<ForeName>O M</ForeName>
<Initials>OM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Oguntoye</LastName>
<ForeName>O S</ForeName>
<Initials>OS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Babatunde</LastName>
<ForeName>A S</ForeName>
<Initials>AS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Akinola</LastName>
<ForeName>O B</ForeName>
<Initials>OB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Aguiar</LastName>
<ForeName>A C C</ForeName>
<Initials>AC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Andrade</LastName>
<ForeName>I M</ForeName>
<Initials>IM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Souza</LastName>
<ForeName>N B</ForeName>
<Initials>NB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Krettli</LastName>
<ForeName>A U</ForeName>
<Initials>AU</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745858</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983801</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Is deqi an indicator of clinical efficacy of acupuncture? A systematic review.</ArticleTitle>
<Pagination>
<MedlinePgn>750140</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/750140</ELocationID>
<Abstract>
<AbstractText>Objective. Despite the systematic literature review of the current evidence, we aim to answer the question " is Deqi an indicator of clinical effects in acupuncture treatment?" Methods. We systematically searched CNKI, VIP, Wanfang Data, PubMed, Embase, and the CENTRAL for three types of study: (1) empirical research probing into the role of Deqi in acupuncture; (2) mechanism studies examining the effect of Deqi on physiological parameters in animal models and human subjects; (3) clinical studies that compared the outcome of acupuncture with Deqi with that of acupuncture without Deqi. Two reviewers independently extracted data, undertook qualitative or quantitative analysis, and summarized findings. Results. The ancient Chinese acupuncturists valued the role of Deqi as a diagnostic tool, a prognosis predictor, and a necessary part of the therapeutic procedure. Findings from modern experimental research provided preliminary evidence for the physiological mechanism that produced Deqi. Few clinical studies generated conflicting evidence of the comparative effectiveness of acupuncture with Deqi versus acupuncture without Deqi for a variety of conditions. Conclusion. The current evidence base is not solid enough to draw any conclusion regarding the predicative value of natural Deqi for clinical efficacy or the therapeutic value of manipulation-facilitated Deqi. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Shuo</ForeName>
<Initials>S</Initials>
<Affiliation>Center for Evidence-Based Medicine, Tianjin University of Traditional Chinese Medicine, 312 Anshanxi Road, Nankai District, Tianjin 300193, China.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Mu</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xiao</LastName>
<ForeName>Lu</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zheng</LastName>
<ForeName>Wen-Ke</ForeName>
<Initials>WK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Chun-Xiang</ForeName>
<Initials>CX</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Li</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shang</LastName>
<ForeName>Hong-Cai</ForeName>
<Initials>HC</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747467</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983802</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Effects of deqi on autonomic balance in adult tinnitus patients: study design of a randomized controlled trial.</ArticleTitle>
<Pagination>
<MedlinePgn>756012</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/756012</ELocationID>
<Abstract>
<AbstractText>Background. Recent reports suggest that a proportion of tinnitus patients suffer from mental illness. Autonomic nervous system plays a useful role in tinnitus therapy since electrical vagal nerve stimulation (VNS) has been frequently used to alleviate tinnitus-induced depression in clinic. heart rate variability (HRV), which is reflective of autonomic nervous system function, has been proved to be modulated by acupuncture. In the present study, we aim to compare the effect of deqi sensation on heart rate variability in adult tinnitus patients. Methods. Thirty participants are randomly assigned to verum acupuncture (creating deqi) or shallow acupuncture (not creating deqi) at Baihui (Du-20), Shenting (Du-24), Tinghui (GB-2), Waiguan (SJ-5), and Zulinqi (GB-41) for 3 weeks. The primary outcome measure is heart rate variability, which is measured at the first acupuncture, as well as the last acupuncture. Discussion. Completion of this trial will help to identify the role of deqi sensation in acupuncture effect for tinnitus and reveal an autonomic modulation mechanism for acupuncture effect. Trial Registration. This trial is registered with International Standard Randomised Controlled Trial Number ISRCTN58013563. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Qian-Qian</ForeName>
<Initials>QQ</Initials>
<Affiliation>Acupuncture and Moxibustion Center, Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, 23 Meishuguanhou Street, Dongcheng District, Beijing 100010, China.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Shi</LastName>
<ForeName>Guang-Xia</ForeName>
<Initials>GX</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fu</LastName>
<ForeName>Xin-Xing</ForeName>
<Initials>XX</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Han</LastName>
<ForeName>Li-Li</ForeName>
<Initials>LL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Li-Ying</ForeName>
<Initials>LY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liu</LastName>
<ForeName>Cun-Zhi</ForeName>
<Initials>CZ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Lin-Peng</ForeName>
<Initials>LP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hou</LastName>
<ForeName>Na</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745851</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983803</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>The Effect of Sodium Tanshinone IIA Sulfate and Simvastatin on Elevated Serum Levels of Inflammatory Markers in Patients with Coronary Heart Disease: A Study Protocol for a Randomized Controlled Trial.</ArticleTitle>
<Pagination>
<MedlinePgn>756519</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/756519</ELocationID>
<Abstract>
<AbstractText Label="UNLABELLED">Background. Coronary heart disease (CHD) due to atherosclerotic inflammation remains a significant threat to global health despite the success of the lipid-lowering, anti-inflammatory statins. Tanshinone IIA, a potent anti-inflammatory compound derived from Traditional Chinese Medicine (TCM), may be able to supplement statins by further reducing levels of circulating inflammatory markers correlated to cardiovascular risk. Here, we present the protocol of a randomized controlled trial (RCT) that will investigate the synergistic effect of sodium tanshinone IIA sulfate and simvastatin on reducing elevated inflammatory markers in patients with CHD.</AbstractText>
<AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Seventy-two inpatients with confirmed CHD, elevated serum high-sensitivity C-reactive protein (Hs-CRP) level, and a TCM diagnosis of blood stasis syndrome will be enrolled and randomized 1 : 1 into the control or experimental group. Intervention. All subjects will receive a standard Western therapy including 20 mg simvastatin orally once per evening. Patients in the experimental group will additionally receive a daily 80 mg dose of sodium tanshinone IIA sulfate intravenously, diluted into 250 mL 0.9% NaCl solution. The treatment period will be 14 days. Outcomes. Primary outcome parameter: serum Hs-CRP level. Secondary outcome parameters: other circulating inflammatory markers (including IL-6, TNF α , VCAM-1, CD40, sCD40L, MCP-1, and MMP-9), improvement in symptoms of angina and blood stasis syndrome, and safety. This trial is registered with ChiCTR-TRC-12002361.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shang</LastName>
<ForeName>Qinghua</ForeName>
<Initials>Q</Initials>
<Affiliation>Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China ; Department of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Hanjay</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Siming</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Hao</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747599</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983804</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Long-term exercise and risk of metabolic and cardiac diseases: the erlangen fitness and prevention study.</ArticleTitle>
<Pagination>
<MedlinePgn>768431</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/768431</ELocationID>
<Abstract>
<AbstractText>In female subjects, ageing and the menopausal transition contribute to a rapid increase of metabolic and cardiac risk factors. Exercise may be an option to positively impact various risk factors prone to severe metabolic and cardiac diseases and events. This study was conducted to determine the long-term effect of a multipurpose exercise program on metabolic and cardiac risk scores in postmenopausal women. 137 osteopenic Caucasian females (55.4 ± 3.2 yrs), 1-8 years postmenopausal, were included in the study. Eighty-six subjects joined the exercise group (EG) and performed an intense multipurpose exercise program which was carefully supervised during the 12-year period, while 51 females maintained their habitual physical activity (CG). Main outcome measures were 10-year coronary heart disease risk (10 y CHD risk), metabolic syndrome Z-score (MetS Index), and 10-year myocardial infarction risk (10 y hard CHD risk). Significant between-group differences all in favor of the EG were determined for 10 y-CHD risk (EG: 2.65 ± 2.09% versus CG: 5.40 ± 3.30%; P = 0.001), MetS-Index (EG: -0.42 ± 1.03% versus CG: 1.61 ± 1.88; P = 0.001), and 10 y-hard-CHD risk (EG: 2.06 ± 1.17% versus CG: 3.26 ± 1.31%; P = 0.001). Although the nonrandomized design may prevent definite evidence, the intense multi-purpose exercise program determined the long-term efficacy and feasibility of an exercise program to significantly impact metabolic and cardiac risk scores in postmenopausal women. This trial is registered with ClinicalTrials.gov NCT01177761. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kemmler</LastName>
<ForeName>Wolfgang</ForeName>
<Initials>W</Initials>
<Affiliation>Institute of Medical Physics, University of Erlangen-Nuremberg, Henkestraße 91, 91052 Erlangen, Germany.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>von Stengel</LastName>
<ForeName>Simon</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bebenek</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kalender</LastName>
<ForeName>Willi A</ForeName>
<Initials>WA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745878</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983805</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Biofeedback therapy combined with traditional chinese medicine prescription improves the symptoms, surface myoelectricity, and anal canal pressure of the patients with spleen deficiency constipation.</ArticleTitle>
<Pagination>
<MedlinePgn>830714</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/830714</ELocationID>
<Abstract>
<AbstractText>In order to observe the clinical therapeutic effects of Yiqi Kaimi Prescription and biofeedback therapy on treating constipation with deficiency of spleen qi, the 30 cases in the control group were given oral administration of Yiqi Kaimi Prescription, in combination with anus-lifting exercise; the 30 cases in the treatment group were given biofeedback therapy on the basis of the afore mentioned methods for the control group. The TCM symptom scores and anorectal pressures before and after treatment were observed and evaluated. There were significant differences in TCM symptom scores, anorectal pressure, and clinical recovery rate before and after treatment. In the treatment group, the total recovery rate was 86.66%, while in the control group it was 50%; there were significant differences between the two groups (P &lt; 0.01). Yiqi Kaimi Prescription coupled with biofeedback therapy is clinically effective for treating constipation with deficiency of spleen qi, and thus this method is applicable for functional constipation with deficiency of spleen qi. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yao</LastName>
<ForeName>Yi-Bo</ForeName>
<Initials>YB</Initials>
<Affiliation>Department of Anorectal Surgery, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 725 South Wanping Road, Shanghai 200030, China.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Cao</LastName>
<ForeName>Yong-Qing</ForeName>
<Initials>YQ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Guo</LastName>
<ForeName>Xiu-Tian</ForeName>
<Initials>XT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yi</LastName>
<ForeName>Jin</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liang</LastName>
<ForeName>Hong-Tao</ForeName>
<Initials>HT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Chen</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>Jin-Gen</ForeName>
<Initials>JG</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745844</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983806</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Therapeutic Effect of the Tuber of Alisma orientale on Lipopolysaccharide-Induced Acute Lung Injury.</ArticleTitle>
<Pagination>
<MedlinePgn>863892</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/863892</ELocationID>
<Abstract>
<AbstractText>Although Alisma orientale, an ethnic herb, has been prescribed for treating various diseases in Asian traditional medicine, experimental evidence to support its therapeutic effects is lacking. Here, we sought to determine whether A. orientale has a therapeutic effect on acute lung injury (ALI). Ethanol extract of the tuber of A. orientale (EEAO) was prepared and fingerprinted by HPLC for its constituents. Mice received an intraperitoneal (i.p.) injection of lipopolysaccharide (LPS) for the induction of ALI. At 2 h after LPS treatment, mice received an intratracheal (i.t.) spraying of various amounts of EEAO to the lung. Bioluminescence imaging of transgenic NF- κ B/luciferase reporter mice shows that i.t. EEAO posttreatment suppressed lung inflammation. In similar experiments with C57BL/6 mice, EEAO posttreatment significantly improved lung inflammation, as assessed by H&amp;E staining of lung sections, counting of neutrophils in bronchoalveolar lavage fluid, and semiquantitative RT-PCR analyses of proinflammatory cytokines and Nrf2-dependent genes in the inflamed lungs. Furthermore, EEAO posttreatment enhanced the survival of mice that received a lethal dose of LPS. Together, our results provide evidence that A. orientale has a therapeutic effect on ALI induced by sepsis. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kim</LastName>
<ForeName>Kyun Ha</ForeName>
<Initials>KH</Initials>
<Affiliation>School of Korean Medicine, Pusan National University, Yangsan 626-870, Republic of Korea.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Kwun</LastName>
<ForeName>Min Jung</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Choi</LastName>
<ForeName>Jun-Yong</ForeName>
<Initials>JY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ahn</LastName>
<ForeName>Kyung-Seop</ForeName>
<Initials>KS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Oh</LastName>
<ForeName>Sei-Ryang</ForeName>
<Initials>SR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Yong Gyu</ForeName>
<Initials>YG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Christman</LastName>
<ForeName>John W</ForeName>
<Initials>JW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sadikot</LastName>
<ForeName>Ruxana T</ForeName>
<Initials>RT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Han</LastName>
<ForeName>Chang Woo</ForeName>
<Initials>CW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Joo</LastName>
<ForeName>Myungsoo</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745860</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983807</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1741-427X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Evidence-based complementary and alternative medicine : eCAM</Title>
<ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Electroacupuncture and rosiglitazone combined therapy as a means of treating insulin resistance and type 2 diabetes mellitus: a randomized controlled trial.</ArticleTitle>
<Pagination>
<MedlinePgn>969824</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/969824</ELocationID>
<Abstract>
<AbstractText>Aims. To evaluate the efficacy of rosiglitazone (TZD) and electroacupuncture (EA) combined therapy as a treatment for type 2 diabetes mellitus (T2DM) patients by randomized single-blind placebo controlled clinical trial. Methods. A total of 31 newly diagnostic T2DM patients, who fulfilled the study's eligibility criteria, were recruited. The individuals were randomly assigned into two groups, the control group (TZD, N = 15) and the experimental group (TZD + EA, N = 16). Changes in their plasma free fatty acid (FFA), glucose, and insulin levels, together with their homeostasis model assessment (HOMA) indices, were statistically compared before and after treatment. Hypoglycemic activity (%) was also compared between these two groups. Results. There was no significant difference in hypoglycemic activity between the TZD and TZD + EA group. The effectiveness of the combined therapy seems to derive from an improvement in insulin resistance and a significant lowering of the secreted insulin rather than the effect of TZD alone on T2DM. The combined treatment had no significant adverse effects. A lower plasma FFA concentration is likely to be the mechanism that causes this effect. Conclusion. This combined therapy seems to suppress endogenous insulin secretion by improving insulin resistance via a mechanism involving a reduction in plasma FFA. This trial is registered with ClinicalTrials.gov NCT01577095. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Rong-Tsung</ForeName>
<Initials>RT</Initials>
<Affiliation>Department of Internal Medicine and Emergency Medicine, Division of Endocrinology and Metabolism, Tungs' Taichung Metro Harbor Hospital, Taichung County, Taiwan.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Pai</LastName>
<ForeName>Huei-Chin</ForeName>
<Initials>HC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lee</LastName>
<ForeName>Yu-Chen</ForeName>
<Initials>YC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tzeng</LastName>
<ForeName>Chung-Yuh</ForeName>
<Initials>CY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chang</LastName>
<ForeName>Chin-Hsien</ForeName>
<Initials>CH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hung</LastName>
<ForeName>Pei-Hsiu</ForeName>
<Initials>PH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Ying-I</ForeName>
<Initials>YI</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hsu</LastName>
<ForeName>Tai-Hao</ForeName>
<Initials>TH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tsai</LastName>
<ForeName>Chin-Chun</ForeName>
<Initials>CC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lin</LastName>
<ForeName>Jaung-Geng</ForeName>
<Initials>JG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chang</LastName>
<ForeName>Shih-Liang</ForeName>
<Initials>SL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
<NlmUniqueID>101215021</NlmUniqueID>
<ISSNLinking>1741-427X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745852</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982571</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2151-8378</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2013 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Female pelvic medicine &amp; reconstructive surgery</Title>
<ISOAbbreviation>Female Pelvic Med Reconstr Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Informed consent.</ArticleTitle>
<Pagination>
<MedlinePgn>253</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/SPV.0b013e3182a474f0</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bent</LastName>
<ForeName>Alfred</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Editorial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Female Pelvic Med Reconstr Surg</MedlineTA>
<NlmUniqueID>101528690</NlmUniqueID>
<ISSNLinking>2151-8378</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Communication</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Informed Consent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Physician-Patient Relations</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Surgical Mesh</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982572</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2151-8378</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2013 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Female pelvic medicine &amp; reconstructive surgery</Title>
<ISOAbbreviation>Female Pelvic Med Reconstr Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>The role of smooth muscle cells in the pathophysiology of pelvic organ prolapse.</ArticleTitle>
<Pagination>
<MedlinePgn>254-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/SPV.0b013e31829ff74d</ELocationID>
<Abstract>
<AbstractText>Pelvic organ prolapse (POP) is a prevalent and disabling condition. The pathophysiology of prolapse is multifactorial, and no single mechanism adequately explains all aspects of its development. The pathophysiology of POP is complex and incompletely understood. Smooth muscle (SM), an integral part of the vaginal wall and endopelvic structures that support the pelvic viscera, has also been implicated in the pathophysiology of POP. In this article, we review the role of smooth muscle cells (SMC) in the pathophysiology of POP, also addressing the anatomy of SM in pelvic floor, morphometric analysis, biomechanical properties, and potential mechanisms. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mei</LastName>
<ForeName>Shanshan</ForeName>
<Initials>S</Initials>
<Affiliation>Department of Obstetrics and Gynecology, Guangzhou Women and Children's Medical Center, Guangzhou, China.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Ye</LastName>
<ForeName>Ming</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gil</LastName>
<ForeName>Laura</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Jianping</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Yanping</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Candiotti</LastName>
<ForeName>Keith</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takacs</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Female Pelvic Med Reconstr Surg</MedlineTA>
<NlmUniqueID>101528690</NlmUniqueID>
<ISSNLinking>2151-8378</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Biomechanical Phenomena</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myocytes, Smooth Muscle</DescriptorName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pelvic Floor</DescriptorName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pelvic Organ Prolapse</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="Y">physiopathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982573</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2151-8378</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2013 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Female pelvic medicine &amp; reconstructive surgery</Title>
<ISOAbbreviation>Female Pelvic Med Reconstr Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Outcomes of a comprehensive nonsurgical approach to pelvic floor rehabilitation for urinary symptoms, defecatory dysfunction, and pelvic pain.</ArticleTitle>
<Pagination>
<MedlinePgn>260-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/SPV.0b013e31829cbb9b</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The authors' intent was to determine the clinical efficacy of comprehensive pelvic floor rehabilitation among women with symptoms of pelvic floor dysfunction (PFD).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We performed a retrospective analysis of women referred to an academic female pelvic medicine and reconstructive surgery practice for PFD. Data were gathered from the records of 778 women referred for pelvic floor therapy for urinary, bowel, pelvic pain, and sexual symptoms over the course of 4 years.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients who completed at least 5 therapy sessions reported a mean symptom improvement of 80% in each of the 3 main categories analyzed, namely, urinary incontinence, defecatory dysfunction, and pelvic pain.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Comprehensive, nonoperative management of PFD including pelvic floor muscle training, biofeedback, electrogalvanic stimulation, constipation management, behavioral modification, incontinence devices, and pharmacotherapy including vaginal estrogen is effective in the treatment of women with PFD.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Starr</LastName>
<ForeName>Julie A</ForeName>
<Initials>JA</Initials>
<Affiliation>Department of Obstetrics, Gynecology, and Women's Health, University of Missouri School of Medicine, Columbia, MO, USA. starrja@health.missouri.edu</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Drobnis</LastName>
<ForeName>Erma Z</ForeName>
<Initials>EZ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lenger</LastName>
<ForeName>Stacy</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Parrot</LastName>
<ForeName>Jessica</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Barrier</LastName>
<ForeName>Breton</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Foster</LastName>
<ForeName>Raymond</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Female Pelvic Med Reconstr Surg</MedlineTA>
<NlmUniqueID>101528690</NlmUniqueID>
<ISSNLinking>2151-8378</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Estrogens</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Vaginal Creams, Foams, and Jellies</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Anal Canal</DescriptorName>
<QualifierName MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Biofeedback, Psychology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Constipation</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="N">rehabilitation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Counseling</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Electric Stimulation Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Electromyography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Estrogens</DescriptorName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Exercise Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fecal Incontinence</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="N">rehabilitation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Manometry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
<QualifierName MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pelvic Floor Disorders</DescriptorName>
<QualifierName MajorTopicYN="N">complications</QualifierName>
<QualifierName MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName MajorTopicYN="Y">rehabilitation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pelvic Pain</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="N">rehabilitation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Physical Examination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Self Report</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Urinary Incontinence</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="N">rehabilitation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vaginal Creams, Foams, and Jellies</DescriptorName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982574</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2151-8378</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2013 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Female pelvic medicine &amp; reconstructive surgery</Title>
<ISOAbbreviation>Female Pelvic Med Reconstr Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Robotic virtual reality simulation plus standard robotic orientation versus standard robotic orientation alone: a randomized controlled trial.</ArticleTitle>
<Pagination>
<MedlinePgn>266-70</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/SPV.0b013e3182a09101</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this study was to compare the effect of virtual reality simulation training plus robotic orientation versus robotic orientation alone on performance of surgical tasks using an inanimate model.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Surgical resident physicians were enrolled in this assessor-blinded randomized controlled trial. Residents were randomized to receive either (1) robotic virtual reality simulation training plus standard robotic orientation or (2) standard robotic orientation alone. Performance of surgical tasks was assessed at baseline and after the intervention. Nine of 33 modules from the da Vinci Skills Simulator were chosen. Experts in robotic surgery evaluated each resident's videotaped performance of the inanimate model using the Global Rating Scale (GRS) and Objective Structured Assessment of Technical Skills-modified for robotic-assisted surgery (rOSATS).</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Nine resident physicians were enrolled in the simulation group and 9 in the control group. As a whole, participants improved their total time, time to incision, and suture time from baseline to repeat testing on the inanimate model (P = 0.001, 0.003, &lt;0.001, respectively). Both groups improved their GRS and rOSATS scores significantly (both P &lt; 0.001); however, the GRS overall pass rate was higher in the simulation group compared with the control group (89% vs 44%, P = 0.066).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Standard robotic orientation and/or robotic virtual reality simulation improve surgical skills on an inanimate model, although this may be a function of the initial "practice" on the inanimate model and repeat testing of a known task. However, robotic virtual reality simulation training increases GRS pass rates consistent with improved robotic technical skills learned in a virtual reality environment.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Vaccaro</LastName>
<ForeName>Christine M</ForeName>
<Initials>CM</Initials>
<Affiliation>Division of Urogynecology and Pelvic Reconstructive Surgery, Madigan Healthcare System, Tacoma, WA, USA. vaccaro.christine@gmail.com</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Crisp</LastName>
<ForeName>Catrina C</ForeName>
<Initials>CC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fellner</LastName>
<ForeName>Angela N</ForeName>
<Initials>AN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jackson</LastName>
<ForeName>Christopher</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kleeman</LastName>
<ForeName>Steven D</ForeName>
<Initials>SD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pavelka</LastName>
<ForeName>James</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Comparative Study</PublicationType>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Female Pelvic Med Reconstr Surg</MedlineTA>
<NlmUniqueID>101528690</NlmUniqueID>
<ISSNLinking>2151-8378</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Clinical Competence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Computer Simulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">General Surgery</DescriptorName>
<QualifierName MajorTopicYN="N">education</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gynecology</DescriptorName>
<QualifierName MajorTopicYN="N">education</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Internship and Residency</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Laparoscopy</DescriptorName>
<QualifierName MajorTopicYN="Y">education</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Learning Curve</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Obstetrics</DescriptorName>
<QualifierName MajorTopicYN="N">education</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Operative Time</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Robotics</DescriptorName>
<QualifierName MajorTopicYN="Y">education</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Video Recording</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982575</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2151-8378</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2013 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Female pelvic medicine &amp; reconstructive surgery</Title>
<ISOAbbreviation>Female Pelvic Med Reconstr Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Impact of physical therapy on quality of life and function after vaginal reconstructive surgery.</ArticleTitle>
<Pagination>
<MedlinePgn>271-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/SPV.0b013e31829c64ea</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Although pelvic floor physical therapy (PFPT) can be beneficial for complaints after vaginal reconstructive surgery, it is not routinely offered to all patients. We sought to evaluate the role of perioperative PFPT in improving quality of life and function after prolapse repairs.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">This randomized controlled trial compared PFPT to standard care after vaginal reconstructive surgery. The intervention group received PFPT 2 weeks preoperatively and 2, 4, 6, 8, and 12 weeks postoperatively, as well as a physician assessment. Control subjects underwent a physician's assessment alone at the same time points postoperatively. Both groups completed pelvic organ prolapse quantification examinations, intravaginal electromyography (EMG), voiding diaries, and validated questionnaires at baseline and 12 weeks. The primary outcome was change in the World Health Organization Quality of Life-BREF scale after surgery.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty-nine women completed the study: 24 women in the PFPT group and 25 women in the control group. At 12 weeks, condition-specific questionnaires improved for the entire sample, confirming effectiveness of surgery. Nevertheless, no significant differences were noted between the groups despite therapy with PFPT. However, intravaginal EMG measures were notably affected by the intervention. The PFPT group showed significantly lower averages across all measurements of rest, indicating positive impact on muscle function. Pearson correlations revealed associations with better scores on the World Health Organization Quality of Life-BREF physical domain and greater EMG relaxation, supporting effects from PFPT on quality of life.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Pelvic symptoms improved in all subjects after vaginal reconstructive surgery. Whereas PFPT did not result in detectable subjective differences in this short-term study, superior muscular function suggested benefit from the intervention.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pauls</LastName>
<ForeName>Rachel N</ForeName>
<Initials>RN</Initials>
<Affiliation>Department of Obstetrics and Gynecology, TriHealth Good Samaritan Hospital, Cincinnati, OH, USA. Rachel_Pauls@trihealth.com</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Crisp</LastName>
<ForeName>Catrina C</ForeName>
<Initials>CC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Novicki</LastName>
<ForeName>Kathleen</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fellner</LastName>
<ForeName>Angela N</ForeName>
<Initials>AN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kleeman</LastName>
<ForeName>Steven D</ForeName>
<Initials>SD</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Female Pelvic Med Reconstr Surg</MedlineTA>
<NlmUniqueID>101528690</NlmUniqueID>
<ISSNLinking>2151-8378</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Electromyography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Exercise Therapy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Muscle Relaxation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Patient Education as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pelvic Organ Prolapse</DescriptorName>
<QualifierName MajorTopicYN="N">complications</QualifierName>
<QualifierName MajorTopicYN="Y">rehabilitation</QualifierName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pelvic Pain</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Quality of Life</DescriptorName>
<QualifierName MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rest</DescriptorName>
<QualifierName MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sexual Behavior</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vagina</DescriptorName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982576</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2151-8378</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2013 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Female pelvic medicine &amp; reconstructive surgery</Title>
<ISOAbbreviation>Female Pelvic Med Reconstr Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Apical descent in the office and the operating room: the effect of prolapse size.</ArticleTitle>
<Pagination>
<MedlinePgn>278-81</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/SPV.0b013e31829c6365</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The support of the uterine cervix with Valsalva or cough assessed in the clinic and the support of the uterine cervix with traction in the operating room often differs. The objectives of this study were to test the null hypothesis that the difference between preoperative and intraoperative values of pelvic organ prolapse quantification (POP-Q) point C is not related to prolapse size and to determine if other factors exist that predict this difference.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">This is a retrospective review of women who had a vaginal hysterectomy in the Female Pelvic Medicine and Reconstructive Surgery division between 2005 and 2011 and had preoperative and intraoperative POP-Q point C recorded. A difference of 5 cm was established by a panel of urogynecologists as clinically significant. Student t tests and χ analyses were used and a logistic regression performed.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 206 subjects included. The mean difference in point C between the 2 clinical settings was 3.5 cm. A difference of 5 cm or greater was present in 33%. The mean difference in point C was larger for women with lesser stages of prolapse (stage 1, 5.8 cm; stage 2, 3.0 cm; stage 3/4, 1.4 cm; P&lt;0.001). A difference of 5 cm or greater in point C was more often present in women with lesser stages of prolapse: 70.3% of women with stage 1 prolapse, 9.3% of women with stage 2 prolapse, and 8.5% of women with stage 3 prolapse (P&lt;0.001).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We reject our null hypothesis. A difference of 5 cm or greater between POP-Q point C in the clinic and the POP-Q point C in the operating room occurred more frequently in women with lesser stages of prolapse.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Crosby</LastName>
<ForeName>Erin C</ForeName>
<Initials>EC</Initials>
<Affiliation>Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA. ecrosby@med.umich.edu</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Sharp</LastName>
<ForeName>Kristen M</ForeName>
<Initials>KM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gasperut</LastName>
<ForeName>Adrian</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Delancey</LastName>
<ForeName>John O L</ForeName>
<Initials>JO</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morgan</LastName>
<ForeName>Daniel M</ForeName>
<Initials>DM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Female Pelvic Med Reconstr Surg</MedlineTA>
<NlmUniqueID>101528690</NlmUniqueID>
<ISSNLinking>2151-8378</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Anatomic Landmarks</DescriptorName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cough</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hysterectomy, Vaginal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Operating Rooms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pelvic Organ Prolapse</DescriptorName>
<QualifierName MajorTopicYN="Y">pathology</QualifierName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Physicians' Offices</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Severity of Illness Index</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Traction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Valsalva Maneuver</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982577</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2151-8378</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2013 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Female pelvic medicine &amp; reconstructive surgery</Title>
<ISOAbbreviation>Female Pelvic Med Reconstr Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Defining patients' knowledge and perceptions of vaginal mesh surgery.</ArticleTitle>
<Pagination>
<MedlinePgn>282-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/SPV.0b013e31829ff765</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Given recent government investigations and media coverage of the controversy regarding mesh surgery, we sought to define patients' knowledge and perceptions of vaginal mesh surgery.</AbstractText>
<AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">An anonymous survey was distributed to a convenience sample of new patients at urogynecology and female urology clinics at a single medical center during April to June 2012. The survey assessed patients' demographics, information sources, and beliefs and concerns regarding mesh surgery. The Fisher's exact test was used to identify predictors of patients' beliefs regarding mesh. Logistic and linear regressions were used to identify predictors of aversion to surgery and higher concern regarding future surgery.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred sixty-four women completed the survey; 62.2% (102/164) indicated knowledge of mesh surgery for prolapse and/or incontinence and were included in subsequent analyses. The mean ± SD age was 58.0 ± 12.5 years, and 24.5% reported prior mesh surgery. The most common information source was television commercials (57.8%); only 23.5% of the women reported receiving information from a medical professional. Participants indicated the following regarding vaginal mesh: class-action lawsuit in progress (55/102 [54.0%]), causes pain (47/102 [47.1%]), possibility of rejection (35/102 [34.3%]), can cause bleeding and become exposed vaginally (30/102 [29.4%]), and should be removed owing to recall (28/102 [27.5%]). Of these women, 22.1% (19/86) indicated they would not consider mesh surgery. On multivariable logistic regression, level of concern, information from friends/family, and knowledge of class-action lawsuit predicted aversion to mesh surgery.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Nearly two thirds of new patients had knowledge of vaginal mesh surgery. We identified considerable misinformation and aversion to future mesh surgery among these women.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Brown</LastName>
<ForeName>Lindsay K</ForeName>
<Initials>LK</Initials>
<Affiliation>Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Fenner</LastName>
<ForeName>Dee E</ForeName>
<Initials>DE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Berger</LastName>
<ForeName>Mitchell B</ForeName>
<Initials>MB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Delancey</LastName>
<ForeName>John O L</ForeName>
<Initials>JO</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morgan</LastName>
<ForeName>Daniel M</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Patel</LastName>
<ForeName>Divya A</ForeName>
<Initials>DA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schimpf</LastName>
<ForeName>Megan O</ForeName>
<Initials>MO</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Female Pelvic Med Reconstr Surg</MedlineTA>
<NlmUniqueID>101528690</NlmUniqueID>
<ISSNLinking>2151-8378</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Communication</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Health Knowledge, Attitudes, Practice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Information Seeking Behavior</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Jurisprudence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pain</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Patient Acceptance of Health Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pelvic Organ Prolapse</DescriptorName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prosthesis Failure</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Surgical Mesh</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Television</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Urinary Incontinence, Stress</DescriptorName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vagina</DescriptorName>
<QualifierName MajorTopicYN="Y">surgery</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982578</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2151-8378</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2013 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Female pelvic medicine &amp; reconstructive surgery</Title>
<ISOAbbreviation>Female Pelvic Med Reconstr Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Botulinum toxin type A (BOTOX) for refractory myofascial pelvic pain.</ArticleTitle>
<Pagination>
<MedlinePgn>288-92</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/SPV.0b013e3182989fd8</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess intralevator botulinum toxin type A (Botox) injections for refractory myofascial pelvic pain with short tight pelvic floor.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective cohort study of all women with intralevator Botox injection (100-300 Units) from 2005 through 2010 for refractory myofascial pelvic pain. Primary outcomes were self-reported pain on palpation and symptom improvement. Secondary outcomes included postinjection complications and a second injection. Pain was assessed during digital palpation of the pelvic floor muscles using a scale of 0 to 10, with 10 being the worst possible pain. Follow-up occurred at less than 6 weeks after injection and again at 6 weeks or more. Data are presented as median (interquartile range) or proportion.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-one patients met eligibility criteria; 2 patients were lostto follow-up and excluded. The median age was 55.0 years (38.0-62.0 years). Before Botox injection, the median pain score was 9.5 (8.0-10.0). Twenty-nine patients (93.5%) returned for the first follow-up visit; 79.3% reported improvement in pain, whereas 20.7% reported no improvement. The median pain with levator palpation was significantly lower than before injection (P&lt;0.0001). Eighteen women (58.0%) had a second follow-up visit with a median pain score that remained lower than before injection (P&lt;0.0001). Fifteen (51.7%) women elected to have a second Botox injection; the median time to the second injection was 4.0 months (3.0-7.0 months). Three (10.3%) women developed de novo urinary retention, 2 patients (6.9%) reported fecal incontinence, and 3 patients (10.3%) reported constipation and/or rectal pain; all adverse effects resolved spontaneously.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Intralevator injection of Botox demonstrates effectiveness in women with refractory myofascial pelvic pain with few self-limiting adverse effects.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Adelowo</LastName>
<ForeName>Amos</ForeName>
<Initials>A</Initials>
<Affiliation>Division of Urogynecology, Mount Auburn Hospital, Cambridge, MA, USA. aadelowo@mah.harvard.edu</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Hacker</LastName>
<ForeName>Michele R</ForeName>
<Initials>MR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shapiro</LastName>
<ForeName>Alex</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Modest</LastName>
<ForeName>Anna Merport</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Elkadry</LastName>
<ForeName>Eman</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>8UL1TR000170-05</GrantID>
<Acronym>TR</Acronym>
<Agency>NCATS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>UL1 TR000170</GrantID>
<Acronym>TR</Acronym>
<Agency>NCATS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Female Pelvic Med Reconstr Surg</MedlineTA>
<NlmUniqueID>101528690</NlmUniqueID>
<ISSNLinking>2151-8378</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Neuromuscular Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>onabotulinumtoxinA</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.69</RegistryNumber>
<NameOfSubstance>Botulinum Toxins, Type A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Botulinum Toxins, Type A</DescriptorName>
<QualifierName MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Constipation</DescriptorName>
<QualifierName MajorTopicYN="N">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fecal Incontinence</DescriptorName>
<QualifierName MajorTopicYN="N">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Injections, Intramuscular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Myofascial Pain Syndromes</DescriptorName>
<QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Neuromuscular Agents</DescriptorName>
<QualifierName MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pain Measurement</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pain, Intractable</DescriptorName>
<QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pelvic Pain</DescriptorName>
<QualifierName MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Urinary Retention</DescriptorName>
<QualifierName MajorTopicYN="N">chemically induced</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS485470 [Available on 09/01/14]</OtherID>
<OtherID Source="NLM">PMC3757523 [Available on 09/01/14]</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982579</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2151-8378</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2013 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Female pelvic medicine &amp; reconstructive surgery</Title>
<ISOAbbreviation>Female Pelvic Med Reconstr Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Readability of common health-related quality-of-life instruments in female pelvic medicine.</ArticleTitle>
<Pagination>
<MedlinePgn>293-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/SPV.0b013e31828ab3e2</ELocationID>
<Abstract>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The average American adult reads below the eighth-grade level. To determine whether self-reported health-related quality-of-life questionnaires used for pelvic floor disorders are appropriate for American women, we measured reading levels of questionnaires for urinary incontinence (UI), pelvic organ prolapse (POP), and fecal incontinence (FI).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">An online literature search identified questionnaires addressing UI, POP, and FI. Readability was assessed using Flesch-Kincaid reading level and ease formulas. Flesch-Kincaid grade level indicates the average grade one is expected to completely and lucidly comprehend the written text. Flesch-Kincaid reading ease score, from 0 to 100, indicates how easy the written text can be read.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Questionnaires were categorized by UI, POP, FI, and combined pelvic floor symptoms. The median Flesch-Kincaid reading level was 7.2, 10.1, 7.6, and 9.7, for UI, POP, FI, and combined pelvic floor symptoms, respectively. Reading levels varied greatly between questionnaires, with only 54% of questionnaires written below the eighth-grade level.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We identified significant variation in reading levels among the questionnaires and found the 2 most commonly used questionnaires per survey in 2008 at Society of Urodynamics and Female Pelvic Medicine and Urogenital Reconstruction were above the recommended eighth-grade reading level. As specialty societies focus on standardizing questionnaires for research, reading levels should be considered so they are generalizable to larger populations of women with pelvic floor disorders.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Alas</LastName>
<ForeName>Alexandriah N</ForeName>
<Initials>AN</Initials>
<Affiliation>Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Beverly Hills, CA, USA. angerj@cshs.org</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Bergman</LastName>
<ForeName>Jonathan</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dunivan</LastName>
<ForeName>Gena C</ForeName>
<Initials>GC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rashid</LastName>
<ForeName>Rezoana</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morrisroe</LastName>
<ForeName>Shelby N</ForeName>
<Initials>SN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rogers</LastName>
<ForeName>Rebecca G</ForeName>
<Initials>RG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Anger</LastName>
<ForeName>Jennifer T</ForeName>
<Initials>JT</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>1 K23 DK080227-01</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Female Pelvic Med Reconstr Surg</MedlineTA>
<NlmUniqueID>101528690</NlmUniqueID>
<ISSNLinking>2151-8378</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Comprehension</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Educational Status</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fecal Incontinence</DescriptorName>
<QualifierName MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pelvic Floor Disorders</DescriptorName>
<QualifierName MajorTopicYN="Y">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pelvic Organ Prolapse</DescriptorName>
<QualifierName MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Quality of Life</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Questionnaires</DescriptorName>
<QualifierName MajorTopicYN="Y">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Urinary Incontinence</DescriptorName>
<QualifierName MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982580</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2151-8378</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2013 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Female pelvic medicine &amp; reconstructive surgery</Title>
<ISOAbbreviation>Female Pelvic Med Reconstr Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Rectal mesh erosion after robotic sacrocolpopexy.</ArticleTitle>
<Pagination>
<MedlinePgn>298-300</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/SPV.0b013e31823d29ca</ELocationID>
<Abstract>
<AbstractText>We report an unusual case of rectal mesh erosion presenting 16 months after robotic sacrocolpopexy. The patient initially underwent a robotic sacrocolpopexy, lysis of adhesions, midurethral sling, and posterior colporrhaphy for symptomatic grade 2 pelvic organ prolapse and urodynamic stress incontinence. Her postoperative recovery was uneventful. Sixteen months later, an anterior 2 × 2-cm rectal mesh erosion was noted on the colonoscopy performed when she presented with hematochezia. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hirai</LastName>
<ForeName>Cori-Ann</ForeName>
<Initials>CA</Initials>
<Affiliation>Department of Obstetrics &amp; Gynecology, University of Hawaii, Honolulu, HI, USA. cmhirai@gmail.com</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Bohrer</LastName>
<ForeName>Justin C</ForeName>
<Initials>JC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ruel</LastName>
<ForeName>Matthew</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Minaglia</LastName>
<ForeName>Steven M</ForeName>
<Initials>SM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Case Reports</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Female Pelvic Med Reconstr Surg</MedlineTA>
<NlmUniqueID>101528690</NlmUniqueID>
<ISSNLinking>2151-8378</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Colonoscopy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pelvic Organ Prolapse</DescriptorName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prosthesis Failure</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Rectal Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sacrum</DescriptorName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Surgical Mesh</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Urinary Incontinence, Stress</DescriptorName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vagina</DescriptorName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982581</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2151-8378</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2013 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Female pelvic medicine &amp; reconstructive surgery</Title>
<ISOAbbreviation>Female Pelvic Med Reconstr Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Erosion of pelvicol used in sacrocolpopexy.</ArticleTitle>
<Pagination>
<MedlinePgn>301-2</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/SPV.0b013e3182a116c0</ELocationID>
<Abstract>
<AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Biologic graft materials are used more frequently in pelvic reconstructive surgeries. We describe here the complete process of removal of such a biologic graft in the office.</AbstractText>
<AbstractText Label="CASE" NlmCategory="METHODS">We report a case of a 69-year-old woman with pig dermal graft erosion 1 year after placement. The patient presented with complaints of vaginal discharge. Upon examination, the graft material was seen eroding through the vaginal apex. The pig tissue was removed whole and intact in the office without complications.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Transvaginal removal of pig tissue in the office relieved the patient's symptoms.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mukati</LastName>
<ForeName>Marium S</ForeName>
<Initials>MS</Initials>
<Affiliation>Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Shobeiri</LastName>
<ForeName>S Abbas</ForeName>
<Initials>SA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Case Reports</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Female Pelvic Med Reconstr Surg</MedlineTA>
<NlmUniqueID>101528690</NlmUniqueID>
<ISSNLinking>2151-8378</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>9007-34-5</RegistryNumber>
<NameOfSubstance>Collagen</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Bioprosthesis</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Collagen</DescriptorName>
<QualifierName MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prosthesis Failure</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sacrum</DescriptorName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vagina</DescriptorName>
<QualifierName MajorTopicYN="Y">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vaginal Discharge</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982582</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2151-8378</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2013 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Female pelvic medicine &amp; reconstructive surgery</Title>
<ISOAbbreviation>Female Pelvic Med Reconstr Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Surgically shortened vagina lengthened by laparoscopic Davydov procedure.</ArticleTitle>
<Pagination>
<MedlinePgn>303-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/SPV.0b013e3182a11ae8</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The laparoscopic Davydov procedure is a neovagina surgical technique most commonly used in patients with vaginal agenesis. We present a unique case of vaginal length restoration using this procedure in a patient with vaginal shortening after multiple vaginal surgeries.</AbstractText>
<AbstractText Label="CASE" NlmCategory="METHODS">A 62-year-old patient presented to our office after multiple vaginal surgeries with symptoms suggestive of cystocele, rectocele, vaginal vault prolapse, and dyspareunia. Excessive vaginal shortening and a painful vaginal apex were also noted upon initial examination. A laparoscopic Davydov procedure was performed to lengthen the vagina and to eliminate the apical pain.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The laparoscopic Davydov procedure is a surgical option for patients with surgically shortened vaginas and dyspareunia.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Moriarty</LastName>
<ForeName>Christopher R</ForeName>
<Initials>CR</Initials>
<Affiliation>Atlanta Urogynecology Associates, Atlanta, GA, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Miklos</LastName>
<ForeName>John R</ForeName>
<Initials>JR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moore</LastName>
<ForeName>Robert D</ForeName>
<Initials>RD</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Case Reports</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Female Pelvic Med Reconstr Surg</MedlineTA>
<NlmUniqueID>101528690</NlmUniqueID>
<ISSNLinking>2151-8378</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Constriction, Pathologic</DescriptorName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dyspareunia</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
<QualifierName MajorTopicYN="Y">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gynecologic Surgical Procedures</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Laparoscopy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Reoperation</DescriptorName>
<QualifierName MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vagina</DescriptorName>
<QualifierName MajorTopicYN="Y">pathology</QualifierName>
<QualifierName MajorTopicYN="Y">surgery</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982583</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2151-8378</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2013 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Female pelvic medicine &amp; reconstructive surgery</Title>
<ISOAbbreviation>Female Pelvic Med Reconstr Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Unique complication of a Shirodkar cerclage: remote formation of a vesicocervical fistula in a patient with the history of cervical cerclage placement: a case report and literature review.</ArticleTitle>
<Pagination>
<MedlinePgn>306-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/SPV.0b013e3182996cee</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cervical cerclage placement is an accepted treatment for cervical insufficiency and recurrent second-trimester pregnancy loss. The most commonly described complications of cerclage include rupture of fetal membranes, intra-amniotic infection, endometritis, and peripartum bleeding. We present a unique case of a vesicocervical fistula formation remote from cerclage placement.</AbstractText>
<AbstractText Label="CASE" NlmCategory="METHODS">A vesicocervical fistula was diagnosed in a 51-year-old patient who presented with a chief complaint of vaginal bleeding. The fistula was found on cystoscopic examination after the extrusion, from the cervix, of Mersilene tape from a Shirodkar cerclage placed 13 years earlier for management of cervical insufficiency.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although the presented condition was managed conservatively, one should discuss remote formation of urogenital fistulae as a rare complication of cervical cerclage at the time of informed consent.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Madueke-Laveaux</LastName>
<ForeName>Obianuju Sandra</ForeName>
<Initials>OS</Initials>
<Affiliation>Department of Obstetrics and Gynecology, Geisinger Medical Center, Danville, PA, USA. somadueke@gmail.com</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Platte</LastName>
<ForeName>Raisa</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Poplawsky</LastName>
<ForeName>Deborah</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Case Reports</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Female Pelvic Med Reconstr Surg</MedlineTA>
<NlmUniqueID>101528690</NlmUniqueID>
<ISSNLinking>2151-8378</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cerclage, Cervical</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Fistula</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sutures</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Urinary Bladder Fistula</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Uterine Cervical Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
<QualifierName MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982584</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2151-8378</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2013 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Female pelvic medicine &amp; reconstructive surgery</Title>
<ISOAbbreviation>Female Pelvic Med Reconstr Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Mesh extrusion through the internal cervical os: an unusual complication following laparoscopic sacrocervicopexy.</ArticleTitle>
<Pagination>
<MedlinePgn>309-11</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/SPV.0b013e318292eb6d</ELocationID>
<Abstract>
<AbstractText>Mesh extrusion or exposure is a known complication of procedures using synthetic mesh for vaginal vault and pelvic organ suspension. Preservation of the uterine cervix is thought to be protective against such complications, as the well-vascularized in situ cervix provides an added barrier between the mesh and the colpotomy incision, limiting potential exposure to the vaginal flora. We describe a case of a 55-year-old multipara, who presented with vaginal discharge following a supracervical hysterectomy with sacrocervicopexy and was found to have a delayed mesh extrusion though the endocervical os. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Moulder</LastName>
<ForeName>Janelle K</ForeName>
<Initials>JK</Initials>
<Affiliation>Department of Obstetrics, Brigham and Women's Hospital, Boston, MA, USA. janelle.moulder@gmail.com</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Cohen</LastName>
<ForeName>Sarah L</ForeName>
<Initials>SL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morse</LastName>
<ForeName>Abraham N</ForeName>
<Initials>AN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Einarsson</LastName>
<ForeName>Jon I</ForeName>
<Initials>JI</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Case Reports</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Female Pelvic Med Reconstr Surg</MedlineTA>
<NlmUniqueID>101528690</NlmUniqueID>
<ISSNLinking>2151-8378</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cervix Uteri</DescriptorName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Pelvic Organ Prolapse</DescriptorName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Prosthesis Failure</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Sacrum</DescriptorName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Surgical Mesh</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Uterine Cervical Diseases</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vaginal Discharge</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982585</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2151-8378</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>19</Volume>
<Issue>5</Issue>
<PubDate>
<MedlineDate>2013 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Female pelvic medicine &amp; reconstructive surgery</Title>
<ISOAbbreviation>Female Pelvic Med Reconstr Surg</ISOAbbreviation>
</Journal>
<ArticleTitle>Labial fusion causing recurrent cyst formation and a novel approach to surgical management.</ArticleTitle>
<Pagination>
<MedlinePgn>312-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/SPV.0b013e318292460e</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Labial fusion may occur as a result of lichen sclerosus, lichen planus, genital mutilation, obstetric laceration, and atrophic vaginitis. Koebner phenomenon, or reformation of scar tissue over the clitoris after trauma to the involved tissue, may confound attempts at surgical management.</AbstractText>
<AbstractText Label="CASE" NlmCategory="METHODS">A 22-year-old nulligravid patient presented with labia minora fusion that had been present since childhood. Her most bothersome symptoms were the recurrence of periclitoral pseudocysts with pain and discharge after spontaneous or needle drainage. Her symptoms and examination findings persisted despite a prolonged course of topical clobetasol, and she desired surgical intervention. A silastic vessel loop was placed through the tract between her clitoris and fused overlying labia. The ends of the vessel loop were brought together and tied in a fashion similar to cutting setons used to manage complex anal fistulae. Over the subsequent weeks, additional ties were used to sequentially tighten the loop and gradually divide the fused labia, ultimately exposing the patient's normal clitoris, which was uninjured by the procedure. Topical clobetasol was used throughout the process to prevent reagglutination of the labia.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our experience suggests that adaptation of a cutting seton may be used effectively in the surgical management of labial fusion to allow for gradual division of the skin bridge while minimizing the risk of recurrence of agglutination.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Selco</LastName>
<ForeName>Mitchell M</ForeName>
<Initials>MM</Initials>
<Affiliation>College of Osteopathic Medicine, Touro University, Vallejo, CA, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Doss</LastName>
<ForeName>Roderick H</ForeName>
<Initials>RH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gruber</LastName>
<ForeName>Daniel D</ForeName>
<Initials>DD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shippey</LastName>
<ForeName>Stuart H</ForeName>
<Initials>SH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Case Reports</PublicationType>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Female Pelvic Med Reconstr Surg</MedlineTA>
<NlmUniqueID>101528690</NlmUniqueID>
<ISSNLinking>2151-8378</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cysts</DescriptorName>
<QualifierName MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Gynecologic Surgical Procedures</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Recurrence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vulvar Diseases</DescriptorName>
<QualifierName MajorTopicYN="N">complications</QualifierName>
<QualifierName MajorTopicYN="Y">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983674</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1664-462X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Frontiers in plant science</Title>
<ISOAbbreviation>Front Plant Sci</ISOAbbreviation>
</Journal>
<ArticleTitle>The effects of rising atmospheric carbon dioxide on shoot-root nitrogen and water signaling.</ArticleTitle>
<Pagination>
<MedlinePgn>304</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3389/fpls.2013.00304</ELocationID>
<Abstract>
<AbstractText>Terrestrial higher plants are composed of roots and shoots, distinct organs that conduct complementary functions in dissimilar environments. For example, roots are responsible for acquiring water and nutrients such as inorganic nitrogen from the soil, yet shoots consume the majority of these resources. The success of such a relationship depends on excellent root-shoot communications. Increased net photosynthesis and decreased shoot nitrogen and water use at elevated CO2 fundamentally alter these source-sink relations. Lower than predicted productivity gains at elevated CO2 under nitrogen or water stress may indicate shoot-root signaling lacks plasticity to respond to rising atmospheric CO2 concentrations. The following presents recent research results on shoot-root nitrogen and water signaling, emphasizing the influence that rising atmospheric carbon dioxide levels are having on these source-sink interactions. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Easlon</LastName>
<ForeName>Hsien Ming</ForeName>
<Initials>HM</Initials>
<Affiliation>Department of Plant Sciences, University of California at Davis Davis, CA, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Bloom</LastName>
<ForeName>Arnold J</ForeName>
<Initials>AJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Switzerland</Country>
<MedlineTA>Front Plant Sci</MedlineTA>
<NlmUniqueID>101568200</NlmUniqueID>
<ISSNLinking>1664-462X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3739423</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">carbon dioxide</Keyword>
<Keyword MajorTopicYN="N">chilling</Keyword>
<Keyword MajorTopicYN="N">drought</Keyword>
<Keyword MajorTopicYN="N">nitrate assimilation</Keyword>
<Keyword MajorTopicYN="N">nitrogen</Keyword>
<Keyword MajorTopicYN="N">salinity</Keyword>
<Keyword MajorTopicYN="N">water</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983650</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1554-7914</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>9</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Gastroenterology &amp; hepatology</Title>
<ISOAbbreviation>Gastroenterol Hepatol  (N Y)</ISOAbbreviation>
</Journal>
<ArticleTitle>Letter from the editor.</ArticleTitle>
<Pagination>
<MedlinePgn>67</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lichtenstein</LastName>
<ForeName>Gary R</ForeName>
<Initials>GR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Gastroenterol Hepatol  (N Y)</MedlineTA>
<NlmUniqueID>101262648</NlmUniqueID>
<ISSNLinking>1554-7914</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3754773</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983651</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1554-7914</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>9</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Gastroenterology &amp; hepatology</Title>
<ISOAbbreviation>Gastroenterol Hepatol  (N Y)</ISOAbbreviation>
</Journal>
<ArticleTitle>Gastro-hep news.</ArticleTitle>
<Pagination>
<MedlinePgn>76-7</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Rapposelli</LastName>
<ForeName>Dee</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Gastroenterol Hepatol  (N Y)</MedlineTA>
<NlmUniqueID>101262648</NlmUniqueID>
<ISSNLinking>1554-7914</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3754774</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983652</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1554-7914</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>9</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Gastroenterology &amp; hepatology</Title>
<ISOAbbreviation>Gastroenterol Hepatol  (N Y)</ISOAbbreviation>
</Journal>
<ArticleTitle>What role does wheat play in the symptoms of irritable bowel syndrome?</ArticleTitle>
<Pagination>
<MedlinePgn>85-91</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Recently, increasing attention has been paid to the pathologic role of food in irritable bowel syndrome (IBS). Nevertheless, healthcare providers often avoid addressing diet with their patients because of a lack of training, guideline consensus, and high-quality data. Recent literature supports the existence of a subgroup of IBS patients with undiagnosed nonceliac gluten sensitivity (NCGS), a term that is used to describe individuals who experience gastrointestinal and extraintestinal symptoms as a result of immunologic, morphologic, or symptomatic abnormalities that are precipitated by the ingestion of gluten. NCGS represents an important subgroup of patients with IBS who are highly treatable via dietary modification. Gluten may influence gastrointestinal symptoms through immune activation or alteration of intestinal permeability, but the true role of food in functional gastrointestinal symptomatology remains unclear. For example, gluten is just 1 component of the complex milieu of nutrients found in wheat and related grains, and NCGS likely represents only the tip of the iceberg as it pertains to the role of food in IBS. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Eswaran</LastName>
<ForeName>Shanti</ForeName>
<Initials>S</Initials>
<Affiliation>Dr. Eswaran is a Clinical Lecturer at the University of Michigan Health System in Ann Arbor, Michigan. Dr. Goel is a Resident Physician in the Department of Internal Medicine at New York-Presbyterian Hospital, Columbia University in New York, New York. Dr. Chey is a Professor of Medicine, Director of the GI Physiology Laboratory, Co-Director of the Michigan Bowel Control Program, and H. Marvin Pollard Institute Scholar, all at the University of Michigan Health System in Ann Arbor, Michigan.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Goel</LastName>
<ForeName>Akash</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chey</LastName>
<ForeName>William D</ForeName>
<Initials>WD</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Gastroenterol Hepatol  (N Y)</MedlineTA>
<NlmUniqueID>101262648</NlmUniqueID>
<ISSNLinking>1554-7914</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3754775</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Celiac disease</Keyword>
<Keyword MajorTopicYN="N">food</Keyword>
<Keyword MajorTopicYN="N">gluten sensitivity</Keyword>
<Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword>
<Keyword MajorTopicYN="N">wheat intolerance</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983653</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1554-7914</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>9</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Gastroenterology &amp; hepatology</Title>
<ISOAbbreviation>Gastroenterol Hepatol  (N Y)</ISOAbbreviation>
</Journal>
<ArticleTitle>The potential applications of capsule endoscopy in pediatric patients compared with adult patients.</ArticleTitle>
<Pagination>
<MedlinePgn>92-7</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Capsule endoscopy (CE) avoids the ionizing radiation, deep sedation, and general anesthesia required by other imaging modalities, making it particularly valuable in the evaluation of gastrointestinal disease in pediatric patients. In examining the use of CE in pediatric and adult patients through a review of the literature, it was observed that CE is most frequently indicated for the evaluation of Crohn's disease (CD) in pediatric patients and most frequently indicated for obscure gastrointestinal bleeding (OGIB) in adults, although OGIB is a more frequent indication than CD in pediatric patients younger than 8 years of age. Diagnostic accuracy has been good and comparable to that of magnetic resonance enterography, and capsule retention rates as well as other adverse events appear to be low in pediatric patients. Research is needed to explore broader indications and applications of CE in the diagnosis and monitoring of gastrointestinal disease. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Cohen</LastName>
<ForeName>Stanley A</ForeName>
<Initials>SA</Initials>
<Affiliation>Dr. Cohen is an Adjunct Clinical Professor of Pediatrics at Emory University School of Medicine in Atlanta, Georgia, and Director of IBD Research at the Children's Center for Digestive Health Care in Atlanta, Georgia.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Gastroenterol Hepatol  (N Y)</MedlineTA>
<NlmUniqueID>101262648</NlmUniqueID>
<ISSNLinking>1554-7914</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3754776</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Capsule endoscopy</Keyword>
<Keyword MajorTopicYN="N">Crohn’s disease</Keyword>
<Keyword MajorTopicYN="N">esophageal capsule endoscopy</Keyword>
<Keyword MajorTopicYN="N">obscure gastrointestinal bleeding</Keyword>
<Keyword MajorTopicYN="N">patency capsule</Keyword>
<Keyword MajorTopicYN="N">pediatric gastrointestinal disease</Keyword>
<Keyword MajorTopicYN="N">small bowel follow-through</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983654</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1554-7914</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>9</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Gastroenterology &amp; hepatology</Title>
<ISOAbbreviation>Gastroenterol Hepatol  (N Y)</ISOAbbreviation>
</Journal>
<ArticleTitle>Endotherapy for organized pancreatic necrosis.</ArticleTitle>
<Pagination>
<MedlinePgn>98-127</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kozarek</LastName>
<ForeName>Richard</ForeName>
<Initials>R</Initials>
<Affiliation>Executive Director, Digestive Disease Institute Virginia Mason Medical Center Seattle, Washington.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Gastroenterol Hepatol  (N Y)</MedlineTA>
<NlmUniqueID>101262648</NlmUniqueID>
<ISSNLinking>1554-7914</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3754777</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983655</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1554-7914</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>9</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Gastroenterology &amp; hepatology</Title>
<ISOAbbreviation>Gastroenterol Hepatol  (N Y)</ISOAbbreviation>
</Journal>
<ArticleTitle>Measuring structural damage in Crohn's disease.</ArticleTitle>
<Pagination>
<MedlinePgn>103-4</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Cosnes</LastName>
<ForeName>Jacques</ForeName>
<Initials>J</Initials>
<Affiliation>Chief, Service Hépato-Gastroentérologie et Nutrition Hôpital Saint Antoine Paris, France.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Gastroenterol Hepatol  (N Y)</MedlineTA>
<NlmUniqueID>101262648</NlmUniqueID>
<ISSNLinking>1554-7914</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3754768</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983656</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1554-7914</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>9</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Gastroenterology &amp; hepatology</Title>
<ISOAbbreviation>Gastroenterol Hepatol  (N Y)</ISOAbbreviation>
</Journal>
<ArticleTitle>Early recognition of alpha-1 antitrypsin deficiency and considerations for liver transplantation.</ArticleTitle>
<Pagination>
<MedlinePgn>110-2</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tzakis</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
<Affiliation>Director Transplant Center Cleveland Clinic Florida Weston, Florida.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Gastroenterol Hepatol  (N Y)</MedlineTA>
<NlmUniqueID>101262648</NlmUniqueID>
<ISSNLinking>1554-7914</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3754769</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983657</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1554-7914</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>9</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Gastroenterology &amp; hepatology</Title>
<ISOAbbreviation>Gastroenterol Hepatol  (N Y)</ISOAbbreviation>
</Journal>
<ArticleTitle>New tests for the evaluation of laryngopharyngeal reflux.</ArticleTitle>
<Pagination>
<MedlinePgn>115-7</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Vaezi</LastName>
<ForeName>Michael F</ForeName>
<Initials>MF</Initials>
<Affiliation>Clinical Director, Division of Gastroenterology, Hepatology, and Nutrition Director, Center for Swallowing and Esophageal Disorders Professor of Medicine Vanderbilt University Medical Center Nashville, Tennessee.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Gastroenterol Hepatol  (N Y)</MedlineTA>
<NlmUniqueID>101262648</NlmUniqueID>
<ISSNLinking>1554-7914</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3754770</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983658</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1554-7914</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>9</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Gastroenterology &amp; hepatology</Title>
<ISOAbbreviation>Gastroenterol Hepatol  (N Y)</ISOAbbreviation>
</Journal>
<ArticleTitle>A rare case of acute hepatitis B virus infection causing guillain-barré syndrome.</ArticleTitle>
<Pagination>
<MedlinePgn>121-3</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yimam</LastName>
<ForeName>Kidist K</ForeName>
<Initials>KK</Initials>
<Affiliation>Division of Gastroenterology, California Pacific Medical Center, San Francisco, California;</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Merriman</LastName>
<ForeName>Raphael B</ForeName>
<Initials>RB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Todd Frederick</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Gastroenterol Hepatol  (N Y)</MedlineTA>
<NlmUniqueID>101262648</NlmUniqueID>
<ISSNLinking>1554-7914</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3754771</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983659</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1554-7914</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>9</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Gastroenterology &amp; hepatology</Title>
<ISOAbbreviation>Gastroenterol Hepatol  (N Y)</ISOAbbreviation>
</Journal>
<ArticleTitle>Extrahepatic manifestations of acute hepatitis B virus infection.</ArticleTitle>
<Pagination>
<MedlinePgn>123-6</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kappus</LastName>
<ForeName>Matthew R</ForeName>
<Initials>MR</Initials>
<Affiliation>Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University, Richmond, Virginia.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Sterling</LastName>
<ForeName>Richard K</ForeName>
<Initials>RK</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Gastroenterol Hepatol  (N Y)</MedlineTA>
<NlmUniqueID>101262648</NlmUniqueID>
<ISSNLinking>1554-7914</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3754772</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983680</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1687-6121</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Gastroenterology research and practice</Title>
<ISOAbbreviation>Gastroenterol Res Pract</ISOAbbreviation>
</Journal>
<ArticleTitle>Helicobacter pylori-Induced Chronic Gastritis and Assessing Risks for Gastric Cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>393015</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/393015</ELocationID>
<Abstract>
<AbstractText>Chronic gastritis is an inflammation of the gastric mucosa and has multiple etiologies. Here we discuss the pathological alterations induced by Helicobacter pylori (HP) leading to chronic gastritis and the epigenetic bases underlying these changes. We review the histology of the normal gastric mucosa and overview the role of HP in the multistep cascade of GC. We attempt to define the role of the Operative Link for Gastritis Assessment (OLGA) staging system in assessing the risk of GC. The epigenetic bases of chronic gastritis, mainly DNA methylation, are presented through examples such as (i) the methylation of the promoter region of E-cadherin in HP-induced chronic gastritis and its reversion after HP eradication and (ii) the association of methylation of the promoter region of Reprimo, a p53-mediated cell cycle arrest gene, with aggressive HP strains in high risk areas for GC. In addition, we discuss the finding of RPRM as a circulating cell-free DNA, offering the opportunity for noninvasive risk assessment of GC. Finally, the integration of OLGA and tissue biomarkers, by systems pathology approach, suggests that severe atrophy has a greater risk for GC development if, in addition, overexpressed p73. This trial is registered with ClinicalTrials.gov NCT01774266. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Carrasco</LastName>
<ForeName>Gonzalo</ForeName>
<Initials>G</Initials>
<Affiliation>Department of Pathology, Mount Sinai School of Medicine, 1425 Madison Ave, New York, NY 10029, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Corvalan</LastName>
<ForeName>Alejandro H</ForeName>
<Initials>AH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>Gastroenterol Res Pract</MedlineTA>
<NlmUniqueID>101475557</NlmUniqueID>
<ISSNLinking>1687-6121</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745848</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983681</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1687-6121</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Gastroenterology research and practice</Title>
<ISOAbbreviation>Gastroenterol Res Pract</ISOAbbreviation>
</Journal>
<ArticleTitle>Helicobacter pylori Infection and Upper Gastrointestinal Disorders.</ArticleTitle>
<Pagination>
<MedlinePgn>896209</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/896209</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kate</LastName>
<ForeName>Vikram</ForeName>
<Initials>V</Initials>
<Affiliation>Department of General and Gastrointestinal Surgery, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry 605006, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Maroju</LastName>
<ForeName>Nanda K</ForeName>
<Initials>NK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ananthakrishnan</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>Gastroenterol Res Pract</MedlineTA>
<NlmUniqueID>101475557</NlmUniqueID>
<ISSNLinking>1687-6121</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745847</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23321956</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>09</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1555-8932</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>8</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Genes &amp; nutrition</Title>
<ISOAbbreviation>Genes Nutr</ISOAbbreviation>
</Journal>
<ArticleTitle>Longevity in the red flour beetle Tribolium castaneum is enhanced by broccoli and depends on nrf-2, jnk-1 and foxo-1 homologous genes.</ArticleTitle>
<Pagination>
<MedlinePgn>439-48</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s12263-012-0330-6</ELocationID>
<Abstract>
<AbstractText>Diet is generally believed to affect the aging process. The effects of complex foods on life span can be investigated using simple models that produce rapid results and allow the identification of food-gene interactions. Here, we show that 1 % lyophilized broccoli, added to flour as a dietary source, significantly increases the life span of the red flour beetle (Tribolium castaneum) under physiological conditions (32 °C) and under heat stress (42 °C). The beneficial effects of broccoli could also be reproduced by supplementing flour with the isothiocyanate sulforaphane at concentrations found in the broccoli-supplemented diet. We identified stress-resistant genes responsible for these effects on longevity by microinjecting pupae with double-stranded RNA to induce RNA interference (RNAi). The knockdown of transcripts encoding homologs of Nrf-2, Jnk-1 and Foxo-1 reduced the life span of beetles and abrogated the beneficial effects of broccoli, whereas the knockdown of Sirt-1 and Sirt-3 had no impact in either scenario. In conclusion, T. castaneum is a suitable model organism to investigate food-gene interactions that affect stress resistance and longevity, and RNAi can be used to identify functionally relevant genes. As a proof of principle, we have shown here that broccoli increases the longevity of beetles and mediates its effect through signaling pathways that include key stress-resistant factors such as Nrf-2, Jnk-1 and Foxo-1. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Grünwald</LastName>
<ForeName>Stefanie</ForeName>
<Initials>S</Initials>
<Affiliation>Molecular Nutrition Research, Interdisciplinary Research Center, Justus-Liebig-University of Giessen, Heinrich-Buff-Ring 26-32, 35392, Giessen, Germany.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Stellzig</LastName>
<ForeName>Julia</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Adam</LastName>
<ForeName>Iris V</ForeName>
<Initials>IV</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Weber</LastName>
<ForeName>Kristine</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Binger</LastName>
<ForeName>Sarai</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Boll</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Knorr</LastName>
<ForeName>Eileen</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Twyman</LastName>
<ForeName>Richard M</ForeName>
<Initials>RM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vilcinskas</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wenzel</LastName>
<ForeName>Uwe</ForeName>
<Initials>U</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>01</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Genes Nutr</MedlineTA>
<NlmUniqueID>101280108</NlmUniqueID>
<ISSNLinking>1555-8932</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3755130</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23378263</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>09</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1555-8932</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>8</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Genes &amp; nutrition</Title>
<ISOAbbreviation>Genes Nutr</ISOAbbreviation>
</Journal>
<ArticleTitle>hZip1 (hSLC39A1) regulates zinc homoeostasis in gut epithelial cells.</ArticleTitle>
<Pagination>
<MedlinePgn>475-86</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s12263-013-0332-z</ELocationID>
<Abstract>
<AbstractText>Zinc is an essential trace element required for enzyme catalysis, gene regulation and signal transduction. Zinc absorption takes place in the small intestine; however, the mechanisms by which cells accumulate zinc are not entirely clear. Zip1 (SLC39A1) is a predicted transmembrane protein that is postulated, but not conclusively proven to mediate zinc influx in gut cells. The aim of this study was to investigate a role for hZip1 in mediating zinc uptake in human enterocytes. Both hZip1 mRNA and protein were detected in human intestinal tissue. In non-differentiated Caco-2 human gut cells, hZip1 was partially localised to the endoplasmic reticulum. In contrast, in differentiated Caco-2 cells cultured in extracellular matrix, the hZip1 protein was located in proximity to the apical microvilli. Lack of surface antibody binding and internalisation indicated that hZip1 was not present on the plasma membrane. Functional studies to establish a role for hZip1 in cellular zinc accumulation were carried out using (65)Zn. In Caco-2 cells harbouring an hZip1 overexpression construct, cellular zinc accumulation was enhanced relative to the control. Conversely, Caco-2 cells with an hZip1 siRNA construct showed reduced zinc accumulation. In summary, we show that the Caco-2 cell differentiation endorses targeting of hZip1 to a region near the apical domain. Given the absence of hZip1 at the apical plasma membrane, we propose that hZip1 may act as an intracellular sensor to regulate zinc homoeostasis in human gut cells. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Michalczyk</LastName>
<ForeName>Agnes A</ForeName>
<Initials>AA</Initials>
<Affiliation>Centre for Cellular and Molecular Biology, School of Life and Environmental Sciences, Deakin University, 221 Burwood Highway, Burwood, Melbourne, VIC, 3125, Australia.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Ackland</LastName>
<ForeName>M Leigh</ForeName>
<Initials>ML</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>02</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Genes Nutr</MedlineTA>
<NlmUniqueID>101280108</NlmUniqueID>
<ISSNLinking>1555-8932</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3755131</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23417480</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>09</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1555-8932</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>8</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Genes &amp; nutrition</Title>
<ISOAbbreviation>Genes Nutr</ISOAbbreviation>
</Journal>
<ArticleTitle>Timed high-fat diet in the evening affects the hepatic circadian clock and PPARα-mediated lipogenic gene expressions in mice.</ArticleTitle>
<Pagination>
<MedlinePgn>457-63</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s12263-013-0333-y</ELocationID>
<Abstract>
<AbstractText>A long-term high-fat diet may result in a fatty liver. However, whether or not high-fat diets affect the hepatic circadian clock is controversial. The objective of this study is to investigate the effects of timed high-fat diet on the hepatic circadian clock and clock-controlled peroxisome proliferator-activated receptor (PPAR) α-mediated lipogenic gene expressions. Mice were orally administered high-fat milk in the evening for 4 weeks. The results showed that some hepatic clock genes, such as Clock, brain-muscle-Arnt-like 1 (Bmal1), Period 2 (Per2), and Cryptochrome 2 (Cry2) exhibited obvious changes in rhythms and/or amplitudes. Alterations in the expression of clock genes, in turn, further altered the circadian rhythm of PPARα expression. Among the PPARα target genes, cholesterol 7α-hydroxylase (CYP7A1), 3-hydroxy-3-methylglutaryl-coenzyme A reductase, low-density lipoprotein receptor, lipoprotein lipase, and diacylglycerol acyltransferase (DGAT) showed marked changes in rhythms and/or amplitudes. In particular, significant changes in the expressions of DGAT and CYP7A1 were observed. The effects of a high-fat diet on the expression of lipogenic genes in the liver were accompanied by increased hepatic cholesterol and triglyceride levels. These results suggest that timed high-fat diets at night could change the hepatic circadian expressions of clock genes Clock, Bmal1, Per2, and Cry2 and subsequently alter the circadian expression of PPARα-mediated lipogenic genes, resulting in hepatic lipid accumulation. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Xiaoyan</ForeName>
<Initials>X</Initials>
<Affiliation>Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, Jiangsu Province, China.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Xue</LastName>
<ForeName>Jie</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Juan</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xie</LastName>
<ForeName>Meilin</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>02</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Genes Nutr</MedlineTA>
<NlmUniqueID>101280108</NlmUniqueID>
<ISSNLinking>1555-8932</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3755129</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23475806</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>09</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1555-8932</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>8</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Genes &amp; nutrition</Title>
<ISOAbbreviation>Genes Nutr</ISOAbbreviation>
</Journal>
<ArticleTitle>Social sciences for food and health research.</ArticleTitle>
<Pagination>
<MedlinePgn>435-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s12263-013-0334-x</ELocationID>
<Abstract>
<AbstractText>Healthier eating is a global challenge for chronic disease control. Food and Health Research in Europe (FAHRE) surveyed research structures and programmes in 32 countries, and reviewed research needs and gaps across nine themes. Food processing and safety research, nutrition and molecular research, and disease-based clinical research are strong; but research is weak on determinants of disease and healthier eating through policies and changing behaviours. Biomedical and commercial research for patents contrast with social research for the public interest. More funding and capacity support should go to social research in the food and health sector. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>McCarthy</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
<Affiliation>Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place, London, WC1E 6BT, UK, m.mccarthy@ucl.ac.uk.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>03</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Genes Nutr</MedlineTA>
<NlmUniqueID>101280108</NlmUniqueID>
<ISSNLinking>1555-8932</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3755134</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23479116</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>09</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1555-8932</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>8</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Genes &amp; nutrition</Title>
<ISOAbbreviation>Genes Nutr</ISOAbbreviation>
</Journal>
<ArticleTitle>Associations of the lactase persistence allele and lactose intake with body composition among multiethnic children.</ArticleTitle>
<Pagination>
<MedlinePgn>487-94</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s12263-013-0335-9</ELocationID>
<Abstract>
<AbstractText>Childhood obesity is a worldwide health concern with a multifaceted and sometimes confounding etiology. Dairy products have been implicated as both pro- and anti-obesogenic, perhaps due to the confounding relationship between dairy, lactose consumption, and potential genetic predisposition. We aimed to understand how lactase persistence influenced obesity-related traits by observing the relationships among lactose consumption, a single nucleotide polymorphism (SNP) near the lactase (LCT) gene and body composition parameters in a sample of multiethnic children (n = 296, 7-12 years old). We hypothesized that individuals with the lactase persistence (LP) allele of the LCT SNP (rs4988235) would exhibit a greater degree of adiposity and that this relationship would be mediated by lactose consumption. Body composition variables were measured using dual X-ray absorptiometry and a registered dietitian assessed dietary intake of lactose. Statistical models were adjusted for sex, age, pubertal stage, ethnic group, genetic admixture, socio-economic status, and total energy intake. Our findings indicate a positive, significant association between the LP allele and body mass index (p = 0.034), fat mass index (FMI) (p = 0.043), and waist circumference (p = 0.008), with associations being stronger in males than in females. Our results also reveal that lactose consumption is positively and nearly significantly associated with FMI. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Malek</LastName>
<ForeName>Adil J</ForeName>
<Initials>AJ</Initials>
<Affiliation>Department of Nutrition Sciences, University of Alabama at Birmingham, Webb 449A-1720 Second Avenue South, Birmingham, AL, 35294-3360, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Klimentidis</LastName>
<ForeName>Yann C</ForeName>
<Initials>YC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kell</LastName>
<ForeName>Kenneth P</ForeName>
<Initials>KP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fernández</LastName>
<ForeName>José R</ForeName>
<Initials>JR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30 DK056336</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P60 DK079626</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DA025095</GrantID>
<Acronym>DA</Acronym>
<Agency>NIDA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 HL007457</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>T32 HL105349</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>03</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Genes Nutr</MedlineTA>
<NlmUniqueID>101280108</NlmUniqueID>
<ISSNLinking>1555-8932</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3755137</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23526194</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>09</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1555-8932</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>8</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Genes &amp; nutrition</Title>
<ISOAbbreviation>Genes Nutr</ISOAbbreviation>
</Journal>
<ArticleTitle>Obesity polymorphisms identified in genome-wide association studies interact with n-3 polyunsaturated fatty acid intake and modify the genetic association with adiposity phenotypes in Yup'ik people.</ArticleTitle>
<Pagination>
<MedlinePgn>495-505</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s12263-013-0340-z</ELocationID>
<Abstract>
<AbstractText>n-3 Polyunsaturated fatty acids (n-3 PUFAs) have anti-obesity effects that may modulate risk of obesity, in part, through interactions with genetic factors. Genome-wide association studies (GWAS) have identified genetic variants associated with body mass index (BMI); however, the extent to which these variants influence adiposity through interactions with n-3 PUFAs remains unknown. We evaluated 10 highly replicated obesity GWAS single nucleotide polymorphisms (SNPs) for individual and cumulative associations with adiposity phenotypes in a cross-sectional sample of Yup'ik people (n = 1,073) and evaluated whether genetic associations with obesity were modulated by n-3 PUFA intake. A genetic risk score (GRS) was calculated by adding the BMI-increasing alleles across all 10 SNPs. Dietary intake of n-3 PUFAs was estimated using nitrogen stable isotope ratio (δ(15)N) of red blood cells, and genotype-phenotype analyses were tested in linear models accounting for familial correlations. GRS was positively associated with BMI (p = 0.012), PBF (p = 0.022), ThC (p = 0.025), and waist circumference (p = 0.038). The variance in adiposity phenotypes explained by the GRS included BMI (0.7 %), PBF (0.3 %), ThC (0.7 %), and WC (0.5 %). GRS interactions with n-3 PUFAs modified the association with adiposity and accounted for more than twice the phenotypic variation (~1-2 %), relative to GRS associations alone. Obesity GWAS SNPs contribute to adiposity in this study population of Yup'ik people and interactions with n-3 PUFA intake potentiated the risk of fat accumulation among individuals with high obesity GRS. These data suggest the anti-obesity effects of n-3 PUFAs among Yup'ik people may, in part, be dependent upon an individual's genetic predisposition to obesity. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lemas</LastName>
<ForeName>Dominick J</ForeName>
<Initials>DJ</Initials>
<Affiliation>Institute of Arctic Biology, Center for Alaska Native Health Research, University of Alaska Fairbanks, 311 Irving I Building, PO Box 757000, Fairbanks, AK, 99775-7000, USA, dominck.lemas@ucdenver.edu.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Klimentidis</LastName>
<ForeName>Yann C</ForeName>
<Initials>YC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wiener</LastName>
<ForeName>Howard H</ForeName>
<Initials>HH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>O'Brien</LastName>
<ForeName>Diane M</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hopkins</LastName>
<ForeName>Scarlett E</ForeName>
<Initials>SE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Allison</LastName>
<ForeName>David B</ForeName>
<Initials>DB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fernandez</LastName>
<ForeName>Jose R</ForeName>
<Initials>JR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tiwari</LastName>
<ForeName>Hemant K</ForeName>
<Initials>HK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Boyer</LastName>
<ForeName>Bert B</ForeName>
<Initials>BB</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P20 RR016430</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 DK056336</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P30 GM103325</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 DK074842</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>03</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Genes Nutr</MedlineTA>
<NlmUniqueID>101280108</NlmUniqueID>
<ISSNLinking>1555-8932</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3755132</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23588623</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>09</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1555-8932</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>8</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Genes &amp; nutrition</Title>
<ISOAbbreviation>Genes Nutr</ISOAbbreviation>
</Journal>
<ArticleTitle>The nutrigenomic investigation of C57BL/6N mice fed a short-term high-fat diet highlights early changes in clock genes expression.</ArticleTitle>
<Pagination>
<MedlinePgn>465-74</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s12263-013-0344-8</ELocationID>
<Abstract>
<AbstractText>Mice fed long-term high-fat diets (HFD) are an established model for human metabolic disorders, such as obesity and diabetes. However, also the effects of short-term HFD feeding should be investigated to understand which are the first events that trigger the onset of a pre-disease condition, the so-called metabolic syndrome, that increases the risk of developing clinical diseases. In this study, C57BL/6N mice were fed a control diet (CTR) or a HFD for 1 (T1) or 2 weeks (T2). Metabolic and histological effects were examined. Cecum transcriptomes of HFD and CTR mice were compared at T2 by microarray analysis. Differentially expressed genes were validated by real-time PCR in the cecum and in the liver. After 2 weeks of diet administration, HFD mice showed an altered expression pattern in only seven genes, four of which are involved in the circadian clock regulatory pathway. Real-time PCR confirmed microarray results of the cecum and revealed the same trend of clock gene expression changes in the liver. These findings suggest that clock genes may play an important role in early controlling gut output systems in response to HFD in mice and that their expression change may also represent an early signaling of the development of an intestinal pro-inflammatory status. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lizier</LastName>
<ForeName>Michela</ForeName>
<Initials>M</Initials>
<Affiliation>Centro Ricerche Biotecnologiche, Istituto di Microbiologia, Università Cattolica del Sacro Cuore, via Milano 24, 26100, Cremona, Italy, michela.lizier@humanitasresearch.it.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Bomba</LastName>
<ForeName>Lorenzo</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Minuti</LastName>
<ForeName>Andrea</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chegdani</LastName>
<ForeName>Fatima</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Capraro</LastName>
<ForeName>Jessica</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tondelli</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mazza</LastName>
<ForeName>Raffaele</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Callegari</LastName>
<ForeName>Maria Luisa</ForeName>
<Initials>ML</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Trevisi</LastName>
<ForeName>Erminio</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rossi</LastName>
<ForeName>Filippo</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Marsan</LastName>
<ForeName>Paolo Ajmone</ForeName>
<Initials>PA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lucchini</LastName>
<ForeName>Franco</ForeName>
<Initials>F</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>04</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Genes Nutr</MedlineTA>
<NlmUniqueID>101280108</NlmUniqueID>
<ISSNLinking>1555-8932</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3755136</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23595524</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>09</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1555-8932</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>8</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Genes &amp; nutrition</Title>
<ISOAbbreviation>Genes Nutr</ISOAbbreviation>
</Journal>
<ArticleTitle>Nutrigenomics approach elucidates health-promoting effects of high vegetable intake in lean and obese men.</ArticleTitle>
<Pagination>
<MedlinePgn>507-21</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s12263-013-0343-9</ELocationID>
<Abstract>
<AbstractText>We aimed to explore whether vegetable consumption according to guidelines has beneficial health effects determined with classical biomarkers and nutrigenomics technologies. Fifteen lean (age 36 ± 7 years; BMI 23.4 ± 1.7 kg m(-2)) and 17 obese (age 40 ± 6 years; BMI 30.3 ± 2.4 kg m(-2)) men consumed 50- or 200-g vegetables for 4 weeks in a randomized, crossover trial. Afterward, all subjects underwent 4 weeks of energy restriction (60 % of normal energy intake). Despite the limited weight loss of 1.7 ± 2.4 kg for the lean and 2.1 ± 1.9 kg for the obese due to energy restriction, beneficial health effects were found, including lower total cholesterol, LDL cholesterol and HbA1c concentrations. The high vegetable intake resulted in increased levels of plasma amino acid metabolites, decreased levels of 9-HODE and prostaglandin D3 and decreased levels of ASAT and ALP compared to low vegetable intake. Adipose tissue gene expression changes in response to vegetable intake were identified, and sets of selected genes were submitted to network analysis. The network of inflammation genes illustrated a central role for NFkB in (adipose tissue) modulation of inflammation by increased vegetable intake, in lean as well as obese subjects. In obese subjects, high vegetable intake also resulted in changes related to energy metabolism, adhesion and inflammation. By inclusion of sensitive omics technologies and comparing the changes induced by high vegetable intake with changes induced by energy restriction, it has been shown that part of vegetables' health benefits are mediated by changes in energy metabolism, inflammatory processes and oxidative stress. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pasman</LastName>
<ForeName>W J</ForeName>
<Initials>WJ</Initials>
<Affiliation>TNO, P.O. Box 360, 3700 AJ, Zeist, The Netherlands, wilrike.pasman@tno.nl.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>van Erk</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Klöpping</LastName>
<ForeName>W A A</ForeName>
<Initials>WA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pellis</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wopereis</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bijlsma</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hendriks</LastName>
<ForeName>H F J</ForeName>
<Initials>HF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kardinaal</LastName>
<ForeName>A F M</ForeName>
<Initials>AF</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>04</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Genes Nutr</MedlineTA>
<NlmUniqueID>101280108</NlmUniqueID>
<ISSNLinking>1555-8932</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3755133</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23881689</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>09</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">1555-8932</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>8</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2013</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Genes &amp; nutrition</Title>
<ISOAbbreviation>Genes Nutr</ISOAbbreviation>
</Journal>
<ArticleTitle>HMGA2 expression in white adipose tissue linking cellular senescence with diabetes.</ArticleTitle>
<Pagination>
<MedlinePgn>449-56</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s12263-013-0354-6</ELocationID>
<Abstract>
<AbstractText>There is a clear link between overweight, gain of white adipose tissue, and diabetes type 2 (T2D). The molecular mechanism of the gain of adipose tissue is linked with the expression of high mobility group protein AT-hook 2 (HMGA2), and recent studies revealed an association with a SNP near HMGA2. In this study, we investigated the gene expression of HMGA2, p14 (Arf) , CDKN1A, and BAX in human abdominal subcutaneous white adipose tissue from 157 patients. We found a significant higher HMGA2 expression in obese individuals than in non-obese patients. Furthermore, the HMGA2 expression in white adipose tissue in patient with type 2 diabetes was significantly higher than in nondiabetic patients. There is an association between the DNA-binding nonhistone protein HMGA2 and the risk of developing T2D that remains mechanistically unexplained so far. Likewise, p14(Arf), an inducer of cellular senescence, has been associated with the occurrence of T2D. The data of the present study provide evidence that both proteins act within the same network to drive proliferation of adipose tissue stem and precursor cells, senescence, and increased risk of T2D, respectively. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Markowski</LastName>
<ForeName>Dominique Nadine</ForeName>
<Initials>DN</Initials>
<Affiliation>Center of Human Genetics, University of Bremen, Leobener Strasse ZHG, 28359, Bremen, Germany.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Thies</LastName>
<ForeName>Helge Wilhelm</ForeName>
<Initials>HW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gottlieb</LastName>
<ForeName>Andrea</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wenk</LastName>
<ForeName>Heiner</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wischnewsky</LastName>
<ForeName>Manfred</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bullerdiek</LastName>
<ForeName>Jörn</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Genes Nutr</MedlineTA>
<NlmUniqueID>101280108</NlmUniqueID>
<ISSNLinking>1555-8932</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3755135</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984076</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">2090-3154</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>Genetics research international</Title>
<ISOAbbreviation>Genet Res Int</ISOAbbreviation>
</Journal>
<ArticleTitle>Hidden Y Chromosome Mosaicism in 48 Egyptian Patients with Turner's Syndrome.</ArticleTitle>
<Pagination>
<MedlinePgn>463529</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/463529</ELocationID>
<Abstract>
<AbstractText>Background. The presence of Y chromosome material in Turner's syndrome (TS) patients is a risk factor for the development of gonadoblastoma. Although conventional cytogenetic analysis is the definitive diagnosis of TS, low level Y chromosome mosaicism may be missed. Molecular analysis has demonstrated a higher proportion of mosaicism, but there is controversy regarding the prevalence of Y chromosome-derived material in those patients. Aim and Methods. This study was conducted to investigate the prevalence of hidden Y chromosome mosaicism in 48 TS Egyptian patients using polymerase chain reaction (PCR) for molecular DNA analysis of SRY gene and compare our results with those in the literature. Results. None of TS patients had a cytogenetically obvious Y chromosome; Y chromosome material was detected only at molecular analysis. SRY gene was found in 9 TS patients (18.75%) with the classical 45,X karyotype, whereas all other patients were SRY negative. Conclusion. Cytogenetically undetected Y chromosome mosaicism is common in TS patients; these data reinforce the need for adequate diagnosis of Y chromosome material in those patients. Molecular screening for Y chromosome-derived DNA should be routinely carried out in all TS patients. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>El-Eshmawy</LastName>
<ForeName>Mervat M</ForeName>
<Initials>MM</Initials>
<Affiliation>Internal Medicine Department, Mansoura Specialized Medical Hospital, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Yahia</LastName>
<ForeName>Sohier</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>El-Dahtory</LastName>
<ForeName>Faeza A</ForeName>
<Initials>FA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hamed</LastName>
<ForeName>Sahar</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>El Hadidy</LastName>
<ForeName>El Hadidy M</ForeName>
<Initials>el HM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ragab</LastName>
<ForeName>Mohamed</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>Genet Res Int</MedlineTA>
<NlmUniqueID>101571472</NlmUniqueID>
<ISSNLinking>2090-3162</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3745850</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982606</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1538-5159</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2013</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Health physics</Title>
<ISOAbbreviation>Health Phys</ISOAbbreviation>
</Journal>
<ArticleTitle>Evaluation of vegetables in Tsukuba for contamination with radioactive materials from the accident at Fukushima Daiichi nuclear power plant.</ArticleTitle>
<Pagination>
<MedlinePgn>311-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/HP.0b013e3182895759</ELocationID>
<Abstract>
<AbstractText>A large amount of radioactive material was released into the atmosphere after the accident of the Fukushima Daiichi Nuclear Power Plant following the Tohoku earthquake on 11 March 2011, and traces of these materials were detected in Tsukuba. Because radioactive materials can adhere to vegetables, the authors made a qualitative evaluation of vegetables in Tsukuba, estimated internal exposure dose based on quantitative measurement results, and investigated several decontamination methods. Qualitative analysis of vegetable contamination was done by autoradiography. Quantitative analysis was done using a high-purity germanium detector. To assess decontamination, two methods were tested: one with running water and the other with boiling water. In addition, boiled soup stock was measured. In the qualitative evaluation by autoradiography, radioactive materials were not uniformly distributed but adhered to vegetables in clumps and hot spots. In the quantitative evaluation to measure contamination of outer and inner leaves of sanchu lettuce, it was observed that the concentration of I was 8,031.35 ± 764.79 Bq kg in the outer leaves and 115.28 ± 20.63 Bq kg in the inner leaves. In addition, the concentration of Cs was 1,371.93 ± 366.45 Bq kg in the outer leaves and 9.68 ± 15.03 Bq kg in the inner leaves. This suggests that one can greatly reduce internal exposure dose by removing the outer leaves if one has to eat vegetables just after a nuclear accident. In the decontamination assessment, a decontamination efficiency of up to 70% was achieved by boiling vegetables for 20 min. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Isobe</LastName>
<ForeName>Tomonori</ForeName>
<Initials>T</Initials>
<Affiliation>Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1, Tennodai, Tsukuba-shi, Ibaraki 305-8575, Japan. tiso@md.tsukuba.ac.jp</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Mori</LastName>
<ForeName>Yutaro</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takada</LastName>
<ForeName>Kenta</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sato</LastName>
<ForeName>Eisuke</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takahashi</LastName>
<ForeName>Hideki</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sekiguchi</LastName>
<ForeName>Takao</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yoshimura</LastName>
<ForeName>Yousuke</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sakurai</LastName>
<ForeName>Hideyuki</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sakae</LastName>
<ForeName>Takeji</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Health Phys</MedlineTA>
<NlmUniqueID>2985093R</NlmUniqueID>
<ISSNLinking>0017-9078</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Cesium Radioisotopes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Iodine Radioisotopes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Radioactive Pollutants</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>00072J7XWS</RegistryNumber>
<NameOfSubstance>Germanium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Autoradiography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cesium Radioisotopes</DescriptorName>
<QualifierName MajorTopicYN="N">analysis</QualifierName>
<QualifierName MajorTopicYN="N">isolation &amp; purification</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Decontamination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Food Contamination</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Fukushima Nuclear Accident</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Germanium</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Iodine Radioisotopes</DescriptorName>
<QualifierName MajorTopicYN="N">analysis</QualifierName>
<QualifierName MajorTopicYN="N">isolation &amp; purification</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Nuclear Power Plants</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Radiation Monitoring</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radioactive Pollutants</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
<QualifierName MajorTopicYN="N">isolation &amp; purification</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Vegetables</DescriptorName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982607</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1538-5159</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2013</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Health physics</Title>
<ISOAbbreviation>Health Phys</ISOAbbreviation>
</Journal>
<ArticleTitle>Investigation of photon shielding property changes in curing high density concrete.</ArticleTitle>
<Pagination>
<MedlinePgn>318-25</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/HP.0b013e31829651d3</ELocationID>
<Abstract>
<AbstractText>High density concrete is usually used for radiation shielding around radiotherapy treatment rooms. Because the concrete is specified differently at the design, construction, and verification stages, the relationship between the intended performance and the actual performance of the shielding material might not be entirely clear. In this study, cylindrical samples of high density shielding concrete were taken as each section of a new radiotherapy bunker was poured. The shielding performance of each sample [measured by beam attenuation and tenth-value layers (TVL)] was evaluated for 15 MV and 6 MV x-ray beams and for the 1.25 MeV monoenergetic gamma beam from a Co source. Transmission curves to 3 TVL were mapped for a representative sample. The samples were also imaged and analyzed using Co Cone Beam Computed Tomography (CoCBCT). Results indicate no significant change in the TVL of high density concrete samples as they cure. The minor fluctuations in shielding properties observed are explained by the heterogeneous structure of the samples as indicated in the CoCBCT images. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Marsh</LastName>
<ForeName>Matthew B</ForeName>
<Initials>MB</Initials>
<Affiliation>Department of Physics, Queen's University, Kingston, Ontario, Canada.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Peters</LastName>
<ForeName>Christopher</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rawluk</LastName>
<ForeName>Nicholas</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Schreiner</LastName>
<ForeName>L John</ForeName>
<Initials>LJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<Agency>Canadian Institutes of Health Research</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Health Phys</MedlineTA>
<NlmUniqueID>2985093R</NlmUniqueID>
<ISSNLinking>0017-9078</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cone-Beam Computed Tomography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Construction Materials</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Photons</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Quality Control</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radiation Protection</DescriptorName>
<QualifierName MajorTopicYN="Y">instrumentation</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982608</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1538-5159</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2013</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Health physics</Title>
<ISOAbbreviation>Health Phys</ISOAbbreviation>
</Journal>
<ArticleTitle>Long lived gamma emitting radionuclides in incense.</ArticleTitle>
<Pagination>
<MedlinePgn>326-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/HP.0b013e3182983fbb</ELocationID>
<Abstract>
<AbstractText>A study of long-lived gamma emitters in incense was performed. The incense samples originated from seven different countries, and the investigated radionuclides were Ra, Ra, and K. Gamma spectroscopy revealed the presence of all three investigated radionuclides in all samples. Interestingly, the activity concentrations revealed a clear bimodal distribution that distinguished samples that were natural incense from others that were processed incense. The activity concentrations in the latter group were found to be one order of magnitude greater than in the former group. Consequently, the estimated annual effective dose from the latter group was one order of magnitude higher than that of the former group. Nonetheless, the doses from both groups were found to be some three orders of magnitude less than the average worldwide exposure to inhaled natural radionuclides. This finding suggests the radiological safety of incense for the investigated radionuclides. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Alrefae</LastName>
<ForeName>Tareq</ForeName>
<Initials>T</Initials>
<Affiliation>Department of Physics, Faculty of Science, Kuwait University, Khaldia, Kuwait. tareq@washington.edu</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Health Phys</MedlineTA>
<NlmUniqueID>2985093R</NlmUniqueID>
<ISSNLinking>0017-9078</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Radioisotopes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Smoke</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Gamma Rays</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Half-Life</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Radiation Monitoring</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radioisotopes</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Smoke</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982609</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1538-5159</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2013</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Health physics</Title>
<ISOAbbreviation>Health Phys</ISOAbbreviation>
</Journal>
<ArticleTitle>Realistic approach to estimate lens doses and cataract radiation risk in cardiology when personal dosimeters have not been regularly used.</ArticleTitle>
<Pagination>
<MedlinePgn>330-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/HP.0b013e318299b5d9</ELocationID>
<Abstract>
<AbstractText>Interventional fluoroscopic guided cardiac procedures lead to radiation exposure to the lenses of the eyes of cardiologists, which over time may be associated with an increased risk of cataracts. This study derives radiation doses to the lens of the eye in cardiac catheterization laboratories from measurements of individual procedures to allow for estimates of such doses for those cases when personal dosimeters have not been used regularly. Using active electronic dosimeters at the C-arm (at 95 cm from the isocenter), scatter radiation doses have been measured for cardiac procedures and estimated radiation doses to the lenses of the cardiologists for different groups of procedures (diagnostic, PTCAs, and valvular). Correlation factors with kerma area product included in the patient dose reports have been derived. The mean, median, and third quartile scatter dose values per procedure at the C-arm for 1,969 procedures were 0.99, 0.78 and 1.25 mSv, respectively; for coronary angiography, 0.51, 0.45, and 0.61 mSv, respectively; for PTCAs, 1.29, 1.07, and 1.56 mSv; and for valvular procedures, 1.64, 1.45, and 2.66 mSv, respectively. For all the procedures, the ratio between the scatter dose at the C-arm and the kerma area product resulted in between 10.3-11.3 μSv Gy cm. The experimental results of this study allow for realistic estimations of the dose to the lenses of the eyes from the workload of the cardiologists and from the level of use of radiation protection tools when personal dosimeters have not been regularly used. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Vañó</LastName>
<ForeName>Eliseo</ForeName>
<Initials>E</Initials>
<Affiliation>Medical Physics Service, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain. eliseov@med.ucm.es</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Fernández</LastName>
<ForeName>José M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sánchez</LastName>
<ForeName>Roberto M</ForeName>
<Initials>RM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dauer</LastName>
<ForeName>Lawrence T</ForeName>
<Initials>LT</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Health Phys</MedlineTA>
<NlmUniqueID>2985093R</NlmUniqueID>
<ISSNLinking>0017-9078</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Cardiology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cataract</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Hospitals, University</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Individualized Medicine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Lens, Crystalline</DescriptorName>
<QualifierName MajorTopicYN="Y">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Occupational Exposure</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radiation Dosage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radiation Injuries</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radiation Monitoring</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radiation Protection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Risk</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Scattering, Radiation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982610</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1538-5159</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2013</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Health physics</Title>
<ISOAbbreviation>Health Phys</ISOAbbreviation>
</Journal>
<ArticleTitle>Daily radionuclide ingestion and internal radiation doses in Aomori prefecture, Japan.</ArticleTitle>
<Pagination>
<MedlinePgn>340-50</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/HP.0b013e31829ae95f</ELocationID>
<Abstract>
<AbstractText>To assess internal annual dose in the general public in Aomori Prefecture, Japan, 80 duplicate cooked diet samples, equivalent to the food consumed over a 400-d period by one person, were collected from 100 volunteers in Aomori City and the village of Rokkasho during 2006–2010 and were analyzed for 11 radionuclides. To obtain average rates of ingestion of radionuclides, the volunteers were selected from among office, fisheries, agricultural, and livestock farm workers. Committed effective doses from ingestion of the diet over a 1-y period were calculated from the analytical results and from International Commission on Radiological Protection dose coefficients; for 40K, an internal effective dose rate from the literature was used. Fisheries workers had significantly higher combined internal annual dose than the other workers, possibly because of high rates of ingestion of marine products known to have high 210Po concentrations. The average internal dose rate, weighted by the numbers of households in each worker group in Aomori Prefecture, was estimated at 0.47 mSv y-1. Polonium-210 contributed 49% of this value. The sum of committed effective dose rates for 210Po, 210Pb, 228Ra, and 14C and the effective dose rate of 40K accounted for approximately 99% of the average internal dose rate.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ohtsuka</LastName>
<ForeName>Yoshihito</ForeName>
<Initials>Y</Initials>
<Affiliation>Department of Radioecology, Institute for Environmental Sciences, Rokkasho, Aomori, 039-3212, Japan. ohtsuka@ies.or.jp</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Kakiuchi</LastName>
<ForeName>Hideki</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Akata</LastName>
<ForeName>Naofumi</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Takaku</LastName>
<ForeName>Yuichi</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hisamatsu</LastName>
<ForeName>Shun'ichi</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Health Phys</MedlineTA>
<NlmUniqueID>2985093R</NlmUniqueID>
<ISSNLinking>0017-9078</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Radioisotopes</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Diet</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Eating</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Food Contamination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Japan</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Radiation Dosage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radiation Monitoring</DescriptorName>
<QualifierName MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radioactivity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radioisotopes</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982611</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1538-5159</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2013</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Health physics</Title>
<ISOAbbreviation>Health Phys</ISOAbbreviation>
</Journal>
<ArticleTitle>Development of serum copper-based biological dosimetry in whole body gamma irradiation of mice.</ArticleTitle>
<Pagination>
<MedlinePgn>351-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/HP.0b013e31829aea95</ELocationID>
<Abstract>
<AbstractText>A new biological dosimeter based on serum copper has been developed. Serum copper in mice subjected to a 60Co source at a dose rate of 0.5 Gy min-1 was detected using the bis(cyclohexanone) oxaldihydrazone colorimetric method. The dose range was from 0.5–7 Gy. The results demonstrate that serum copper decreases with increasing dose. A linear dose response is obtained. The detection limit based on serum copper is the same as that with the lower limit of dose assessment; i.e., about 1 Gy. The decrease in serum copper continues until the 28th day after gamma radiation. The absorbed doses in mice assessed using the linear curve are close to “blind” doses of 4 and 6 Gy. Therefore, serum copper is a quick, simple, and accurate biomarker for early assessment of radiation exposure of mice in the range of 0.5–7 Gy.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Xiao-hong</ForeName>
<Initials>XH</Initials>
<Affiliation>Department of Nuclear Science and Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 210006, PR China.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Min</LastName>
<ForeName>Xuan-yu</ForeName>
<Initials>XY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Ai-lian</ForeName>
<Initials>AL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lou</LastName>
<ForeName>Zhi-chao</ForeName>
<Initials>ZC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Ya-nan</ForeName>
<Initials>YN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hu</LastName>
<ForeName>Xiao-dan</ForeName>
<Initials>XD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Hai-qian</ForeName>
<Initials>HQ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Health Phys</MedlineTA>
<NlmUniqueID>2985093R</NlmUniqueID>
<ISSNLinking>0017-9078</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Cobalt Radioisotopes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>789U1901C5</RegistryNumber>
<NameOfSubstance>Copper</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cobalt Radioisotopes</DescriptorName>
<QualifierName MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Colorimetry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Copper</DescriptorName>
<QualifierName MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Gamma Rays</DescriptorName>
<QualifierName MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radiometry</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Whole-Body Irradiation</DescriptorName>
<QualifierName MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982612</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1538-5159</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2013</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Health physics</Title>
<ISOAbbreviation>Health Phys</ISOAbbreviation>
</Journal>
<ArticleTitle>Radioactive seed localization with 125I for nonpalpable lesions prior to breast lumpectomy and/or excisional biopsy: methodology, safety, and experience of initial year.</ArticleTitle>
<Pagination>
<MedlinePgn>356-65</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/HP.0b013e31829c03e1</ELocationID>
<Abstract>
<AbstractText>The use of radioactive seed localization (RSL) as an alternative to wire localizations (WL) for nonpalpable breast lesions is rapidly gaining acceptance because of its advantages for both the patient and the surgical staff. This paper examines the initial experience with over 1,200 patients seen at a comprehensive cancer center. Radiation safety procedures for radiology, surgery, and pathology were implemented, and radioactive material inventory control was maintained using an intranet-based program. Surgical probes allowed for discrimination between 125I seed photon energies from 99mTc administered for sentinel node testing. A total of 1,127 patients (median age of 57.2 y) underwent RSL procedures with 1,223 seeds implanted. Implanted seed depth ranged from 10.3-107.8 mm. The median length of time from RSL implant to surgical excision was 2 d. The median 125I activity at time of implant was 3.1 MBq (1.9 to 4.6). The median dose rate from patients with a single seed was 9.5 µSv h-1 and 0.5 µSv h-1 at contact and 1 m, respectively. The maximum contact dose rate was 187 µSv h-1 from a superficially placed seed. RSL performed greater than 1 d before surgery is a viable alternative to WL, allowing flexibility in scheduling, minimizing day of surgery procedures, and improving workflow in breast imaging and surgery. RSL has been shown to be a safe and effective procedure for preoperative localization under mammographic and ultrasound guidance, which can be managed with the use of customized radiation protection controls.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dauer</LastName>
<ForeName>Lawrence T</ForeName>
<Initials>LT</Initials>
<Affiliation>Department of Medical Physics, Memorial Sloan-Kettering CancerCenter, New York, NY 10021, USA. dauerl@mskcc.org</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Thornton</LastName>
<ForeName>Cynthia</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Miodownik</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Boylan</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Holahan</LastName>
<ForeName>Brian</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>King</LastName>
<ForeName>Valencia</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brogi</LastName>
<ForeName>Edi</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morrow</LastName>
<ForeName>Monica</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morris</LastName>
<ForeName>Elizabeth A</ForeName>
<Initials>EA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>St Germain</LastName>
<ForeName>Jean</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Health Phys</MedlineTA>
<NlmUniqueID>2985093R</NlmUniqueID>
<ISSNLinking>0017-9078</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Iodine Radioisotopes</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Breast Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="N">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Iodine Radioisotopes</DescriptorName>
<QualifierName MajorTopicYN="N">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Mammography</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N">instrumentation</QualifierName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Mastectomy, Segmental</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Operating Rooms</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Preoperative Period</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radiation Dosage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radioactivity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Safety</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Ultrasonography, Mammary</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N">instrumentation</QualifierName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982613</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1538-5159</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2013</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Health physics</Title>
<ISOAbbreviation>Health Phys</ISOAbbreviation>
</Journal>
<ArticleTitle>Biodosimetry of restoration workers for the Tokyo Electric Power Company (TEPCO) Fukushima Daiichi nuclear power station accident.</ArticleTitle>
<Pagination>
<MedlinePgn>366-73</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/HP.0b013e3182995e42</ELocationID>
<Abstract>
<AbstractText>The biological dose of nuclear workers engaged in emergency response tasks at Tokyo Electric Power Company (TEPCO) Fukushima Daiichi Nuclear Power Station was estimated in the present study. As the national core center for radiation emergency medical preparedness in Japan, the National Institute of Radiological Sciences (NIRS) received all individuals who were suspected of being overexposed to acute radiation. In the course of health examinations at NIRS, biological dosimetry was performed by the dicentric chromosome assay (DCA). Twelve individuals were examined from 21 March-1 July 2011. The results indicated that the estimated exposure doses for all individuals were lower than 30 mGy, with the mean value of about 101 mGy. These results by DCA were in accordance with those obtained by physical dosimetry based on personal dosimeter recording assessment. The results corroborate the fact that no acute radiation syndrome was observed among the workers examined. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Suto</LastName>
<ForeName>Yumiko</ForeName>
<Initials>Y</Initials>
<Affiliation>Department of Radiation Dosimetry, Research Center for Radiation Emergency Medicine, National Institute of Radiological Sciences, Chiba, Japan. y-suto@nirs.go.jp</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Hirai</LastName>
<ForeName>Momoki</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Akiyama</LastName>
<ForeName>Miho</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kobashi</LastName>
<ForeName>Gen</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Itokawa</LastName>
<ForeName>Masanari</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Akashi</LastName>
<ForeName>Makoto</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sugiura</LastName>
<ForeName>Nobuyuki</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Health Phys</MedlineTA>
<NlmUniqueID>2985093R</NlmUniqueID>
<ISSNLinking>0017-9078</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chromosomes, Human</DescriptorName>
<QualifierName MajorTopicYN="N">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Fukushima Nuclear Accident</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic">Japan</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Nuclear Power Plants</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Occupational Exposure</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radiation Dosage</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radiometry</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982614</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1538-5159</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2013</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Health physics</Title>
<ISOAbbreviation>Health Phys</ISOAbbreviation>
</Journal>
<ArticleTitle>The effect of X-ray scattering by water in the irradiation of cell cultures for the dosimetric characterization of a new prototype of IORT (Intra-Operative Radiation Therapy) device: Monte Carlo simulation and experimental validation.</ArticleTitle>
<Pagination>
<MedlinePgn>374-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/HP.0b013e318295733f</ELocationID>
<Abstract>
<AbstractText>The electron beam emitted backward by plasma focus devices is being considered as a radiation source for Intra-Operative Radiation Therapy (IORT) applications. Radiobiological investigations have been conducted to assess the potential of this new prototype of IORT device. A standard x-ray beam, ISO-H60, was used for comparison, irradiating cell cultures in a holder filled with an aqueous solution. The influence of scattering by the culture water and by the walls of the holder was investigated to determine their influence on the dose delivered to the cell culture. MCNPX simulations were run and experimental measurements conducted. The effect of scattering by the holder was found to be negligible; scattering by the culture water was determined to give an increase in dose of the order of 10%.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ceccolini</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
<Affiliation>Montecuccolino Nuclear Engeneering Laboratory, University of Bologna, via dei Colli 16, I4037-1:1996, 40136 Bologna, Italy.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Ferrari</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Castelluccio</LastName>
<ForeName>D M</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mostacci</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sumini</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
<PublicationType>Validation Studies</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Health Phys</MedlineTA>
<NlmUniqueID>2985093R</NlmUniqueID>
<ISSNLinking>0017-9078</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>059QF0KO0R</RegistryNumber>
<NameOfSubstance>Water</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Cell Culture Techniques</DescriptorName>
<QualifierName MajorTopicYN="Y">instrumentation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Intraoperative Period</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Monte Carlo Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Radiotherapy</DescriptorName>
<QualifierName MajorTopicYN="Y">instrumentation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Scattering, Radiation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Thermoluminescent Dosimetry</DescriptorName>
<QualifierName MajorTopicYN="Y">instrumentation</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Water</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">X-Rays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982615</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1538-5159</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2013</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Health physics</Title>
<ISOAbbreviation>Health Phys</ISOAbbreviation>
</Journal>
<ArticleTitle>Measurement of internal radiation exposure among decontamination workers in villages near the crippled Fukushima Daiichi Nuclear Power Plant.</ArticleTitle>
<Pagination>
<MedlinePgn>379-81</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/HP.0b013e318297ad92</ELocationID>
<Abstract>
<AbstractText>Decontamination workers may face a high risk of exposure to internal irradiation through inhalation during decontamination activities; there is, however, little previous research on the levels of internal contamination during decontamination procedures. The authors reviewed the medical records, including whole body counter measurements, of decontamination workers in villages near the crippled Fukushima Daiichi Nuclear Power Plant to assess their levels of internal radiation exposure. In total, 83 decontamination workers were enrolled in this study. They were regularly engaged in decontamination activities in highly contaminated areas where surface 137Cs deposition density was over 100 kBq m-2. The present study showed low levels of internal exposure among the decontamination workers near the Fukushima Daiichi nuclear plant. The cesium burdens of all the decontamination workers were below detection limits. They had reported no acute health problems. The resuspension of radioactive materials may cause minimal internal contamination during decontamination activities.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tsubokura</LastName>
<ForeName>Masaharu</ForeName>
<Initials>M</Initials>
<Affiliation>Division of Social Communication System for Advanced Clinical Research, Institute of Medical Science, University of Tokyo, Tokyo. tsubokura-tky@umin.ac.jp</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Nihei</LastName>
<ForeName>Masahiko</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sato</LastName>
<ForeName>Katsumi</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Masaki</LastName>
<ForeName>Shin</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sakuma</LastName>
<ForeName>Yu</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kato</LastName>
<ForeName>Shigeaki</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sugimoto</LastName>
<ForeName>Amina</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nomura</LastName>
<ForeName>Shuhei</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Matsumura</LastName>
<ForeName>Tomoko</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Miyazaki</LastName>
<ForeName>Makoto</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hayano</LastName>
<ForeName>Ryugo</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shibuya</LastName>
<ForeName>Kenji</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kami</LastName>
<ForeName>Masahiro</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sasaki</LastName>
<ForeName>Taro</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Health Phys</MedlineTA>
<NlmUniqueID>2985093R</NlmUniqueID>
<ISSNLinking>0017-9078</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Soil</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Decontamination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Fukushima Nuclear Accident</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Medical Records</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Nuclear Power Plants</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Occupational Exposure</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Radiation Monitoring</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Soil</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23982616</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>11</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1538-5159</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>105</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2013</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Health physics</Title>
<ISOAbbreviation>Health Phys</ISOAbbreviation>
</Journal>
<ArticleTitle>Calixarene cleansing formulation for uranium skin contamination.</ArticleTitle>
<Pagination>
<MedlinePgn>382-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/HP.0b013e318298e8d3</ELocationID>
<Abstract>
<AbstractText>An oil-in-water cleansing emulsion containing calixarene molecule, an actinide specific chelating agent, was formulated in order to improve the decontamination of uranium from the skin. Commonly commercialized cosmetic ingredients such as surfactants, mineral oil, or viscosifying agents were used in preparing the calixarene emulsion. The formulation was characterized in terms of size and apparent viscosity measurements and then was tested for its ability to limit uranyl ion permeation through excoriated pig-ear skin explants in 24-h penetration studies. Calixarene emulsion effectiveness was compared with two other reference treatments consisting of DTPA and EHBP solutions. Application of calixarene emulsion induced the highest decontamination effect with an 87% decrease in uranium diffusion flux. By contrast, EHBP and DTPA solutions only allowed a 50% and 55% reduction of uranium permeation, respectively, and had the same effect as a simple dilution of the contamination by pure water. Uranium diffusion decrease was attributed to uranyl ion-specific chelation by calixarene within the formulation, since no significant effect was obtained after application of the same emulsion without calixarene. Thus, calixarene cleansing emulsion could be considered as a promising treatment in case of accidental contamination of the skin by highly diffusible uranium compounds.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Phan</LastName>
<ForeName>Guillaume</ForeName>
<Initials>G</Initials>
<Affiliation>Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PRP-HOM, SDI, LRC, Fontenay-aux-Roses, France. guillaume.phan@irsn.fr</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Semili</LastName>
<ForeName>Naïma</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bouvier-Capely</LastName>
<ForeName>Céline</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Landon</LastName>
<ForeName>Géraldine</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mekhloufi</LastName>
<ForeName>Ghozlene</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Huang</LastName>
<ForeName>Nicolas</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rebière</LastName>
<ForeName>François</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Agarande</LastName>
<ForeName>Michelle</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fattal</LastName>
<ForeName>Elias</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Health Phys</MedlineTA>
<NlmUniqueID>2985093R</NlmUniqueID>
<ISSNLinking>0017-9078</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Chelating Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Emulsions</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Oils</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>059QF0KO0R</RegistryNumber>
<NameOfSubstance>Water</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>130036-26-9</RegistryNumber>
<NameOfSubstance>Calixarenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>4OC371KSTK</RegistryNumber>
<NameOfSubstance>Uranium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Calixarenes</DescriptorName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chelating Agents</DescriptorName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Decontamination</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Emulsions</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Oils</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Permeability</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Skin</DescriptorName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName MajorTopicYN="N">drug effects</QualifierName>
<QualifierName MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Swine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Uranium</DescriptorName>
<QualifierName MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y">isolation &amp; purification</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Viscosity</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N">Water</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983908</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1995-705X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>14</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Heart views : the official journal of the Gulf Heart Association</Title>
<ISOAbbreviation>Heart Views</ISOAbbreviation>
</Journal>
<ArticleTitle>Short-term effects of ivabradine in patients with chronic stable ischemic heart disease.</ArticleTitle>
<Pagination>
<MedlinePgn>53-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/1995-705X.115495</ELocationID>
<Abstract>
<AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Ivabradine is a novel selective If current inhibitor with anti-ischemic and antianginal activity.</AbstractText>
<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the effect of the selective If current inhibitor ivabradine on heart rate, angina pectoris, and functional capacity in stable patients with chronic coronary artery disease on maximally tolerated medical therapy.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Consecutive patients from the out-patient cardiology clinic with stable coronary artery disease documented by coronary angiography were included. Patients had to be on maximally tolerated medical therapy with β-blockers, angiotensin-converting enzyme inhibitors or receptor blockers (ACE-I or ARB), antiplatelets, statins, nitrates, and anti-metabolics with a baseline heart rate of at least 70 beats per minute. All patients underwent assessment of angina (Canadian Cardiovascular Society Angina Class: CCS I to IV) and functional capacity (using a validated self-administered questionnaire), at baseline and after 4 months of ivabradine therapy.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty patients were enrolled (mean age 47 ± 7 years, all male, 60% with hypertension, 30% with diabetes mellitus). Patients were on optimal medical regimen of aspirin (100%), β-blocker (100%), statins (100%), clopidogrel (90%), nitrates (35%), anti-metabolics (90%), and ACE-I or ARB (95%). At baseline, the majority of patients (90%) were in CCS class II-IV. All patients were started on ivabradine 5 mg twice daily, and in 12 patients the dose was increased to 7.5 mg twice daily. After 4 months of treatment, the heart rate was significantly reduced from an average of 82 ± 8 to 68 ± 6 bpm (P &lt; 0.001). The reduction in heart rate was accompanied by a significant improvement in functional capacity (score 3.5 ± 0.9 to 4.7 ± 0.7, P &lt; 0.001) and angina classification; at baseline 10% of the patients were in CCS class I compared to 50% after 4 months of therapy (P = 0.01). No symptomatic bradycardia was reported with ivabradine.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The addition of ivabradine to optimal medical therapy in patients with stable coronary artery disease is associated with significant improvement in anginal symptoms and functional capacity.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zaky</LastName>
<ForeName>Hosam</ForeName>
<Initials>H</Initials>
<Affiliation>Dubai Heart Center, Division of Cardiology, Dubai Hospital, Dubai Health Authority, Dubai, UAE.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Elzein</LastName>
<ForeName>Hind</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Alsheikh-Ali</LastName>
<ForeName>Alawi A</ForeName>
<Initials>AA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Al-Mulla</LastName>
<ForeName>Arif</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Heart Views</MedlineTA>
<NlmUniqueID>101316474</NlmUniqueID>
<ISSNLinking>1995-705X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752876</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Heart rate</Keyword>
<Keyword MajorTopicYN="N">ischemic heart disease</Keyword>
<Keyword MajorTopicYN="N">ivabradine</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983909</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1995-705X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>14</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Heart views : the official journal of the Gulf Heart Association</Title>
<ISOAbbreviation>Heart Views</ISOAbbreviation>
</Journal>
<ArticleTitle>Guidewires used in first intentional single wiring strategy for chronic total occlusions of the left anterior descending coronary artery.</ArticleTitle>
<Pagination>
<MedlinePgn>56-61</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/1995-705X.115496</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) of the left anterior descending (LAD) specifically is associated with improved long-term 5 year survival as compared to PCI failure. The procedure is associated with usage of different types of dedicated guidewires by simple or complex techniques aiming to reopen the occluded artery.</AbstractText>
<AbstractText Label="AIM" NlmCategory="OBJECTIVE">To describe types and outcome of guidewires used in LAD-CTO utilizing a first intentional single wiring simple strategy.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">A single center prospective registry for all consecutive patients with a PCI attempt to a native LAD CTO. The initial strategy for lesion crossing was Single wiring.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 30 patients with LAD CTO lesions (100%), were recorded. Mean age was 71.6 + 15 years, 77% were Males, risk factors Hypertension in 63%, Diabetes 27%, Dyslipidemia 57%, smoking 40%, hereditary in 13% of patients. Isolated guidewire (GW) success rate was very high 93%. Single wiring was the prevailing technique used in 97% of successfull lesions (83% of total cases) while only 3% were by multiple wiring techniques. Successful single antegrade wiring represented 63% with a GW success rate of 92% of cases. Successful single retrograde wiring represented 13% with a GW success rate of 67%. Successful Crossing GW types in our patients were 44% Soft Tapered GWs; fielder XT (44%), 36% were Soft Non Tapered Pilot 50 (28%), whisper (8%), while 16% were Stiff Non tapered GWs; Miracle 12 (8%), Miracle 6 (4%), Miracle 3 (4%), and 4% were Stiff Tapered GWs; Progress 200 (4%).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Single wiring as an initial strategy in PCI for LAD-CTO lesions has a high success rate and is associated with a 44% majority of Soft Tapered GWs, 36% Soft Non Tapered, 16% Stiff Non tapered GWs, and 4% Stiff Tapered GWs.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Nassar</LastName>
<ForeName>Yasser S</ForeName>
<Initials>YS</Initials>
<Affiliation>Department of Critical Care, Cairo University, Giza, Egypt.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Boudou</LastName>
<ForeName>Nicolas</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Dumonteil</LastName>
<ForeName>Nicolas</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lhermusier</LastName>
<ForeName>Thibault</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Carrie</LastName>
<ForeName>Didier</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Heart Views</MedlineTA>
<NlmUniqueID>101316474</NlmUniqueID>
<ISSNLinking>1995-705X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752877</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Chronic total occlusion</Keyword>
<Keyword MajorTopicYN="N">first intention</Keyword>
<Keyword MajorTopicYN="N">guidewires</Keyword>
<Keyword MajorTopicYN="N">left anterior descending</Keyword>
<Keyword MajorTopicYN="N">single wiring</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983910</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1995-705X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>14</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Heart views : the official journal of the Gulf Heart Association</Title>
<ISOAbbreviation>Heart Views</ISOAbbreviation>
</Journal>
<ArticleTitle>Intracoronary Reopro during Percutaneous Coronary Intervention in Acute and Stable Patient can Influence Stent Thrombosis Formation (IRPASST) Study.</ArticleTitle>
<Pagination>
<MedlinePgn>62-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/1995-705X.115498</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty, abciximab reduces major adverse cardiac events (MACE). Most clinical trials have studied mainly intravenous administration. Intracoronary (IC) bolus application of abciximab causes very high local drug concentrations and may be more effective in reducing acute and sub-acute stent thrombosis (ST). We studied whether IC bolus administration of abciximab is associated with a reduced ST and target vessels revascularization (TVR); therefore, less MACE rate compared with the standard intravenous IV bolus and infusion application.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">This was a single-center observational study conducted between June 2007 and 2009. We studied a total of 447 patients admitted with either acute coronary intervention (PCI) and stenting. Patients with bleeding disorder, recent major surgery and high blood pressure were excluded. Patients were divided into two groups: Group I (n = 199) patient received IC bolus of abciximab (reopro) 0.25 μg/kg during the PCI in cath lab. Group II (n = 248) received the standard dose of reopro-a bolus intravenous 0.25 μg/kg and maintenance dose of 0.125 μg/kg over 12 h.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no differences between the groups with regard to diabetes mellitus, group I (56%) vs. group II (58%), P = 0.613; ACS, group I (38%) vs. group II (44%), P = 0.175; Dietthylstilbestrol Drug eluted stent (DES) in group I (66.5%) vs. (57.6%) group II, P = 0.056; Bare Metal Stent (BMS) in group I (33%) vs. (40.7%) group II, P=0.093; target vessel revascularization (TRV) was seen in 9 patients (4%) in group I vs. 16 patients (6%) in group II. ST elevation was seen in 4 patients (2%) in group I vs. 7 patients (2.8%) in group II, all presented with STEMI.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this study, there was a trend toward less ST and TVR in patients who received IC reopro vs. intravenous route both in ACS and stable CAD. The percentage of DM was high in both groups (56%), especially in Saudi patients. In-stent restenosis (ISR) was less in group I than in group II, this was mainly associated with BMS usage. The percentage of BMS was more than 30% in both groups, either due to STEMI cases or large vessel size. Randomized controlled trials are warranted to further assess IC application of abciximab in reducing ST.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Balghith</LastName>
<ForeName>Mohammed</ForeName>
<Initials>M</Initials>
<Affiliation>King Saud Bin Abdulaziz University for Health Sciences, KACC, National Guard, Riyadh, Kingdom of Saudi Arabia.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Al-Ghamdi</LastName>
<ForeName>Ali</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zain</LastName>
<ForeName>El Harif</ForeName>
<Initials>el H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Al-Saileek</LastName>
<ForeName>Ahmed</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Heart Views</MedlineTA>
<NlmUniqueID>101316474</NlmUniqueID>
<ISSNLinking>1995-705X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752878</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Abciximab</Keyword>
<Keyword MajorTopicYN="N">acute coronary artery disease</Keyword>
<Keyword MajorTopicYN="N">intracoronary</Keyword>
<Keyword MajorTopicYN="N">intravenous</Keyword>
<Keyword MajorTopicYN="N">stent thrombosis</Keyword>
<Keyword MajorTopicYN="N">tirofiban</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983911</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1995-705X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>14</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Heart views : the official journal of the Gulf Heart Association</Title>
<ISOAbbreviation>Heart Views</ISOAbbreviation>
</Journal>
<ArticleTitle>Right Ventricle Myocardial Performance Index Versus Simpson's Right Ventricle Ejection Fraction in Patients with Isolated Left Ventricle Anterior Myocardial Infarction.</ArticleTitle>
<Pagination>
<MedlinePgn>68-71</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/1995-705X.115500</ELocationID>
<Abstract>
<AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Right ventricle (RV) dysfunction may be secondary to left ventricle (LV) dysfunction in patients of isolated left ventricle anterior myocardial infarction as a consequence of "Ventricular Interdependence". As RV dysfunction is associated with high in-hospital morbidity and mortality, early recognization of RV dysfunction is warranted; but until today it remains a challenging task because of complex structure and asymmetric shape of RV.</AbstractText>
<AbstractText Label="AIMS AND OBJECTIVES" NlmCategory="OBJECTIVE">Our aim in the present study was to compare Simpson's right ventricle ejection fraction (RVEF) with right ventricle myocardial performance index (RV-MPI) to predict RV function in patients with isolated left ventricle anterior myocardial infarction (LV-AMI).</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We conducted the present study at the Department of Cardiology of Jawahar Lal Nehru Medical College and Associate Group of Hospitals, Ajmer. The control group comprised of twenty five. Age, sex, BMI, pulse and blood pressure matched healthy subjects without history of heart disease, systemic hypertension, diabetes, any other systemic illness and with normal findings in resting and exercise ECG, Echocardiography and Coronary Angiography. Sub-group-1 consisted of 25 patients with hemodynamically significant stenosis of proximal left anterior descending artery (LAD) with patent first septal perforator (S1). Sub-group-2 was composed of s5 patients with hemodynamically significant stenosis of both LAD and left circumflex artery (LCx.). Both subgroups had fully patent right coronary artery (RCA) from proximal to distal end.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">RV-MPI value determined using pulsed doppler echocardiography was 0.40 ± 0.19 in healthy subjects. However RV-MPI was increased in both subgroups of LV-AMI with significant increase in subgroup-2 (P &lt; 0.005) as compared to subgroup-1 patients (P &lt; 0.01). Simpson's RVEF was not significantly different between the groups (P &gt; 0.05).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The findings in this study demonstrate that RV-MPI is a more sensitive, non-geometric echocardiographic parameter than Simpson's RVEF in detecting early RV dysfunction. Early detection of RV dysfunction is important to reduce morbidity and mortality in these patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Maheshwari</LastName>
<ForeName>Monika</ForeName>
<Initials>M</Initials>
<Affiliation>Department of Cardiology, Jawahar Lal Nehru Medical College, Ajmer, Rajasthan, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Mittal</LastName>
<ForeName>Sita Ram</ForeName>
<Initials>SR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Heart Views</MedlineTA>
<NlmUniqueID>101316474</NlmUniqueID>
<ISSNLinking>1995-705X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752879</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Isolated left ventricle anterior myocardial infarction</Keyword>
<Keyword MajorTopicYN="N">Simpson's right ventricle ejection fraction</Keyword>
<Keyword MajorTopicYN="N">right ventricle myocardial performance index</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983912</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1995-705X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>14</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Heart views : the official journal of the Gulf Heart Association</Title>
<ISOAbbreviation>Heart Views</ISOAbbreviation>
</Journal>
<ArticleTitle>Stent fracture: how frequently is it recognized?</ArticleTitle>
<Pagination>
<MedlinePgn>72-81</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/1995-705X.115501</ELocationID>
<Abstract>
<AbstractText>In spite of there being several case reports, coronary stent fracture is not a well-recognized entity and incidence rates are likely to be underestimated. In this article, we review different aspects of stent fracture, including incidence, classification, predictors, outcome, diagnosis, and management. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mohsen</LastName>
<ForeName>Mohammed Khalil</ForeName>
<Initials>MK</Initials>
<Affiliation>Heart Hospital, Hamad Medical Corporation, Doha, Qatar.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Alqahtani</LastName>
<ForeName>Awad</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Al Suwaidi</LastName>
<ForeName>Jassim</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Heart Views</MedlineTA>
<NlmUniqueID>101316474</NlmUniqueID>
<ISSNLinking>1995-705X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752880</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Complication of percutaneous coronary intervention (PCI)</Keyword>
<Keyword MajorTopicYN="N">instent restenosis</Keyword>
<Keyword MajorTopicYN="N">stent fracture</Keyword>
<Keyword MajorTopicYN="N">stent thrombosis</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983913</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1995-705X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>14</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Heart views : the official journal of the Gulf Heart Association</Title>
<ISOAbbreviation>Heart Views</ISOAbbreviation>
</Journal>
<ArticleTitle>The place of carotico-subclavian bypass surgery in angina treatment.</ArticleTitle>
<Pagination>
<MedlinePgn>82-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/1995-705X.115502</ELocationID>
<Abstract>
<AbstractText>Coronary-subclavian steal syndrome results from atherosclerotic disease of the proximal subclavian artery, causing reversal of flow in an internal mammary artery used as conduit for coronary artery bypass. In the present case, we discussed the diagnosis and the treatment of coronary steal syndrome in a patient hospitalized due to decompensated cardiac insufficiency. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Tiryakioglu</LastName>
<ForeName>Selma Kenar</ForeName>
<Initials>SK</Initials>
<Affiliation>Department of Cardiology, Acibadem Bursa Hospital, Bursa, Turkey.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Tiryakioglu</LastName>
<ForeName>Osman</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kaya</LastName>
<ForeName>Ugur</ForeName>
<Initials>U</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Heart Views</MedlineTA>
<NlmUniqueID>101316474</NlmUniqueID>
<ISSNLinking>1995-705X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752881</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Angina pectoris</Keyword>
<Keyword MajorTopicYN="N">carotico-subclavian bypass</Keyword>
<Keyword MajorTopicYN="N">coronary subclavian steal</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983914</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1995-705X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>14</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Heart views : the official journal of the Gulf Heart Association</Title>
<ISOAbbreviation>Heart Views</ISOAbbreviation>
</Journal>
<ArticleTitle>Massive lipomatous hypertrophy of the right atria.</ArticleTitle>
<Pagination>
<MedlinePgn>85-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/1995-705X.115504</ELocationID>
<Abstract>
<AbstractText>A case of a 70-year-old female with a history of hypertension, atrial fibrillation, pacer implantation for symptomatic bradycardia, and a prior cerebrovascular accident, and had developed persistent methicillin-sensitive Staphylococcus aureus bacteremia is reported here. As part of her evaluation, a transesophageal echocardiogram was performed, and even though no vegetations were seen on either pacer wires or cardiac valves, a massive homogeneous thickening of the superior portion of the interatrial septum extending to the posterior and roof portions of the right atrial wall as well as to the superior vena cava causing proximal compression of this vessel was noted. Computed tomographic examination of the chest helped to determine that this mass density was not a tumor but in fact intrapericardial fat. Imaging findings and existing literature on this topic are reviewed. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>López-Candales</LastName>
<ForeName>Angel</ForeName>
<Initials>A</Initials>
<Affiliation>Division of Cardiovascular Diseases, University of Cincinnati School of Medicine, Cincinnati, OH, USA.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Heart Views</MedlineTA>
<NlmUniqueID>101316474</NlmUniqueID>
<ISSNLinking>1995-705X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752882</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Computed tomography</Keyword>
<Keyword MajorTopicYN="N">echocardiography</Keyword>
<Keyword MajorTopicYN="N">fossa ovalis</Keyword>
<Keyword MajorTopicYN="N">interatrial septum</Keyword>
<Keyword MajorTopicYN="N">lipomatous hypertrophy</Keyword>
<Keyword MajorTopicYN="N">right atria</Keyword>
<Keyword MajorTopicYN="N">superior vena cava</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983915</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1995-705X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>14</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Heart views : the official journal of the Gulf Heart Association</Title>
<ISOAbbreviation>Heart Views</ISOAbbreviation>
</Journal>
<ArticleTitle>Giant interatrial septal aneurysm mimicking a left atrial mass.</ArticleTitle>
<Pagination>
<MedlinePgn>88-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/1995-705X.115503</ELocationID>
<Abstract>
<AbstractText>Interatrial septal aneurysm (IASA) consists of redundant atrial septal tissue, which bulges into either the left or the right atrium. The clinical implications of this entity are not entirely clear; however, if it is associated with other cardiac abnormalities such as patent foramen ovale and atrial septal defects. It may assume significance by increasing the risk of cardioembolic events such as stroke. We present a case of an individual with giant IASA detected by transesophageal echocardiography, which was mimicking a left atrial mass on transthoracic echocardiography. This case emphasizes the superiority of transesophageal imaging over transthoracic echocardiography for this clinical entity. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Taleb</LastName>
<ForeName>Mohammed</ForeName>
<Initials>M</Initials>
<Affiliation>Department of Medicine, University of Toledo Medical Center, Toledo, Ohio, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Moza</LastName>
<ForeName>Ankush</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Khouri</LastName>
<ForeName>Samer J</ForeName>
<Initials>SJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Heart Views</MedlineTA>
<NlmUniqueID>101316474</NlmUniqueID>
<ISSNLinking>1995-705X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752883</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Atrial mass</Keyword>
<Keyword MajorTopicYN="N">interatrial septal aneurysm</Keyword>
<Keyword MajorTopicYN="N">transesophageal echocardiography</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983916</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1995-705X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>14</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2013</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Heart views : the official journal of the Gulf Heart Association</Title>
<ISOAbbreviation>Heart Views</ISOAbbreviation>
</Journal>
<ArticleTitle>Catheter-induced spiral dissection of the left main coronary artery.</ArticleTitle>
<Pagination>
<MedlinePgn>90-1</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/1995-705X.115494</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Patel</LastName>
<ForeName>Ashfaq</ForeName>
<Initials>A</Initials>
<Affiliation>Department of Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Arabi</LastName>
<ForeName>Abdul R</ForeName>
<Initials>AR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Alkindi</LastName>
<ForeName>Fahad</ForeName>
<Initials>F</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Heart Views</MedlineTA>
<NlmUniqueID>101316474</NlmUniqueID>
<ISSNLinking>1995-705X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752884</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984095</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-5521</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN allergy</Title>
<ISOAbbreviation>ISRN Allergy</ISOAbbreviation>
</Journal>
<ArticleTitle>The challenge of delivering therapeutic aerosols to asthma patients.</ArticleTitle>
<Pagination>
<MedlinePgn>102418</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/102418</ELocationID>
<Abstract>
<AbstractText>The number of people with asthma continues to grow around the world, and asthma remains a poorly controlled disease despite the availability of management guidelines and highly effective medication. Patient noncompliance with therapy is a major reason for poor asthma control. Patients fail to comply with their asthma regimen for a wide variety of reasons, but incorrect use of inhaler devices is amongst the most common. The pressurised metered-dose inhaler (pMDI) is still the most frequently used device worldwide, but many patients fail to use it correctly, even after repeated tuition. Breath-actuated inhalers are easier to use than pMDIs. The rationale behind inhaler choice should be evidence based rather than empirical. When choosing an inhaler device, it is essential that it is easy to use correctly, dosing is consistent, adequate drug is deposited in both central and peripheral airways, and that drug deposition is independent of airflow. Regular checking of inhalation technique is crucial, as correct inhalation is one of the cornerstones of successful asthma management. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Lavorini</LastName>
<ForeName>Federico</ForeName>
<Initials>F</Initials>
<Affiliation>Department of Experimental and Clinical Medicine, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>ISRN Allergy</MedlineTA>
<NlmUniqueID>101605568</NlmUniqueID>
<ISSNLinking>2090-553X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747606</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984096</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-5580</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN cardiology</Title>
<ISOAbbreviation>ISRN Cardiol</ISOAbbreviation>
</Journal>
<ArticleTitle>Adequacy of cancer screening in adult women with congenital heart disease.</ArticleTitle>
<Pagination>
<MedlinePgn>827696</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/827696</ELocationID>
<Abstract>
<AbstractText>Adults with congenital heart disease (ACHD) face noncardiac healthcare challenges as the population ages. We assessed whether women with ACHD have comparable cancer screening rates to non-ACHD women in a cardiac practice and to the general population. We performed a retrospective review of 175 adult women seen in a cardiac care center in 2009-2011. Data on Pap tests, mammography, and colonoscopies, were collected through electronic medical records and primary care provider records. Adequate documentation was available for 100 individuals with ACHD and 40 comparator cardiac patients. The adequacy of screening was determined using guidelines set forth by the American Cancer Society in 2010. Compared with the national average, ACHD patients had significantly lower rates of Pap tests (60% versus 83%, P &lt; 0.001) and mammography (48% versus 72%, P &lt; 0.001). Compared with non-ACHD women in the same practice, ACHD patients had consistently lower rates of mammography (48% versus 81%, P = 0.02) and colonoscopies (54% versus 82%, P = 0.23). As the population of ACHD individuals ages, attention to cancer screening becomes increasingly important but may be overlooked in this population. Primary care physicians and cardiologists should collaborate to ensure appropriate cancer screening for this growing population. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Christman</LastName>
<ForeName>Mitalee P</ForeName>
<Initials>MP</Initials>
<Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Castro-Zarraga</LastName>
<ForeName>Margarita</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Defaria Yeh</LastName>
<ForeName>Doreen</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liberthson</LastName>
<ForeName>Richard R</ForeName>
<Initials>RR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bhatt</LastName>
<ForeName>Ami B</ForeName>
<Initials>AB</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Cardiol</MedlineTA>
<NlmUniqueID>101566293</NlmUniqueID>
<ISSNLinking>2090-5580</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747419</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984078</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-4371</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN dentistry</Title>
<ISOAbbreviation>ISRN Dent</ISOAbbreviation>
</Journal>
<ArticleTitle>Changes in water sorption and solubility of dental adhesive systems after cigarette smoke.</ArticleTitle>
<Pagination>
<MedlinePgn>605847</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/605847</ELocationID>
<Abstract>
<AbstractText>Aim. To evaluate the effect of cigarette smoke on water sorption and solubility of four adhesive systems. Materials and Methods. Sixteen disks of each adhesive system were prepared (Adper Scotchbond Multipurpose Adhesive (SA); Adper Scotchbond Multipurpose Adhesive System (Adhesive + Primer) (SAP); Adper Single Bond Plus (SB); Adper Easy One (EO)). Specimens were desiccated until a constant mass was obtained and divided into two groups (n = 8). One-half of the specimens were immersed in deionized water, while the other half were also immersed, but with daily exposure to tobacco smoke. After 21 days, disks were measured again and stored in desiccators until constant mass was achieved. Data were calculated according to ISO specifications and statistically analyzed. Results. The tobacco smoke only significantly affected the water sorption and solubility of EO. There were significant differences in both analyses among materials tested. The SB exhibited the highest water sorption, followed by EO, which demonstrated significantly higher solubility values than SB. The SA and SAP showed low water sorption and solubility, and there were no significant differences between the two. Conclusion. Regardless of smoke exposure, both simplified adhesive systems presented an inferior performance that could be related to the complex mixture of components in such versions. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Vitória</LastName>
<ForeName>Lívia Andrade</ForeName>
<Initials>LA</Initials>
<Affiliation>Department of Clinical Dentistry, School of Dentistry, Federal University of Bahia, Av. Araújo Pinho, 62, Canela, 40110-150 Salvador, BA, Brazil.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Aguiar</LastName>
<ForeName>Thaiane Rodrigues</ForeName>
<Initials>TR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Santos</LastName>
<ForeName>Poliana Ramos Braga</ForeName>
<Initials>PR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cavalcanti</LastName>
<ForeName>Andrea Nóbrega</ForeName>
<Initials>AN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mathias</LastName>
<ForeName>Paula</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Dent</MedlineTA>
<NlmUniqueID>101560640</NlmUniqueID>
<ISSNLinking>2090-4371</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747503</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984086</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-4592</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN dermatology</Title>
<ISOAbbreviation>ISRN Dermatol</ISOAbbreviation>
</Journal>
<ArticleTitle>Endothelin-1 levels in scleroderma patients: a pilot study.</ArticleTitle>
<Pagination>
<MedlinePgn>125632</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/125632</ELocationID>
<Abstract>
<AbstractText>Endothelin-1 (ET-1) is a potent endogenous vasoconstrictor, which mediates vascular wall cells proliferation, fibrosis, and inflammation through two types of ET-1 receptors (ET-A and ET-B). In our retrospective study the serum levels of ET-1 in 18 systemic sclerosis (SSc) patients with and without digital ulcers (DUs) were assessed to observe possible correlation between the levels of ET-1, the evolution of SSc, and the therapy with an ET-1 antagonist (bosentan). In all our patients, the levels of ET-1 were found higher than normal range and correlate with the severity of the disease. Furthermore we also observed that in patients without DUs the levels of ET-1 were higher and did not correlate with new DUs development. In conclusion, the levels of ET-1 in our studied patients do not correlate with the possible development of DUs. The reduction of ET-1 levels in DUs patients in therapy with bosentan confirms the efficacy of this molecule both for treatment and prevention of digital ulcers. The inhibition of ET-A receptor by its antagonist may activate the opposite ET-B receptors, with well-known function ET-1 degradation and reducing of ET-1 serum level as confirmed in our pilot study. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Cozzani</LastName>
<ForeName>Emanuele</ForeName>
<Initials>E</Initials>
<Affiliation>DISSAL, Section of Dermatology, IRCCS University Hospital San Martino-IST, 16132 Genoa, Italy.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Javor</LastName>
<ForeName>Sanja</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Laborai</LastName>
<ForeName>Erika</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Drosera</LastName>
<ForeName>Massimo</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Parodi</LastName>
<ForeName>Aurora</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Dermatol</MedlineTA>
<NlmUniqueID>101566611</NlmUniqueID>
<ISSNLinking>2090-4592</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747472</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984087</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-4592</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN dermatology</Title>
<ISOAbbreviation>ISRN Dermatol</ISOAbbreviation>
</Journal>
<ArticleTitle>Hemostatic and Wound Healing Properties of Chromolaena odorata Leaf Extract.</ArticleTitle>
<Pagination>
<MedlinePgn>168269</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/168269</ELocationID>
<Abstract>
<AbstractText>Chromolaena odorata (L.) King and Robinson (Siam weed) extract has been used to stop bleeding and in wound healing in many tropical countries. However, its detailed mechanisms have not been elucidated. In this study, we examined the molecular mechanisms by which Siam weed extract (SWE) affected hemostatic and wound healing activities. SWE promoted Balb/c 3T3 fibroblast cell migration and proliferation. Subsequently, we found that heme oxygenase-1 (HO-1), the accelerating wound healing enzyme, was increased at the transcriptional and translational levels by SWE treatments. The HO-1 promoter analyzed with luciferase assay was also increased by treatment of SWE in a dose-dependent manner. This induction may be mediated by several kinase pathways including MEK, p38MAPK, AKT, and JNK. Quantitative real-time PCR using undifferentiated promonocytic cell lines revealed that thromboxane synthase (TXS), a potent vasoconstrictor and platelet aggregator, was increased and MMP-9, an anti platelet aggregator, was decreased in the presence of SWE. Our studies presented that SWE accelerated hemostatic and wound healing activities by altering the expression of genes, including HO-1, TXS, and MMP-9. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pandith</LastName>
<ForeName>Hataichanok</ForeName>
<Initials>H</Initials>
<Affiliation>Department of Biomedical and Diagnostic Sciences, The University of Tennessee, Knoxville, TN 37996, USA ; Department of Pharmacognosy, Faculty of Pharmacy, Mahidol University, 447 Sri Ayutthaya Road, Ratchathewi, Bangkok 10400, Thailand.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Xiaobo</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liggett</LastName>
<ForeName>Jason</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Min</LastName>
<ForeName>Kyung-Won</ForeName>
<Initials>KW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gritsanapan</LastName>
<ForeName>Wandee</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Baek</LastName>
<ForeName>Seung Joon</ForeName>
<Initials>SJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Dermatol</MedlineTA>
<NlmUniqueID>101566611</NlmUniqueID>
<ISSNLinking>2090-4592</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747403</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984088</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-4592</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN dermatology</Title>
<ISOAbbreviation>ISRN Dermatol</ISOAbbreviation>
</Journal>
<ArticleTitle>Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>597927</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/597927</ELocationID>
<Abstract>
<AbstractText>Transforming growth factor-beta (TGF- β ) is a pleiotropic factor, with several different roles in health and disease. TGF- β has been postulated as a dual factor in tumor progression, since it represses epithelial tumor development in early stages, whereas it stimulates tumor progression in advanced stages. During tumorigenesis, cancer cells acquire the capacity to migrate and invade surrounding tissues and to metastasize different organs. The urokinase-type plasminogen activator (uPA) system, comprising uPA, the uPA cell surface receptor, and plasminogen-plasmin, is involved in the proteolytic degradation of the extracellular matrix and regulates key cellular events by activating intracellular signal pathways, which together allow cancer cells to survive, thus, enhancing cell malignance during tumor progression. Due to their importance, uPA and its receptor are tightly transcriptionally regulated in normal development, but are deregulated in cancer, when their activity and expression are related to further development of cancer. TGF- β regulates uPA expression in cancer cells, while uPA, by plasminogen activation, may activate the secreted latent TGF- β , thus, producing a pernicious cycle which contributes to the enhancement of tumor progression. Here we review the specific roles and the interplay between TGF- β and uPA system in cancer cells and their implication in skin cancer. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Santibanez</LastName>
<ForeName>Juan F</ForeName>
<Initials>JF</Initials>
<Affiliation>Laboratory for Experimental Hematology and Stem Cells, Institute for Medical Research, University of Belgrade, Dr. Subotića 4, 11129 Belgrade, Serbia.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Dermatol</MedlineTA>
<NlmUniqueID>101566611</NlmUniqueID>
<ISSNLinking>2090-4592</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3732602</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984079</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-4398</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN gastroenterology</Title>
<ISOAbbreviation>ISRN Gastroenterol</ISOAbbreviation>
</Journal>
<ArticleTitle>ERCP features and outcome in patients with periampullary duodenal diverticulum.</ArticleTitle>
<Pagination>
<MedlinePgn>217261</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/217261</ELocationID>
<Abstract>
<AbstractText>Background. Although periampullary diverticulum is usually asymptomatic and discovered incidentally in patients during endoscopic retrograde cholangiopancreatography (ERCP), it may lead to post-ERCP morbidity. We compared baseline characteristics and clinical data as well as ERCP results in patients with and without periampullary diverticulum. Methods. Clinical, laboratory, and ERCP data of 780 patients referred to the Taleghani Hospital, as a great referral endoscopy center, in Iran were prospectively analyzed. Results. The periampullary diverticulum was identified in 44 patients (5.6%). Cannulation of common bile duct was more failed in patients with diverticulum compared to others (35.5% versus 11.5, P &lt; 0.001). Patients with diverticulum had eight times more often common bile duct stone compared to patients without diverticulum (54.5% versus 12.2%, P &lt; 0.001). Post-ERCP complications were observed in 2.3% and 4.2% of patients with and without diverticulum, respectively, which did not significantly differ in both groups. Conclusion. Because of more failure cannulation in the presence of periampullary diverticulum, ERCP requires more skills in these patients. Prevalence of common bile duct stone was notably higher in patients with diverticulum; therefore, more assessment of bile stone and its complications in these patients is persistently recommended. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mohammad Alizadeh</LastName>
<ForeName>Amir Houshang</ForeName>
<Initials>AH</Initials>
<Affiliation>Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran 19857, Iran.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Afzali</LastName>
<ForeName>Esmaeil Shamsi</ForeName>
<Initials>ES</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shahnazi</LastName>
<ForeName>Anahita</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mousavi</LastName>
<ForeName>Mirhadi</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Doagoo</LastName>
<ForeName>Siavash Zafar</ForeName>
<Initials>SZ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mirsattari</LastName>
<ForeName>Dariush</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zali</LastName>
<ForeName>Mohammad Reza</ForeName>
<Initials>MR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Gastroenterol</MedlineTA>
<NlmUniqueID>101563306</NlmUniqueID>
<ISSNLinking>2090-4398</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747500</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984080</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-441X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN hematology</Title>
<ISOAbbreviation>ISRN Hematol</ISOAbbreviation>
</Journal>
<ArticleTitle>Detailed analysis of diffuse large B cell lymphoma patients: a single-center, retrospective study.</ArticleTitle>
<Pagination>
<MedlinePgn>908191</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/908191</ELocationID>
<Abstract>
<AbstractText>The aim of this single-center, retrospective study was to investigate the impact of rituximab, reconsider the validity of International Prognostic Index (IPI), and evaluate the prognostic role of the cell of origin (CoO) in a relatively young cohort. Three hundred twelve diffuse large B cell lymphoma patients (median age: 52) were included. Rituximab significantly improved the 3- and 5-year progression free survival (PFS) (70% versus 65% and 41% versus 36%, resp.; P &lt; 0.001) but led only to a slight, insignificant increase in 3- and 5-year overall survival (OS) (71% versus 77.3% and %67 versus 74.5%, resp.; P = 0.264). In the young, low risk patient subgroup (aaIPI = 0&amp;1; n = 129), rituximab improved 3- and 5-year PFS and OS rates (P &lt; 0.001 and P = 0.048, resp.). The efficacy of rituximab in young high risk patients was comparable to the literature. CoO data were available in 190 patients. The OS at 3 years was 79% for GC and 64% for non-GC subgroups (P = 0.014). To the best of our knowledge, this is the first study which investigated the impact of R-CHOP in the context of CoO and IPI in a relatively young cohort. CoO was not an independent risk factor for prognosis in the multivariate analysis although patients with GC showed a significant survival advantage in the univariate analysis. CoO was also found to be a significant determinant of response in refractory/relapsed patients. Our results confirm the efficacy of rituximab in low and high risk, young patients outside of a randomized clinical trial setting. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ozbalak</LastName>
<ForeName>Murat</ForeName>
<Initials>M</Initials>
<Affiliation>Division of Haematology, Department of Internal Medicine, Istanbul University, Cerrahpasa Medical Faculty, Cerrahpasa Cd., No. 181, Kocamustafapasa-Fatih, 34098 Istanbul, Turkey.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Ar</LastName>
<ForeName>M Cem</ForeName>
<Initials>MC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tuzuner</LastName>
<ForeName>Nukhet</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Salihoglu</LastName>
<ForeName>Ayse</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Eskazan</LastName>
<ForeName>A Emre</ForeName>
<Initials>AE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ongoren Aydin</LastName>
<ForeName>Seniz</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Baslar</LastName>
<ForeName>Zafer</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Soysal</LastName>
<ForeName>Teoman</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Aydin</LastName>
<ForeName>Yildiz</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Barak Dolgun</LastName>
<ForeName>Anil</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ergonul</LastName>
<ForeName>Onder</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ferhanoglu</LastName>
<ForeName>Burhan</ForeName>
<Initials>B</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Hematol</MedlineTA>
<NlmUniqueID>101567023</NlmUniqueID>
<ISSNLinking>2090-441X</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747433</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984180</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-7478</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN microbiology</Title>
<ISOAbbreviation>ISRN Microbiol</ISOAbbreviation>
</Journal>
<ArticleTitle>Host-Microbe Interactions in Caenorhabditis elegans.</ArticleTitle>
<Pagination>
<MedlinePgn>356451</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/356451</ELocationID>
<Abstract>
<AbstractText>A good understanding of how microbes interact with hosts has a direct bearing on our capability of fighting infectious microbial pathogens and making good use of beneficial ones. Among the model organisms used to study reciprocal actions among microbes and hosts, C. elegans may be the most advantageous in the context of its unique attributes such as the short life cycle, easiness of laboratory maintenance, and the availability of different genetic mutants. This review summarizes the recent advances in understanding host-microbe interactions in C. elegans. Although these investigations have greatly enhanced our understanding of C. elegans-microbe relationships, all but one of them involve only one or few microbial species. We argue here that more research is needed for exploring the evolution and establishment of a complex microbial community in the worm's intestine and its interaction with the host. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Rui</ForeName>
<Initials>R</Initials>
<Affiliation>Department of Environmental Sciences, School of the Coast and Environment, Louisiana State University, Baton Rouge, LA 70803, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Hou</LastName>
<ForeName>Aixin</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Microbiol</MedlineTA>
<NlmUniqueID>101605570</NlmUniqueID>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747393</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984181</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-7478</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN microbiology</Title>
<ISOAbbreviation>ISRN Microbiol</ISOAbbreviation>
</Journal>
<ArticleTitle>Role of flies as vectors of foodborne pathogens in rural areas.</ArticleTitle>
<Pagination>
<MedlinePgn>718780</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/718780</ELocationID>
<Abstract>
<AbstractText>This study aims to evaluate flies as a vector for foodborne pathogens. For this purpose, several flies were collected from different sites from rural areas. These flies were then analyzed for the presence of Enterobacteriaceae, Escherichia coli, Staphylococcus coagulase positive, and Listeria monocytogenes. Another aim of this study was to evaluate some virulence factors of the collected pathogens: susceptibility to some antibiotics and the presence of enterotoxigenic S. aureus. The results showed that flies in the presence of animals demonstrated a significantly higher prevalence of the studied pathogens than those collected in the kitchens, and kitchens situated in the closest proximity to the animal husbandry had a higher count than the kitchens in private houses. Enterobacteriaceae was the indicator organism with the highest microbial counts followed by E. coli and S. aureus. Listeria monocytogenes was not detected from any of the collected flies. The antimicrobial susceptibility test showed that the bacteria carried by the flies possessed multiantibiotic resistance profiles, and enterotoxin A was produced by 17.9% of the confirmed S. aureus isolates. These results demonstrate that flies can transmit foodborne pathogens and their associated toxin and resistance and the areas of higher risk are those in closer proximity to animal production sites. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Barreiro</LastName>
<ForeName>Cláudia</ForeName>
<Initials>C</Initials>
<Affiliation>CBQF-Centro de Biotecnologia e Química Fina, Laboratório Associado, Escola Superior de Biotecnologia, Universidade Católica Portuguesa/Porto, Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Albano</LastName>
<ForeName>Helena</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Silva</LastName>
<ForeName>Joana</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Teixeira</LastName>
<ForeName>Paula</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Microbiol</MedlineTA>
<NlmUniqueID>101605570</NlmUniqueID>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747605</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984093</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-5505</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN neurology</Title>
<ISOAbbreviation>ISRN Neurol</ISOAbbreviation>
</Journal>
<ArticleTitle>The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial.</ArticleTitle>
<Pagination>
<MedlinePgn>370943</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/370943</ELocationID>
<Abstract>
<AbstractText>Preclinical studies suggest that fluoxetine may have neuroprotective properties. In this pilot study forty-two patients with secondary or primary progressive MS were randomized to receive fluoxetine 20 mg twice daily or placebo for 2 years. Every 3 months the Expanded Disability Status Scale (EDSS), 9-hole peg test (9-HPT) and ambulation index (AI) were assessed. Brain MRI scans, Multiple Sclerosis Functional Composite, Fatigue Impact Scale, Guy's neurological disability Scale and SF-36 were performed at baseline, year 1 and year 2. Seven out of 20 (35%) patients in the fluoxetine group and 7 out of 22 (32%) patients in the placebo group had sustained progression on the EDSS, 9-HPT, or AI at 2 years. No differences were identified between the 2 treatment groups with respect to secondary clinical outcomes and T2 lesion load, grey matter volume and white matter volume. An unanticipated low rate of disability progression in the placebo group decreased the statistical power. At least 200 patients would have been needed to detect a 50% treatment effect. This trial shows that fluoxetine was generally well tolerated, but no assumptions can be made about a possible treatment effect. An adequately powered controlled trial of fluoxetine in progressive MS is still warranted. This trial is registered with Current Controlled Trials ISRCTN38456328. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mostert</LastName>
<ForeName>Jop</ForeName>
<Initials>J</Initials>
<Affiliation>Department of Neurology, University Medical Center Groningen, University of Groningen, Postbus 30.001, 9700 RB Groningen, The Netherlands ; Department of Neurology, Rijnstate Hospital, Postbus 9555, 6800 TA Arnhem, The Netherlands.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Heersema</LastName>
<ForeName>Thea</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mahajan</LastName>
<ForeName>Manju</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Van Der Grond</LastName>
<ForeName>Jeroen</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Van Buchem</LastName>
<ForeName>Mark A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>De Keyser</LastName>
<ForeName>Jacques</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Neurol</MedlineTA>
<NlmUniqueID>101568083</NlmUniqueID>
<ISSNLinking>2090-5505</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747490</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984094</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-5505</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN neurology</Title>
<ISOAbbreviation>ISRN Neurol</ISOAbbreviation>
</Journal>
<ArticleTitle>Vitamin E-Induced Changes in Glutamate and GABA Metabolizing Enzymes of Chick Embryo Cerebrum.</ArticleTitle>
<Pagination>
<MedlinePgn>851235</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/851235</ELocationID>
<Abstract>
<AbstractText>Vitamin E exists in eight different forms, four tocopherols and four tocotrienols. It forms an important component of our antioxidant system. The structure of Vitamin E makes it unique and indispensable in protecting cell membranes. α -tocopherol, one of the forms of Vitamin E, is also known to regulate signal transduction pathways by mechanisms that are independent of its antioxidant properties. Vitamin E compounds reduce the production of inflammatory compounds such as prostaglandins. Swollen, dystrophic axons are considered as the hallmark of Vitamin E deficiency in the brains of rats, monkeys, and humans. The present work aimed to study the Vitamin E- ( α -tochopherol acetate-) induced alterations of enzymes involved in metabolism of Glutamate and GABA during developmental neurogenesis of cerebrum. Therefore, cytosolic and crude mitochondrial enzyme activities of glutamine synthetase, aspartate transaminase, alanine transaminase, GABA transaminase, succinic Semialdehyde dehydrogenase, glutamic dehydrogenase, and α -Ketoglutarate dehydrogenase were analysed. Vitamin E induced significant changes in these enzymes thus altering the normal levels of glutamate and GABA during developmental neurogenesis. Such changes are surely to disturb the expression and/or intensity of neurotransmitter signaling during critical periods of brain development. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pereira</LastName>
<ForeName>Ivy</ForeName>
<Initials>I</Initials>
<Affiliation>Physiology and Biochemistry Laboratory, Department of Zoology, Goa University, Panaji, Goa 403206, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Dessai</LastName>
<ForeName>Shanti N</ForeName>
<Initials>SN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pinto</LastName>
<ForeName>Annaliza</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Neurol</MedlineTA>
<NlmUniqueID>101568083</NlmUniqueID>
<ISSNLinking>2090-5505</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747438</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984081</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-4436</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN obstetrics and gynecology</Title>
<ISOAbbreviation>ISRN Obstet Gynecol</ISOAbbreviation>
</Journal>
<ArticleTitle>Expression of the h19 oncofetal gene in premalignant lesions of cervical cancer: a potential targeting approach for development of nonsurgical treatment of high-risk lesions.</ArticleTitle>
<Pagination>
<MedlinePgn>137509</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/137509</ELocationID>
<Abstract>
<AbstractText>Background. Recent data suggest a role for H19 gene in promoting cancer transformation and progression. Cervical cancer, progresses from high-grade lesions (CIN3). At present, it is unclear if CIN lesions express H19. Objectives. To determine H19 expression in patient samples of CIN3 as well as the ability of a construct in which the promoter from the H19 gene drives expression of the diphtheria toxin A chain (DTA) to inhibit cervical cancer cell growth in vitro. Methods. H19 transcript levels were evaluated on 10 biopsies of CIN3 using in situ hybridization. PCR was used to examine H19 expression in cervical cancer cell lines and in two samples from a patient with cervical carcinoma. Cell lines were transfected with H19-DTA to determine its impact on cell number. Results. H19 gene was expressed in the area of CIN3 in 9 out of 10 samples. RT-PCR indicated expression of H19 in cervical cancer samples and in one of the three cell lines examined. Transfection of all cell lines with H19-DTA vector resulted in inhibited cell growth. Conclusions. H19 is expressed in the majority of CIN3 samples. These results suggest that most CIN3 lesions could be targeted by H19-DTA. Further in vivo preclinical studies are thus warranted. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Feigenberg</LastName>
<ForeName>Tomer</ForeName>
<Initials>T</Initials>
<Affiliation>Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Toronto, Princess Margaret Cancer Center, 610 University, Avenue M-700, Toronto, ON, Canada M5T 2M9.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Gofrit</LastName>
<ForeName>Ofer N</ForeName>
<Initials>ON</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pizov</LastName>
<ForeName>Galina</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hochberg</LastName>
<ForeName>Avraham</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Benshushan</LastName>
<ForeName>Abraham</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>ISRN Obstet Gynecol</MedlineTA>
<NlmUniqueID>101558763</NlmUniqueID>
<ISSNLinking>2090-4436</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747480</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984082</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-4436</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN obstetrics and gynecology</Title>
<ISOAbbreviation>ISRN Obstet Gynecol</ISOAbbreviation>
</Journal>
<ArticleTitle>Treatment of Uterine Myoma with 2.5 or 5 mg Mifepristone Daily during 3 Months with 9 Months Posttreatment Followup: Randomized Clinical Trial.</ArticleTitle>
<Pagination>
<MedlinePgn>649030</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/649030</ELocationID>
<Abstract>
<AbstractText>Objectives. To evaluate the efficacy, safety, and quality of life by using 2.5 and mifepristone 5 mg daily doses to treat uterine fibroids over 3 months with a 9-month followup period. Design. Randomized clinical trial. Place. "Eusebio Hernández" Hospital, Havana, Cuba. Subjects. 220 women with symptomatic uterine fibroids. Treatment. One-half (2.5 mg) or one-whole 5 mg mifepristone tablet. Variables to Evaluate Efficacy. Changes in fibroid and uterine volumes, in symptomatic prevalence and intensity, and in quality of life. Results. After 3-month treatment, fibroid volume decreased by 27.9% (CI 95% 20-35) and 45.5% (CI 95% 37-62), in the 2.5 and 5 mg groups, respectively, P = 0.003. There was no difference in the prevalence of symptoms at the end of treatment, unlike after 6- and 9-month followup when there was a difference. Amenorrhea was significantly higher in the 5 mg group, P = 0.001. There were no significant differences in mifepristone side effects between the groups. Both groups displayed a similar improvement in quality of life. Conclusions. The 2.5 mg dosage resulted in a lesser reduction in fibroid size but a similar improvement in quality of life when compared to the 5 mg dose. This trial is registered with ClinicalTrials.gov NCT01786226. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Carbonell</LastName>
<ForeName>Josep Lluis</ForeName>
<Initials>JL</Initials>
<Affiliation>Mediterránea Médica Clinic, C/Salvador Guinot 14, 46017 Valencia, Spain.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Acosta</LastName>
<ForeName>Rita</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pérez</LastName>
<ForeName>Yasmirian</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Garcés</LastName>
<ForeName>Roberto</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sánchez</LastName>
<ForeName>Carlos</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tomasi</LastName>
<ForeName>Giuseppe</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>ISRN Obstet Gynecol</MedlineTA>
<NlmUniqueID>101558763</NlmUniqueID>
<ISSNLinking>2090-4436</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747426</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984083</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-4436</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN obstetrics and gynecology</Title>
<ISOAbbreviation>ISRN Obstet Gynecol</ISOAbbreviation>
</Journal>
<ArticleTitle>Investigating the Relationship between Serum Level of s-Met (Soluble Hepatic Growth Factor Receptor) and Preeclampsia in the First and Second Trimesters of Pregnancy.</ArticleTitle>
<Pagination>
<MedlinePgn>925062</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/925062</ELocationID>
<Abstract>
<AbstractText>Introduction. Preeclampsia (PE) is an important cause of mortality and morbidity for mothers, fetuses, and the newborns. Placenta plays a pivotal role in pathogenesis of PE. Hepatic growth factor (HGF) is a cytokine expressed by the mesenchymal stalk of placental villi during pregnancy and assumes a paracrine role in trophoblasts which express its receptor (c-MET). In the present study, we investigate the diagnostic value of s-Met (the soluble form of the receptor) in the first and second trimesters of pregnancy for early diagnosis of preeclampsia. Method and Materials. This is a case-control study conducted on 95 pregnant women. The serum level of s-Met was measured in the first and second trimesters, and the participants were followed until delivery. 44 individuals with preeclampsia (the case group) and 51 individuals without preeclampsia (the control group) were evaluated. Results. Serum level of s-Met in preeclamptic participants was lower than that of the control group in both the first and the second trimesters (P &lt; 0.0001). In addition, serum levels of s-Met were significantly lower during the first and second trimesters in patients with early, severe preeclampsia compared to those with late, mild preeclampsia (P &lt; 0.0001). The sensitivity and specificity of s-Met in the first and second trimesters were, respectively, (83%, 94%) and (77%, 94%) for early preeclampsia and (88%, 92%) and (86%, 98%) for severe preeclampsia. Conclusion. Considering our findings, serum level of s-Met may be used as a predictive factor for early detection of preeclampsia. Further research is required to corroborate the functional and therapeutic value of s-Met in preeclampsia. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Naghshvar</LastName>
<ForeName>Farshad</ForeName>
<Initials>F</Initials>
<Affiliation>Department of Pathology, Mazandaran University of Medical Sciences, Sari, Iran.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Torabizadeh</LastName>
<ForeName>Zhila</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Moslemi Zadeh</LastName>
<ForeName>Narges</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mirbaha</LastName>
<ForeName>Hooman</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gheshlaghi</LastName>
<ForeName>Parand</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>ISRN Obstet Gynecol</MedlineTA>
<NlmUniqueID>101558763</NlmUniqueID>
<ISSNLinking>2090-4436</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747406</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984084</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-4436</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN obstetrics and gynecology</Title>
<ISOAbbreviation>ISRN Obstet Gynecol</ISOAbbreviation>
</Journal>
<ArticleTitle>Development and adaptation of Iranian youth reproductive health questionnaire.</ArticleTitle>
<Pagination>
<MedlinePgn>950278</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/950278</ELocationID>
<Abstract>
<AbstractText>Iran is a young country, and sexual behavior is shaped in this period. This research aimed to provide an assessment tool to evaluate Iranian youth reproductive health. This multistage research was conducted to design a valid questionnaire in the domains of knowledge, attitude, and behavior of the youth in order to evaluate behavior change programs. For this reason, after conducting a careful literature review and a qualitative research, the questionnaire was prepared. Forward and backward translations were performed. Professionals and students were used to make sure of qualitative and quantitative content and face validity. After conducting the pilot study on 100 students and eliminating defects in performance, reliability was evaluated by test-retest and Cronbach's alpha was calculated. In this study, out of 268 questions, 198 were retained after face and content validity. Self-efficacy of communication with father and mother, self-efficacy of condom use, and self-efficacy of abstinence had the highest Cronbach's alpha. Moreover, communication with parents regarding reproductive health issues and attitude to abstinence had a high Cronbach's alpha, as well. It seems to be a good instrument for assessment of Iranian reproductive health, and we are going to assess youth reproductive health in the future. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mousavi</LastName>
<ForeName>Abbas</ForeName>
<Initials>A</Initials>
<Affiliation>Research Center of Psychiatry, Golestan University of Medical Scinces, Golestan, Iran.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Keramat</LastName>
<ForeName>Afsaneh</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vakilian</LastName>
<ForeName>Katayon</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Esmaeili Vardanjani</LastName>
<ForeName>Safar Ali</ForeName>
<Initials>SA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>ISRN Obstet Gynecol</MedlineTA>
<NlmUniqueID>101558763</NlmUniqueID>
<ISSNLinking>2090-4436</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747441</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984097</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-5661</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN oncology</Title>
<ISOAbbreviation>ISRN Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>Survival Analysis Based on Clinicopathological Data from a Single Institution: Chemotherapy Intensity Would Be Enhanced in Patients with Positive Hormone Receptors and Positive HER2 in China Who Cannot Afford the Target Therapy.</ArticleTitle>
<Pagination>
<MedlinePgn>606398</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/606398</ELocationID>
<Abstract>
<AbstractText>Background. Immunohistochemical markers were often used to classify breast cancer into subtypes. The aim of this study was to estimate death and tumor progression for patients with the major subtypes of breast cancer as classified using immunohistochemical assay and to investigate the patterns of benefit from the therapies over the past years. Methods. The study population included primary, operable 199 invasive ductal breast cancer patients, with the median age of 51.1 years old. All patients underwent local and/or systemic treatments. The clinicopathological characteristics and clinical outcomes were retrospectively reviewed. The expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki67 was analyzed by immunohistochemistry. All patients were classified into the following categories: luminal A, luminal B, HER2 overexpression, and triple-negative subtypes. Result. The median follow-up time was 33 months. Luminal A tumors had the lowest rate of tumor progression (0%, P = 0.006), while luminal B, HER2 over-expression, and triple-negative subtypes were associated with an increased risk of tumor progression (15.4, 19.2, 15.4%). Clinicopathological subtypes retained independent prognostic significance (P = 0.008). There were significant differences by Cox model analyzed in age, menopause, lymph node metastasis, and HER2 for the event of death and tumor progression (P &lt; 0.05), and there were significant differences only in chemotherapy for the event, respectively (P &lt; 0.05). Conclusion. Clinicopathological subtypes of breast cancer could robustly identify the risk of death and tumor progression and were significant in making therapeutic decision. HER2 was the important poor indicator. The chemotherapy intensity would be enhanced for patients with luminal B, especially for HER2 over-expression subgroup. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>Jianyi</ForeName>
<Initials>J</Initials>
<Affiliation>Department of Breast Surgery, Shengjing Hospital of China Medical University, Sanhao Street No. 36, Heping District, Shenyang, Liaoning 110004, China.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Jia</LastName>
<ForeName>Shi</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Wenhai</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Yang</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fei</LastName>
<ForeName>Xiang</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tian</LastName>
<ForeName>Rui</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Oncol</MedlineTA>
<NlmUniqueID>101567026</NlmUniqueID>
<ISSNLinking>2090-5661</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747482</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984098</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-5661</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN oncology</Title>
<ISOAbbreviation>ISRN Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>Accuracy of Self-Reported Screening Mammography Use: Examining Recall among Female Relatives from the Ontario Site of the Breast Cancer Family Registry.</ArticleTitle>
<Pagination>
<MedlinePgn>810573</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/810573</ELocationID>
<Abstract>
<AbstractText>Evidence of the accuracy of self-reported mammography use among women with familial breast cancer risk is limited. This study examined the accuracy of self-reported screening mammography dates in a cohort of 1,114 female relatives of breast cancer cases, aged 26 to 73 from the Ontario site of the Breast Cancer Family Registry. Self-reported dates were compared to dates abstracted from imaging reports. Associations between inaccurate recall and subject characteristics were assessed using multinomial regression. Almost all women (95.2% at baseline, 98.5% at year 1, 99.8% at year 2) accurately reported their mammogram use within the previous 12 months. Women at low familial risk (OR = 1.77, 95% CI: 1.00-3.13), who reported 1 or fewer annual visits to a health professional (OR = 1.97, 95% CI: 1.15, 3.39), exhibited a lower perceived breast cancer risk (OR = 1.90, 95% CI: 1.15, 3.15), and reported a mammogram date more than 12 months previous (OR = 5.22, 95% CI: 3.10, 8.80), were significantly more likely to inaccurately recall their mammogram date. Women with varying levels of familial risk are accurate reporters of their mammogram use. These results present the first evidence of self-reported mammography recall accuracy among women with varying levels of familial risk. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Walker</LastName>
<ForeName>Meghan J</ForeName>
<Initials>MJ</Initials>
<Affiliation>Prevention and Cancer Control, Cancer Care Ontario, Toronto, ON, Canada M5G 2L7 ; Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada M5T 3M7.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Chiarelli</LastName>
<ForeName>Anna M</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mirea</LastName>
<ForeName>Lucia</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Glendon</LastName>
<ForeName>Gord</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ritvo</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Andrulis</LastName>
<ForeName>Irene L</ForeName>
<Initials>IL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Knight</LastName>
<ForeName>Julia A</ForeName>
<Initials>JA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Oncol</MedlineTA>
<NlmUniqueID>101567026</NlmUniqueID>
<ISSNLinking>2090-5661</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747415</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984099</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-5742</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN otolaryngology</Title>
<ISOAbbreviation>ISRN Otolaryngol</ISOAbbreviation>
</Journal>
<ArticleTitle>Can axial-based nodal size criteria be used in other imaging planes to accurately determine "enlarged" head and neck lymph nodes?</ArticleTitle>
<Pagination>
<MedlinePgn>232968</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/232968</ELocationID>
<Abstract>
<AbstractText>Objective. We evaluate if axial-based lymph node size criteria can be applied to coronal and sagittal planes. Methods. Fifty pretreatment computed tomographic (CT) neck exams were evaluated in patients with head and neck squamous cell carcinoma (SCCa) and neck lymphadenopathy. Axial-based size criteria were applied to all 3 imaging planes, measured, and classified as "enlarged" if equal to or exceeding size criteria. Results. 222 lymph nodes were "enlarged" in one imaging plane; however, 53.2% (118/222) of these were "enlarged" in all 3 planes. Classification concordance between axial versus coronal/sagittal planes was poor (kappa = -0.09 and -0.07, resp., P &lt; 0.05). The McNemar test showed systematic misclassification when comparing axial versus coronal (P &lt; 0.001) and axial versus sagittal (P &lt; 0.001) planes. Conclusion. Classification of "enlarged" lymph nodes differs between axial versus coronal/sagittal imaging planes when axial-based nodal size criteria are applied independently to all three imaging planes, and exclusively used without other morphologic nodal data. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bartlett</LastName>
<ForeName>Eric S</ForeName>
<Initials>ES</Initials>
<Affiliation>Princess Margaret Cancer Centre, Joint Department of Medical Imaging, University of Toronto, 610 University Avenue, Room 3-956, Toronto, ON, Canada M5G 2M9.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Walters</LastName>
<ForeName>Thomas D</ForeName>
<Initials>TD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yu</LastName>
<ForeName>Eugene</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Otolaryngol</MedlineTA>
<NlmUniqueID>101605983</NlmUniqueID>
<ISSNLinking>2090-5742</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3741989</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984100</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-5742</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN otolaryngology</Title>
<ISOAbbreviation>ISRN Otolaryngol</ISOAbbreviation>
</Journal>
<ArticleTitle>Effectiveness of 7.5 percent povidone iodine in comparison to 1 percent clotrimazole with lignocaine in the treatment of otomycosis.</ArticleTitle>
<Pagination>
<MedlinePgn>239730</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/239730</ELocationID>
<Abstract>
<AbstractText>Objectives. Otomycosis is a common ENT disease frequenting the tropics. Its recurrent nature poses a great challenge to the treating physician. In spite of a number of antifungals in the market, the frequent nature of this disease warrants repeated use of these drugs, contributing to drug resistance and financial burden on the rural population. Our primary aims were to evaluate the effectiveness of povidone iodine in the treatment of otomycosis and to identify the most common fungal isolate in our population. Study Design and Setting. A single blinded prospective longitudinal study was done over a period of 12 months in a tertiary referral center. 34 patients in the age group 15-70 years clinically diagnosed with otomycosis were included in this study. These individuals were divided into two groups selected randomly. One arm received 7.5% povidone iodine otic drops and the other 1% Clotrimazole and lignocaine drops. Evaluation was based on resolution of symptoms and signs after treatment. Result. Both arms showed improvements which were comparable thus suggesting the role of povidone iodine in the management of otomycosis. Conclusion. Povidone iodine is an effective antifungal in the treatment of otomycosis. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Philip</LastName>
<ForeName>Ajay</ForeName>
<Initials>A</Initials>
<Affiliation>Department of ENT Unit-1, Christian Medical College, Indian Subcontinent, Vellore 632004, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Thomas</LastName>
<ForeName>Regi</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Job</LastName>
<ForeName>Anand</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sundaresan</LastName>
<ForeName>V Rajan</ForeName>
<Initials>VR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Anandan</LastName>
<ForeName>Shalini</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Albert</LastName>
<ForeName>Rita Ruby</ForeName>
<Initials>RR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Otolaryngol</MedlineTA>
<NlmUniqueID>101605983</NlmUniqueID>
<ISSNLinking>2090-5742</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747501</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984101</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-5742</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN otolaryngology</Title>
<ISOAbbreviation>ISRN Otolaryngol</ISOAbbreviation>
</Journal>
<ArticleTitle>Changing trends in oesophageal endoscopy: a systematic review of transnasal oesophagoscopy.</ArticleTitle>
<Pagination>
<MedlinePgn>586973</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/586973</ELocationID>
<Abstract>
<AbstractText>The safety, efficacy, and economic implications of using transnasal oesophagoscopy (TNE) are compared with conventional rigid or flexible oesophagoscopy for oesophageal disorders in otorhinolaryngology (ORL) clinics in this systematic review. Eleven electronic databases were searched for articles on transnasal oesophagoscopy. A total of 67 relevant titles were identified and 39 abstracts were screened of which 17 full- text articles were included in this report. There was fair level of evidence to suggest that TNE was effective for screening examination in patients with dysphagia, globus pharyngeus, and reflux symptoms and for detection of metachronous oesophageal carcinoma. TNE can also be used to biopsy suspicious lesions in the upper aerodigestive tract, placement of wireless pH capsule, transnasal balloon dilation of the oesophagus, secondary tracheoesophageal puncture, and management of foreign bodies. TNE was well tolerated and can be safely performed in an office setting with topical anaesthesia. Complications associated with TNE were mild and uncommon. There was evidence to suggest potential cost savings by performing TNE in the office setting compared with conventional investigation and examination for dysphagia. TNE may lead to a change in practice from investigation and treatment in the operating theatre or day care center to an office-based practice. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sabirin</LastName>
<ForeName>Junainah</ForeName>
<Initials>J</Initials>
<Affiliation>Health Technology Assessment Section, Ministry of Health Malaysia, Federal Government Administrative Centre, 62590 Putrajaya, Malaysia.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Abd Rahman</LastName>
<ForeName>Maharita</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rajan</LastName>
<ForeName>Philip</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Otolaryngol</MedlineTA>
<NlmUniqueID>101605983</NlmUniqueID>
<ISSNLinking>2090-5742</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747410</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984102</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-5742</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN otolaryngology</Title>
<ISOAbbreviation>ISRN Otolaryngol</ISOAbbreviation>
</Journal>
<ArticleTitle>The prevalence of frontal cells and their relation to frontal sinusitis: a radiological study of the frontal recess area.</ArticleTitle>
<Pagination>
<MedlinePgn>687582</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/687582</ELocationID>
<Abstract>
<AbstractText>Background. The frontal recess area represents a challenge to ENT surgeons due to its narrow confines and variable anatomy. Several types of cells have been described in this area. The agger nasi cells are the most constant ones. The frontal cells, originally classified by Kuhn into 4 types, have been reported in the literature to exist in 20%-41% of frontal recesses. Aim of the Study. To identify the prevalence of frontal recess cells and their relation to frontal sinus disease. Methods. Coronal and axial CT scans of paranasal sinuses of 70 patients admitted for functional endoscopic sinus surgery (FESS) were reviewed to identify the agger nasi, frontal cells, and frontal sinus disease. Data was collated for right and left sides separately. Results. Of the 140 sides reviewed, 126 (90%) had agger nasi and 110 (78.571%) had frontal cells. 37 frontal sinuses were free of mucosal disease, 48 were partly opacified, and 50 were totally opacified. There was no significant difference found in frontal sinus mucosal disease in presence or absence of frontal cells or agger nasi. Conclusions. The current study shows that frontal cells might be underreported in the literature, as the prevalence identified is noticeably higher than previous studies. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Eweiss</LastName>
<ForeName>Ahmed Z</ForeName>
<Initials>AZ</Initials>
<Affiliation>Department of Otolaryngology, Derriford Hospital, Plymouth, UK ; Department of Otolaryngology, Faculty of Medicine, University of Alexandria, Egypt.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Khalil</LastName>
<ForeName>Hisham S</ForeName>
<Initials>HS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Otolaryngol</MedlineTA>
<NlmUniqueID>101605983</NlmUniqueID>
<ISSNLinking>2090-5742</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3741994</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984106</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-6145</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN pharmaceutics</Title>
<ISOAbbreviation>ISRN Pharm</ISOAbbreviation>
</Journal>
<ArticleTitle>Comparison of various generations of superporous hydrogels based on chitosan-acrylamide and in vitro drug release.</ArticleTitle>
<Pagination>
<MedlinePgn>624841</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/624841</ELocationID>
<Abstract>
<AbstractText>The aim of the current research work was to prepare and evaluate different generations of superporous hydrogels (SPH) of acrylamide and chitosan using gas blowing technique and evaluate them for swelling, mechanical properties, FTIR, SEM, XRD, and in vitro drug release. The ingredients used were acrylamide, N,N'-methylene bisacrylamide, chitosan, Pluronic F127, ammonium per sulfate-N,N,N',N'-tetramethylenediamine, and sodium bicarbonate. All ingredients were mixed sequentially with thorough stirring. The effect of different drying conditions on properties of SPH was also evaluated. Ethanol treated batched showed maximum swelling properties due to uniform pores as indicated in SEM studies. Equilibrium swelling time was less than 10 min in all batches. Freeze drying led to lowering of density which is also supported by porosity and void fraction data. Maximum mechanical strength was found in superporous hydrogel interpenetrating networks due to crosslinked polymeric network. 70% drug was released at the end of 2 h, and further the release was sustained till the end of 24 h. In vitro drug release kinetics showed that drug release occurs by diffusion and follows Super Case II transport indicating that mechanism of drug release is not clear. Superporous hydrogel interpenetrating networks can be successfully used as sustained release gastroretentive devices. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bhalla</LastName>
<ForeName>Shikha</ForeName>
<Initials>S</Initials>
<Affiliation>Ganpati Institute of Pharmacy, Bilaspur, Yamunanagar, Haryana 135102, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Nagpal</LastName>
<ForeName>Manju</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Pharm</MedlineTA>
<NlmUniqueID>101571023</NlmUniqueID>
<ISSNLinking>2090-6145</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747453</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984089</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-5165</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN pharmacology</Title>
<ISOAbbreviation>ISRN Pharmacol</ISOAbbreviation>
</Journal>
<ArticleTitle>A Scientific Validation of Antihyperglycemic and Antihyperlipidemic Attributes of Trichosanthes dioica.</ArticleTitle>
<Pagination>
<MedlinePgn>473059</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/473059</ELocationID>
<Abstract>
<AbstractText>The present study was undertaken to scientifically validate the antidiabetic activity of aqueous fruit extract of Trichosanthes dioica Roxb. (Family: Cucurbitaceae) which has been traditionally used for managing diabetes mellitus. This plant commonly known as "Sespadula" in English has not been explored scientifically so far for its glycemic potential except by our research group. The study was conducted with variable doses on normal, mild, and severe diabetics models, and several biochemical parameters including blood glucose level (BGL) were assessed. Maximum fall in BGL of 23.8% in normal rats and of 31.3% in mild diabetic rats was observed during their fasting blood glucose (FBG) and glucose tolerance test (GTT) with the dose of 1000 mg kg(-1). In severely diabetic animals after 4 weeks treatment with FBG, postprandial glucose, total cholesterol, and triglyceride levels were reduced by 28.7, 30.7, 57.2, and 18.5%, whereas high density lipoprotein, total protein, hemoglobin, and body weight were increased by 33.0, 36.7, 15.7 and 16.7%, respectively. Moreover, urine sugar was reduced from +4 to +1. Thus, the study scientifically validates the traditional use of T. diocia in diabetes management and could be developed as an effective oral agent for treating diabetes mellitus and complications associated with it. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Rai</LastName>
<ForeName>Prashant Kumar</ForeName>
<Initials>PK</Initials>
<Affiliation>Alternative Therapeutics Unit, Drug Development Division, Medicinal Research Laboratory, Department of Chemistry, University of Allahabad, Allahabad 211 002, India ; Department of NMR, All India Institute of Medical Sciences, New Delhi 110 029, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Gupta</LastName>
<ForeName>Sharad Kumar</ForeName>
<Initials>SK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Srivastava</LastName>
<ForeName>Amrita Kumari</ForeName>
<Initials>AK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gupta</LastName>
<ForeName>Rajesh Kumar</ForeName>
<Initials>RK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Watal</LastName>
<ForeName>Geeta</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Pharmacol</MedlineTA>
<NlmUniqueID>101567048</NlmUniqueID>
<ISSNLinking>2090-5165</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747504</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984090</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-5165</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN pharmacology</Title>
<ISOAbbreviation>ISRN Pharmacol</ISOAbbreviation>
</Journal>
<ArticleTitle>Inhibition of endoplasmic reticulum stress and atherosclerosis by 2-aminopurine in apolipoprotein e-deficient mice.</ArticleTitle>
<Pagination>
<MedlinePgn>847310</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/847310</ELocationID>
<Abstract>
<AbstractText>We previously reported that the apolipoprotein (apo) B48-carrying lipoproteins obtained from apoE knockout (apoE (-/-) ) mice, so called E(-)/B48 lipoproteins, transformed mouse macrophages into foam cells and enhanced the phosphorylation of eukaryotic translation initiation factor 2 α (eIF-2 α ). Furthermore, the eIF-2 α phosphorylation inhibitor, 2-aminopurine (2-AP), attenuated E(-)/B48 lipoprotein-induced foam cell formation. The present report studied the effect of 2-AP on atherosclerosis in apoE (-/-) mice. Our results showed that the level of food intake, bodyweight, plasma cholesterol, and triglycerides was comparable in apoE (-/-) mice treated with or without 2-AP. However, the mean size of atherosclerotic lesions in the aorta sinus as well as the surface area of the entire aorta of 2-AP-treated apoE (-/-) mice were reduced by about 55% and 39%, respectively, compared to samples from untreated control apoE (-/-) mice. In addition, the 2-AP-treated apoE (-/-) mice showed a significant decrease in glucose-regulated protein 78 (GRP78) and phosphorylated eIF-2 α in their aortic samples as compared to levels in untreated control apoE (-/-) mice. These observations suggest that endoplasmic reticulum stress is a causal mechanism for the development of atherosclerosis in apoE (-/-) mice and that therapeutic strategies can be developed for using eIF-2 α phosphorylation inhibitors, such as 2-AP, to prevent or treat atherosclerosis. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Lichun</ForeName>
<Initials>L</Initials>
<Affiliation>Department of Physiology, Meharry Medical College, Nashville, TN 37208, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Dezhi</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wu</LastName>
<ForeName>Dong Fang</ForeName>
<Initials>DF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Guo</LastName>
<ForeName>Zhong Mao</ForeName>
<Initials>ZM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Okoro</LastName>
<ForeName>Emmanuel</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Yang</LastName>
<ForeName>Hong</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Pharmacol</MedlineTA>
<NlmUniqueID>101567048</NlmUniqueID>
<ISSNLinking>2090-5165</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747385</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984091</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-5165</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN pharmacology</Title>
<ISOAbbreviation>ISRN Pharmacol</ISOAbbreviation>
</Journal>
<ArticleTitle>Some Haematological and Biochemical Investigations on Duck Virus Hepatitis following Administration of Glycyrrhizin.</ArticleTitle>
<Pagination>
<MedlinePgn>849412</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/849412</ELocationID>
<Abstract>
<AbstractText>The present study aimed to investigate the protective effect of glycyrrhizin (locally isolated and purified from licorice root) against duck hepatitis virus through the assessment of some hematological and biochemical parameters. One hundred and sixty white Pekin ducklings-one day old-were randomly divided into four equal groups. Group (1) was kept as normal control. Group (2) was inoculated I/P with 10 mg glycyrrhizin/kg BW, three times per week for four weeks. Group (3) was inoculated I/M with 0.5 ml of live attenuated DHV vaccine. Group (4) was inoculated with both glycyrrhizin (10 mg/kg BW I/P, three times per week for four weeks) and live attenuated DHV vaccine (0.5 ml, I/M). Then, all groups of treatment were challenged using virulent DHV except for 20 ducklings from the normal control group which were continued to be kept as negative control. The results revealed that duck hepatitis virus (DHV) caused macrocytic hypochromic anemia, leukopenia, hypoproteinemia, hypoalbuminemia, hyperglycemia, hypercholesterolemia, and marked elevation of liver enzymes and renal parameters. In conclusion, glycyrrhizin injected alone or in combination with DHV vaccine protected or ameliorated the deteriorating effects induced by DHV vaccine and/or duck hepatitis virus infection by improvement of erythrogram and leukogram, as well as liver and kidney functions. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Okda</LastName>
<ForeName>Faten A</ForeName>
<Initials>FA</Initials>
<Affiliation>Department of Parasitology and Animal Diseases, National Research Center, El-Behouse Street, Dokki, P.O. Box 12622, Giza, Egypt.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Yassein</LastName>
<ForeName>Safaa</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ahmed</LastName>
<ForeName>Alaa R</ForeName>
<Initials>AR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Soufy</LastName>
<ForeName>Hamdy</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nasr</LastName>
<ForeName>Soad M</ForeName>
<Initials>SM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Pharmacol</MedlineTA>
<NlmUniqueID>101567048</NlmUniqueID>
<ISSNLinking>2090-5165</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747462</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984092</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-5165</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN pharmacology</Title>
<ISOAbbreviation>ISRN Pharmacol</ISOAbbreviation>
</Journal>
<ArticleTitle>Heparin and related drugs: beyond anticoagulant activity.</ArticleTitle>
<Pagination>
<MedlinePgn>910743</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/910743</ELocationID>
<Abstract>
<AbstractText>Heparin has been widely used as an anticoagulant for more than 80 years. However, there is now considerable evidence that heparin also possesses anti-inflammatory activity, both experimentally and clinically. Importantly in many instances, the anti-inflammatory actions of heparin are independent of anticoagulant activity raising the possibility of developing novel drugs based on heparin that retain the anti-inflammatory activity. Heparin exhibits anti-inflammatory activities via a variety of mechanisms including neutralization of cationic mediators, inhibition of adhesion molecules, and the inhibition of heparanase, all involved in leukocyte recruitment into tissues. It is anticipated that furthering our understanding of the anti-inflammatory actions of heparin will lead to the development of novel anti-inflammatory drugs for a variety of clinical indications. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Page</LastName>
<ForeName>Clive</ForeName>
<Initials>C</Initials>
<Affiliation>Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, 5th Floor, Franklin-Wilkins Building, Waterloo Campus, 150 Stamford Street, London SE1 9NH, UK.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>30</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Pharmacol</MedlineTA>
<NlmUniqueID>101567048</NlmUniqueID>
<ISSNLinking>2090-5165</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747464</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984182</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">2090-7966</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN psychiatry</Title>
<ISOAbbreviation>ISRN Psychiatry</ISOAbbreviation>
</Journal>
<ArticleTitle>Depression symptoms improve after successful weight loss with emotional freedom techniques.</ArticleTitle>
<Pagination>
<MedlinePgn>573532</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/573532</ELocationID>
<Abstract>
<AbstractText>Ninety-six overweight or obese adults were randomly allocated to a four-week EFT treatment or waitlist condition. Waitlist participants crossed over to the EFT group upon completion of wait period. Degree of food craving, perceived power of food, restraint capabilities, and psychological symptoms were assessed at pretreatment, posttreatment and at 12-month follow-up for combined EFT groups. Significant improvements in weight, body mass index, food cravings, subjective power of food, craving restraint and psychological coping for EFT participants from pretreatment to 12-month follow-up (P &lt; 0.05) were reported. The current paper isolates the depression symptom levels of participants, as well as levels of eight other psychological conditions. Significant decreases from pre- to posttreatment were found for depression, interpersonal sensitivity, obsessive-compulsivity, paranoid ideation, and somatization (P &lt; 0.05). Significant decreases from pretreatment to 12-month follow-up were found for depression, interpersonal sensitivity, psychoticism, and hostility. The results point to the role depression, and other mental health conditions may play in the successful maintenance of weight loss. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Stapleton</LastName>
<ForeName>Peta</ForeName>
<Initials>P</Initials>
<Affiliation>Department of Psychology, School of Humanities (Psychology), Bond University, Gold Coast, QLD 4229, Australia.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Church</LastName>
<ForeName>Dawson</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sheldon</LastName>
<ForeName>Terri</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Porter</LastName>
<ForeName>Brett</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Carlopio</LastName>
<ForeName>Cassandra</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Psychiatry</MedlineTA>
<NlmUniqueID>101606355</NlmUniqueID>
<ISSNLinking>2090-7966</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747476</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984103</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-5807</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN urology</Title>
<ISOAbbreviation>ISRN Urol</ISOAbbreviation>
</Journal>
<ArticleTitle>Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management.</ArticleTitle>
<Pagination>
<MedlinePgn>240108</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/240108</ELocationID>
<Abstract>
<AbstractText>The prostate is an androgen-dependent organ. The increase, growth, homeostasis, and function of the prostate largely depend upon the intraprostatic and serum concentrations of androgens. Therefore, androgens are essential for the physiologic growth of prostatic epithelium. Prostate cancer, the second leading cause of death for men, is also androgen dependent, and androgen suppression is the mainstay of treatment for advanced and metastatic disease. In the state of metastatic disease, androgen suppression is a palliative treatment leading to a median progression-free survival of 18-20 months and an overall survival of 24-36 months. Theoretically, the majority of patients will develop hormone-refractory disease provided that they will not die from other causes. Although androgen suppression therapy may be associated with significant and sometimes durable responses, it is not considered a cure, and its potential efficacy is further limited by an array of significant and bothersome adverse effects caused by the suppression of androgens. These effects have potentially significant consequences on a variety of parameters of everyday living and may further decrease health-related quality of life. This review focuses on the aetiology of these adverse effects and provides information on their prevention and management. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sountoulides</LastName>
<ForeName>Petros</ForeName>
<Initials>P</Initials>
<Affiliation>Urology Department, General Hospital of Veria, 55133 Thessaloniki, Greece.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Rountos</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Urol</MedlineTA>
<NlmUniqueID>101566868</NlmUniqueID>
<ISSNLinking>2090-5807</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747499</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984104</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-5807</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN urology</Title>
<ISOAbbreviation>ISRN Urol</ISOAbbreviation>
</Journal>
<ArticleTitle>Should Finasteride Be Routinely Given Preoperatively for TURP?</ArticleTitle>
<Pagination>
<MedlinePgn>458353</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/458353</ELocationID>
<Abstract>
<AbstractText>Objective. The aim of the review was to compare the use of finasteride to placebo in patients undergoing TURP procedures. Material &amp; Methods. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966-November 2011), EMBASE (1980-November 2011), CINAHL, Clinicaltrials.gov, Google Scholar, reference lists of articles, and abstracts from conference proceedings without language restriction for studies comparing finasteride to placebo patients needing TURPs. Results. Four randomised controlled trials were included comparing finasteride to a placebo. A meta-analysis was not conducted due to the disparity present in the results between the studies. Three of the studies found that finasteride could reduce either intra- or postoperative bleeding after TURP. One study found finasteride to significantly lower the microvessel density (MVD) and vascular endothelial growth factor (VEGF). None of the studies reported any long-term complications related to either the medication or the procedure. Conclusion. finasteride reduces bleeding either during or after TURP. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Aboumarzouk</LastName>
<ForeName>O M</ForeName>
<Initials>OM</Initials>
<Affiliation>Department of Urology, University Hospital of Wales, Cardiff CF14 4XW, UK.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Aslam</LastName>
<ForeName>M Z</ForeName>
<Initials>MZ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wedderburn</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Turner</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hughes</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kynaston</LastName>
<ForeName>H G</ForeName>
<Initials>HG</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Urol</MedlineTA>
<NlmUniqueID>101566868</NlmUniqueID>
<ISSNLinking>2090-5807</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3747465</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984105</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-5807</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN urology</Title>
<ISOAbbreviation>ISRN Urol</ISOAbbreviation>
</Journal>
<ArticleTitle>Emergent intervention criterias for controlling sever bleeding after percutaneous nephrolithotomy.</ArticleTitle>
<Pagination>
<MedlinePgn>760272</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/760272</ELocationID>
<Abstract>
<AbstractText>Objectives. To determine when emergent intervention for bleeding after percutaneous nephrolithotomy (PCNL) is required. Methods. We reviewed analysis data of 850 patients who had undergone PCNL in our center. Blood transfusion was needed for 60 (7%) patients during and/or after surgery. We routinely performed followup of the urine output per hour, blood pressure, and hemoglobin levels after PCNL. Five (0.6%) of them had severe bleeding that emergent intervention was needed. Results. The mean age of the 5 patients who had emergent surgery due to severe bleeding was 42.2 (19-56) years. Mean duration of surgery was 44.75 (25-65) minutes. Mean stone size was 27 (15-38) mm. Mean decrease of hemoglobin was 4.8 (3.4-5.8) ng/dL, and unit of transfused blood was 4.4 (3-6). Mean blood pH was 7.21. There were metabolic acidosis and anuria/oliguria in all these patients. One of 5 patients suffered from cardiopulmonary arrest because of massive bleeding four hours after the PCNL, and despite cardiac resuscitation, he died. Hemorrhaging was controlled by open surgery in the other 4 patients. Two patients experienced cardiac arrest during the open surgery but they responded to cardiac resuscitation. There were no metabolic asidosis and anuria/oliguria, and bleeding was managed only with blood transfusion for the other 55 patients. Conclusion. Severe bleeding after PCNL is rare and can be mortal. If metabolic asidosis and anuria/oliguria accompanied the drop of hemoglobin, emergent surgical intervention should be performed because vascular collapse may follow, and it may be too difficult to stabilise the patient. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Oguz</LastName>
<ForeName>Ural</ForeName>
<Initials>U</Initials>
<Affiliation>Department of Urology, Kecioren Training and Research Hospital, Ankara, Turkey.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Resorlu</LastName>
<ForeName>Berkan</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bayindir</LastName>
<ForeName>Mirze</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sahin</LastName>
<ForeName>Tolga</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bozkurt</LastName>
<ForeName>Omer Faruk</ForeName>
<Initials>OF</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Unsal</LastName>
<ForeName>Ali</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Urol</MedlineTA>
<NlmUniqueID>101566868</NlmUniqueID>
<ISSNLinking>2090-5807</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3742047</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984085</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Print">2090-4452</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>2013</Volume>
<PubDate>
<Year>2013</Year>
</PubDate>
</JournalIssue>
<Title>ISRN veterinary science</Title>
<ISOAbbreviation>ISRN Vet Sci</ISOAbbreviation>
</Journal>
<ArticleTitle>Relationship between the Prevalence of Ectoparasites and Associated Risk Factors in Free-Range Pigs in Kenya.</ArticleTitle>
<Pagination>
<MedlinePgn>650890</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2013/650890</ELocationID>
<Abstract>
<AbstractText>A cross-sectional study was undertaken to determine the prevalence of ectoparasites and possible risk factors in free-range pigs from 135 farms of Busia District, Kenya. Three hundred and six pigs were examined for presence of external parasites using standard parasitological methods. Data on management practices including housing and history of acaricide spraying were also collected. The ectoparasites found in the pigs were Haematopinus suis (96.1%), Sarcoptes scabiei (63.7%), and ticks (29.7%). The tick species included Rhipicephalus appendiculatus (70%), Boophilus decoloratus (31%), and Amblyomma variegatum (12%). The occurrence of the infestations was associated with age, being highest in sows (S. scabiei) and finishers (ticks and H. suis). Male pigs had highest prevalences of H. suis and ticks, while female pigs had highest prevalence of S. scabiei. The prevalence of the parasitic infestations was significantly (P &lt; 0.05) associated with their origin being either lower (H. suis and S. scabiei) or higher (ticks) in pigs originating from divisions with high rainfall. Housed pigs had significantly (P &lt; 0.05) lower prevalence of H. suis and ticks than those from households without pig housing. It is concluded that the free-range pigs have high prevalence of ectoparasites, and effective control strategies focussing on improved animal husbandry and acaricide use should be implemented. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kagira</LastName>
<ForeName>John Maina</ForeName>
<Initials>JM</Initials>
<Affiliation>Department of Animal Health and Production, Faculty of Agriculture, Jomo Kenyatta University of Agriculture and Technology, P.O. Box 62000-00200, Nairobi, Kenya.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Kanyari</LastName>
<ForeName>Paul Njuki</ForeName>
<Initials>PN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Maingi</LastName>
<ForeName>Ndicho</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Githigia</LastName>
<ForeName>Samuel Maina</ForeName>
<Initials>SM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ng'ang'a</LastName>
<ForeName>Chege</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gachohi</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>07</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Egypt</Country>
<MedlineTA>ISRN Vet Sci</MedlineTA>
<NlmUniqueID>101568322</NlmUniqueID>
<ISSNLinking>2090-4452</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3742048</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984225</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Adult onset atopic dermatitis: Under-recognized or under-reported?</ArticleTitle>
<Pagination>
<MedlinePgn>167-71</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115508</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kanwar</LastName>
<ForeName>Amrinder Jit</ForeName>
<Initials>AJ</Initials>
<Affiliation>Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Narang</LastName>
<ForeName>Tarun</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752467</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984226</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Achieving hemostasis in dermatology-Part II: Topical hemostatic agents.</ArticleTitle>
<Pagination>
<MedlinePgn>172-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115509</ELocationID>
<Abstract>
<AbstractText>Bleeding is a common occurrence during any dermatologic surgery that disrupts blood vessels. The complications of excess bleeding can include delayed wound healing, hematoma formation, infection, dehiscence, and necrosis. In part one of this review, we discussed the pre-operative, intra-operative, and post-operative management of patients undergoing dermatologic surgery. In Part two, we discuss traditional and new topical hemostatic agents used to achieve hemostasis in dermatological procedures and surgery. We will evaluate the caustic and non-caustic hemostatic agents as well as hemostatic dressings. The mechanisms of action, side effect profile, and advantages and disadvantages of the topical hemostatic agents are provided. Sources for this article were found searching the English literature in PubMed for the time period 1940 to March 2012. A thorough bibliography search was also performed and key references examined. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Glick</LastName>
<ForeName>Jaimie B</ForeName>
<Initials>JB</Initials>
<Affiliation>Department of Dermatology, SUNY Downstate Medical Center, 450 Clarkson Avenue Brooklyn, New York, United States.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Kaur</LastName>
<ForeName>Ravneet R</ForeName>
<Initials>RR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Siegel</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752468</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Dermatologic surgery</Keyword>
<Keyword MajorTopicYN="N">hemostasis</Keyword>
<Keyword MajorTopicYN="N">topical hemostatic agents</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984227</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Hit hard and early: Can the march of psoriasis be halted?</ArticleTitle>
<Pagination>
<MedlinePgn>177-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115510</ELocationID>
<Abstract>
<AbstractText>Psoriasis is increasingly considered a systemic disease with comorbidities. There is sufficient evidence that systemic inflammation lies at the heart of these developments. Considering the chronic nature of psoriasis and its comorbidities, timely manipulation of systemic inflammation could avert both mortality and morbidity. Data from retrospective studies suggest that aggressive treatment of psoriasis with traditional systemic agents and/or biologic drugs improves health outcomes. To maximize treatment outcomes, severe psoriasis needs to be managed as a systemic disease with likely comorbidities. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jandhyala</LastName>
<ForeName>Sridhar</ForeName>
<Initials>S</Initials>
<Affiliation>Department of Dermatology, INHS Sanjivani, Naval Base, Kochi, Kerala, India.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752469</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Comorbidities</Keyword>
<Keyword MajorTopicYN="N">psoriasis</Keyword>
<Keyword MajorTopicYN="N">psoriatic march</Keyword>
<Keyword MajorTopicYN="N">systemic inflammation</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984228</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>To evaluate the efficacy and safety of "RV2427B" cream in Irritant dermatitis care.</ArticleTitle>
<Pagination>
<MedlinePgn>180-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115511</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The treatment of various irritant dermatitis involves the elimination of the casual or favoring factor, the control of aggravating factors, and administration of topical agents. Even though corticosteroids are extensively used in these conditions to reduce the inflammation, it can also result in undesirable side effects. Hence, there is a need for a non steroidal topical agent to be used in these conditions.</AbstractText>
<AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To evaluate the efficacy and tolerance of repairing cream RV 2427B in children and adults in irritant dermatitis care.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">In this phase III open labeled, multicenter, non-controlled, non-randomized trial, irritant dermatitis in children and adults either due to diaper rash, pityriasis alba and irritant dermatitis (eczema), perioral dermatitis, perleche or intertrigo were administered; repairing cream RV 2427 B containing a) 4 % zinc oxide, b) 2.5 % dry colloidal oat extract, (c) 0.5 % oat oil, (d) 0.2% copper sulfate, and (e) 0.1 % zinc sulfate to be applied twice-daily in the affected area. The subjects were evaluated on day 7 and day 21 for both efficacy and tolerance and last visit for cosmetic acceptability. The trial was conducted in accordance with the good clinical practices (GCP) after obtaining ethical clearance from respective Institutional Review Boards. Statistical evaluation was by variance analysis and student test for the quantitative variables, chi-square test for the qualitative variables.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 136 enrolled subjects, 95 completed the study. After 21 days of treatment, 84% of the subjects assessed by the investigator and 76% by the self-assessment for the cream found effective. Investigational product was considered to be safe after 7 and 21 days of use.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Repairing cream RV 2427 B is effective and safe in the management of irritant dermatitis.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bhat</LastName>
<ForeName>Ramesh M</ForeName>
<Initials>RM</Initials>
<Affiliation>Department of Dermatology, Fr Muller Medical College, Mangalore, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Chavda</LastName>
<ForeName>Rajeev</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ribet</LastName>
<ForeName>Virginie</ForeName>
<Initials>V</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752470</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Irritant dermatitis</Keyword>
<Keyword MajorTopicYN="N">repair cream</Keyword>
<Keyword MajorTopicYN="N">zinc oxide</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984229</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Cutaneous metastasis from carcinoma of lung.</ArticleTitle>
<Pagination>
<MedlinePgn>185-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115512</ELocationID>
<Abstract>
<AbstractText>A 65-year-old male with a history of smoking since 30 years presented with breathlessness, hemoptysis, multiple swellings all over the body, and weakness in September 2010 at our hospital. Clinically, a diagnosis of chronic obstructive pulmonary disease (COPD) with cutaneous lymphoma or soft tissue tumor was made. Chest X-ray (CXR) and computed tomography (CT) scan revealed a neoplastic lesion in the right lung with secondary cavitation. Biopsy of the cutaneous nodules showed metastatic deposits from squamous cell carcinoma. Metastatic skin cancer is a relatively rare complication of internal malignancy. The clinical features of metastatic skin disease vary enormously. They may present as erysipeloid, sclerodermoid, alopecia neoplastica or in an inflammatory or bullous form or as multiple nodules as in our case. A high index of suspicion for metastatic deposits is required in an elderly male patient who is a known case of lung cancer or even one who is a chronic smoker and presents with such cutaneous lesions. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pathak</LastName>
<ForeName>Smita</ForeName>
<Initials>S</Initials>
<Affiliation>Department of Pathology, Maharashtra Institute of Medical Education and Research (MIMER) Medical College, Talegaon Dabhade. Pune, Maharashtra, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Joshi</LastName>
<ForeName>Sneha R</ForeName>
<Initials>SR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jaison</LastName>
<ForeName>Janice</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kendre</LastName>
<ForeName>Dipak</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752471</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Carcinoma of lung</Keyword>
<Keyword MajorTopicYN="N">cutaneous metastasis</Keyword>
<Keyword MajorTopicYN="N">smoking</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984230</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Primary cutaneous leiomyosarcoma: A rare malignant neoplasm.</ArticleTitle>
<Pagination>
<MedlinePgn>188-90</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115513</ELocationID>
<Abstract>
<AbstractText>Primary cutaneous leiomyosarcoma (PCL) is an exceedingly uncommon malignant superficial soft tissue sarcoma with a predilection for middle-aged to elderly male. Morphologic differential diagnosis includes a host of other malignant spindle cell neoplasms, thereby necessitating the use of a panel of immunohistochemical markers to arrive at a definitive diagnosis. We report a case of PCL arising in the right leg of a 70-year-old male. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bali</LastName>
<ForeName>Akshay</ForeName>
<Initials>A</Initials>
<Affiliation>Department of Pathology, Jawaharlal Nehru Medical College, Belgaum, Karnataka, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Kangle</LastName>
<ForeName>Ranjit</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Roy</LastName>
<ForeName>Maitrayee</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hungund</LastName>
<ForeName>Bhagyashree</ForeName>
<Initials>B</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752472</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Caldesmon</Keyword>
<Keyword MajorTopicYN="N">cutaneous</Keyword>
<Keyword MajorTopicYN="N">leiomyosarcoma</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984231</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Dowling-Degos disease and hidradenitis suppurativa: Co occurrence or association?</ArticleTitle>
<Pagination>
<MedlinePgn>191-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115514</ELocationID>
<Abstract>
<AbstractText>A 44 year old female patient presented with multiple, painful, relapsing, nodules, plaques with sinuses discharging pus and scars in apocrine gland bearing region since past 17 years. These lesions were clinically and histopathologically suggestive of hidradenitis suppurativa. Our patient was not aware about the flexural pigmentary lesions, comedones and pitted scars which were also clinically and histopathologically suggestive of Dowling-Degos disease. We are reporting a rare interesting association of Dowling Degos disease and hidradenitis suppurativa which is not reported in Indian literature till date. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Choudhary</LastName>
<ForeName>Sanjiv V</ForeName>
<Initials>SV</Initials>
<Affiliation>Department of Dermatology, Jawaharlal Nehru Medical College, Sawangi, Wardha, Maharashtra, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Jain</LastName>
<ForeName>Divya</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Agrawal</LastName>
<ForeName>Piyush</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Singh</LastName>
<ForeName>Adarshlata</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752473</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Association</Keyword>
<Keyword MajorTopicYN="N">Dowling-Degos disease</Keyword>
<Keyword MajorTopicYN="N">hidradenitis suppurativa</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984232</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Facial plexiform neurofibromatosis: A surgical challenge.</ArticleTitle>
<Pagination>
<MedlinePgn>195-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115515</ELocationID>
<Abstract>
<AbstractText>Plexiform neurofibromatosis is a relatively common but potentially devastating manifestation of neurofibromatosis type 1 (NF1). It produces very hideous deformity if the face is involved. Surgical management remains the mainstay of therapy, but in the head and neck region it is limited by the infiltrating nature of these tumors, inherent operative morbidity and high rate of regrowth. We present two cases of facial neurofibromatosis managed in our hospital. The first patient presented with overhanging mass of skin folds on the right side of her face, completely obliterating her right eye. The other patient was a young male having a huge, unsightly swelling over the right cheek, resulting in pulled down right eyelids and right pinna. Physical examination revealed the presence of café au lait macules, freckling in the axillary region and multiple neurofibromas over the trunk. Reconstructive surgical procedure in the form of subtotal excision of tumor mass followed by re draping of the facial skin was performed in both cases. There was evidence of regrowth of the tumor on review after 6 months. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dogra</LastName>
<ForeName>Bharat B</ForeName>
<Initials>BB</Initials>
<Affiliation>Department of Surgery, Padmashri Dr. D Y Patil Medical College Hospital and Research Centre, Pimpri, Pune, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Rana</LastName>
<ForeName>Karamvir Singh</ForeName>
<Initials>KS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752474</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Facial plexiform neurofibromatosis</Keyword>
<Keyword MajorTopicYN="N">regrowth</Keyword>
<Keyword MajorTopicYN="N">subtotal excision</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984233</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Extensive and invasive lymphangioma circumscriptum in a young female: A rare case report and review of the literature.</ArticleTitle>
<Pagination>
<MedlinePgn>199-201</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115516</ELocationID>
<Abstract>
<AbstractText>Lymphatic malformations, or lymphangiomas, are benign proliferations of lymphatics, classified as superficial lymphangioma circumscriptum (LC) and deep (cavernous lymphangioma). LC, as the name suggests, is a well-circumscribed lesion but, rarely, extensive and invasive forms can also be seen. Surgical excision is the main modality of treatment. We report a case of extensive and invasive type of LC where surgical excision is difficult and recurrence is the rule. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kudur</LastName>
<ForeName>Mohan H</ForeName>
<Initials>MH</Initials>
<Affiliation>Department of Dermatology, Srinivas Institute of Medical Sciences and Research Centre, Mukka, Surathkal, Mangalore, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Hulmani</LastName>
<ForeName>Manjunath</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752475</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Extensive</Keyword>
<Keyword MajorTopicYN="N">lymphangioma circumscriptum</Keyword>
<Keyword MajorTopicYN="N">malformed lymphatics</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984234</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Multiple keratoacanthomas developing in healing plaques of Psoriasis.</ArticleTitle>
<Pagination>
<MedlinePgn>202-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115517</ELocationID>
<Abstract>
<AbstractText>A 22 year old male psoriatic patient presented with multiple reddish scaly plaques all over body. After hematological and biochemical investigations the patient was started on oral methotrexate 15 mg weekly. PASI score at the start of treatment was 26.2. After 3 months PASI dropped to 11.5, the dose of methotrexate was tapered to 7.5mg weekly and the patient was maintained on this dose and kept under monthly follow up. Four months later, the patient presented with reddish to hyperpigmented raised firm nodules having a central crater over the healing plaques of psoriasis. Few lesions showed self resolution over a period of 6-12 weeks. Histopathology of the lesion confirmed it to be Keratoacanthoma. We believe the most likely etiologic factors for the multiple KAs in our patient could be a genetic susceptibility stimulated by multiple causes. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Relhan</LastName>
<ForeName>Vineet</ForeName>
<Initials>V</Initials>
<Affiliation>Department of Dermatology and STD, Maulana Azad Medical College and Lok Nayak Hospital, Delhi, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Sinha</LastName>
<ForeName>Surabhi</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Khurana</LastName>
<ForeName>Nita</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Garg</LastName>
<ForeName>Vijay K</ForeName>
<Initials>VK</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752476</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Healing</Keyword>
<Keyword MajorTopicYN="N">Keratoacanthoma</Keyword>
<Keyword MajorTopicYN="N">Psoriasis</Keyword>
<Keyword MajorTopicYN="N">Spontaneous</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984235</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Necrolytic migratory ulceration.</ArticleTitle>
<Pagination>
<MedlinePgn>205-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115518</ELocationID>
<Abstract>
<AbstractText>Endocrine tumors of the gastroenteropancreatic system associated with specific skin manifestations are rare. We report a 53-year-old female who presented with migratory annular and arcuate ulcers on her limbs. Histopathology was similar to necrolytic erythema family which includes necrolytic migratory erythema (NME). Though initial CT scans were normal, follow up scans revealed multiple mass lesions in the tail of pancreas. Her skin lesions responded to oral zinc sulphate and monthly injections of octreotide. Prior to planned FNAC from the mass lesion, patient developed altered sensorium and succumbed to the disease. This case report seems to differ from NME clinically, due to unique finding of deep migrating ulcers which heal with scarring. 'Necrolytic migratory ulceration' thus appears to be a new paraneoplastic manifestation, secondary to pancreatic malignancy. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pakran</LastName>
<ForeName>Jaheersha</ForeName>
<Initials>J</Initials>
<Affiliation>Department of Dermatology, MIMS Hospital, Calicut, Kerala, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Riyaz</LastName>
<ForeName>Najeeba</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752477</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Migratory ulcers</Keyword>
<Keyword MajorTopicYN="N">necrolytic erythema</Keyword>
<Keyword MajorTopicYN="N">necrolytic migratory erythema</Keyword>
<Keyword MajorTopicYN="N">pancreatic tumor</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984236</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Granulosis rubra nasi.</ArticleTitle>
<Pagination>
<MedlinePgn>208-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115519</ELocationID>
<Abstract>
<AbstractText>Granulosis rubra nasi is a rare disorder of the eccrine glands, inherited as an autosomal dominant trait. It is clinically characterized by hyperhidrosis of the central part of the face, most conspicuous on the tip of the nose, followed by appearance of diffuse erythema over the nose, cheeks, chin, and upper lip. It is commonly seen in childhood, but can also occur in adults. This is a case report of a 27-year-old male patient who presented with excessive sweating over the nose. Physical examination of the nose revealed erythema and multiple telangiectatic vesicles. Biopsy findings supported the diagnosis of granulosis rubra nasi. This case is being reported for its rarity since to the best of our knowledge, it has not been reported in Indian subjects so far. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sargunam</LastName>
<ForeName>Cynthia</ForeName>
<Initials>C</Initials>
<Affiliation>Department of Skin and STD, Sree Balaji Medical College and Hospital, Chromepet, Chennai, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Thomas</LastName>
<ForeName>Jayakar</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ahmed</LastName>
<ForeName>N Ashwak</ForeName>
<Initials>NA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752478</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Disorder of eccrine glands</Keyword>
<Keyword MajorTopicYN="N">granulosis rubra nasi</Keyword>
<Keyword MajorTopicYN="N">telengiectasia</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984237</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Cavernous lymphangioma: Two case reports.</ArticleTitle>
<Pagination>
<MedlinePgn>210-2</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115520</ELocationID>
<Abstract>
<AbstractText>Lymphangiomas are congenital malformation of the lymphatic system that involve the skin and subcutaneous tissues. We are reporting two cases of cavernous lymphangioma. These cases are presented for their rarity. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Sargunam</LastName>
<ForeName>Cynthia</ForeName>
<Initials>C</Initials>
<Affiliation>Department of Dermatology, Sree Balaji Medical College and Hospital, Chromepet, Chennai, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Thomas</LastName>
<ForeName>Jayakar</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Raneesha</LastName>
<ForeName>P K</ForeName>
<Initials>PK</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752479</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cavernous lymphangioma</Keyword>
<Keyword MajorTopicYN="N">congenital malformations</Keyword>
<Keyword MajorTopicYN="N">lymphatic malformation</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984238</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Eruptive vellus hair cyst presenting as asymptomatic follicular papules on extremities.</ArticleTitle>
<Pagination>
<MedlinePgn>213-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115521</ELocationID>
<Abstract>
<AbstractText>Eruptive vellus hair cysts were first described in 1977. They usually appear as yellow to reddish-brown papules on the chest. Usual onset is between ages 17 and 24 years, but they may be congenital. Some believe that they may be inherited as an autosomal dominant disorder. Histologically the cyst has a stratified squamous epithelium and it contains laminated keratin and vellus hairs. They are felt to be caused by an abnormality at the infundibular level of the vellus hair. We present this because of this patient's unusual distribution of eruptive vellus hair cysts. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Khatu</LastName>
<ForeName>Swapna</ForeName>
<Initials>S</Initials>
<Affiliation>Department of Dermatology, K. J. Somaiya Medical College, Mumbai, Maharashtra, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Vasani</LastName>
<ForeName>Resham</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Amin</LastName>
<ForeName>Shital</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752480</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Eruptive vellus hair cyst</Keyword>
<Keyword MajorTopicYN="N">infundibular cyst</Keyword>
<Keyword MajorTopicYN="N">steatocystoma multiplex</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984239</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Phacomatosis cesioflammea with Klippel Trenaunay syndrome: A rare association.</ArticleTitle>
<Pagination>
<MedlinePgn>216-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115522</ELocationID>
<Abstract>
<AbstractText>A 30-year-old Indian male presented with bilateral Nevus of Ota, extensive nevus flammeus over the trunk and left lower limb with soft tissue hypertrophy and varicosities affecting the left lower limb. He was otherwise in good general health. A diagnosis of Phacomatosis cesioflammea or Phacomatosis pigmentovasularis Type II with Klippel Trenaunay syndrome was made. The case is being reported on account of its rarity. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Garg</LastName>
<ForeName>Anubhav</ForeName>
<Initials>A</Initials>
<Affiliation>Department of Dermatology, Venereology and Leprosy, RNT Medical College, Udaipur, Rajasthan, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Gupta</LastName>
<ForeName>Lalit K</ForeName>
<Initials>LK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Khare</LastName>
<ForeName>A K</ForeName>
<Initials>AK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kuldeep</LastName>
<ForeName>C M</ForeName>
<Initials>CM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mittal</LastName>
<ForeName>Asit</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mehta</LastName>
<ForeName>Sharad</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752481</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Klippel Trenaunay syndrome</Keyword>
<Keyword MajorTopicYN="N">Nevus of Ota</Keyword>
<Keyword MajorTopicYN="N">Phacomatosis cesioflammea</Keyword>
<Keyword MajorTopicYN="N">Phacomatosis pigmentovascularis</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984240</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>A case of zosteriform Darier's disease with seasonal recurrence.</ArticleTitle>
<Pagination>
<MedlinePgn>219-21</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115523</ELocationID>
<Abstract>
<AbstractText>Darier's disease is an uncommon genodermatosis characterized by keratotic papules in seborrheic distribution. The disease can rarely present in unilateral zosteriform pattern, as a mosaic form following the Blaschko's line. We present a 35-year-old woman with zosteriform pattern of Darier's disease over right infra mammary region. The lesions occurred strictly during summers. Histologically, suprabasal acantholysis with abundant dyskeratotic cells were seen. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gupta</LastName>
<ForeName>Lalit K</ForeName>
<Initials>LK</Initials>
<Affiliation>Department of Dermatology, Venereology and Leprosy, RNT Medical College, Udaipur, Rajasthan, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Garg</LastName>
<ForeName>Anubhav</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Khare</LastName>
<ForeName>Ashok Kumar</ForeName>
<Initials>AK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mittal</LastName>
<ForeName>Asit</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752482</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984241</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>A rare case of woolly hair with unusual associations.</ArticleTitle>
<Pagination>
<MedlinePgn>222-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115524</ELocationID>
<Abstract>
<AbstractText>Woolly hair is a congenital abnormality of scalp hair manifesting as short, kinked hair, which may also involve the hair over the other parts of the body. Keratosis pilaris has been a well known association of woolly hair, and can also be a part of the Naxos or Carvajal syndromes. We herein present a case of woolly hair with associated keratosis pilaris, canaliform dystrophy of nails, increased interdental spaces and recurrent bullous impetigo. Although keratosis pilaris and teeth abnormalities have been reported as isolated associations with woolly hair, such a combination of findings as seen in our patient has not been reported before. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Vasudevan</LastName>
<ForeName>Biju</ForeName>
<Initials>B</Initials>
<Affiliation>Department of Dermatology, Command Hospital (Southern Command), Wanowrie, Pune, Maharashtra, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Verma</LastName>
<ForeName>Rajesh</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pragasam</LastName>
<ForeName>Vijendran</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Badad</LastName>
<ForeName>Ambresh</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752483</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Bullous impetigo</Keyword>
<Keyword MajorTopicYN="N">keratosis pilaris</Keyword>
<Keyword MajorTopicYN="N">woolly hair</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984242</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Pachyonychia congenita: A rare genodermatosis.</ArticleTitle>
<Pagination>
<MedlinePgn>225-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115527</ELocationID>
<Abstract>
<AbstractText>Pachyonychia congenita (PC) is a rare genodermatosis with only 450 cases reported since 1906. It is of two types, type I due to mutation in genes 6a and 16, and 6b and 17 in type II with an autosomal dominant inheritance in both types. A 22 yr old female patient presented in our OPD with hypertrophy of finger and toe nails, palmoplantar keratoderma, oral punctuate leukokeratosis, hyperhidrosis in palms and soles with maceration and malodour since childhood. She had a positive family history with father and grandfather affected but less severely. Microscopy and culture of nail clippings and scrapping were done to rule out fungal infection. On biopsy acanthotic epidermis, parakeratosis, orthokeratosis were seen. No evidence of any associated malignancy was found after thorough workup. She was diagnosed as PC Type 1. She was put on topical steroids and orally on acetretin 25 mg OD. Paring of the nails was done too reduce the thickness of nails &amp; to provide symptomatic relief. She was on a regular treatment for 3-4 months and showed some improvement in the form of reduced palmoplantar hyperkeratosis and reduced oral punctate keratosis but was later lost on followup. She showed no adverse effect to therapy during this period. This case is being reported because of its rarity. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Agarwal</LastName>
<ForeName>Puneet</ForeName>
<Initials>P</Initials>
<Affiliation>Department of Skin and STD, Mahatma Gandhi Medical College, Jaipur, Rajasthan, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Chhaperwal</LastName>
<ForeName>Mahendra K</ForeName>
<Initials>MK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Singh</LastName>
<ForeName>Apurva</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Verma</LastName>
<ForeName>Arvind</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nijhawan</LastName>
<ForeName>Manisha</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Singh</LastName>
<ForeName>Kishore</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mathur</LastName>
<ForeName>Dinesh</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752484</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Nail hypertrophy</Keyword>
<Keyword MajorTopicYN="N">oral leukoplakia</Keyword>
<Keyword MajorTopicYN="N">palmoplantar keratoderma</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984243</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Symmetrical peripheral gangrene associated with peripartum cardiomyopathy.</ArticleTitle>
<Pagination>
<MedlinePgn>228-30</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115528</ELocationID>
<Abstract>
<AbstractText>Symmetrical peripheral gangrene (SPG) is a rare clinical entity. It was first described in late 19(th) century and since then has been reported with array of medical conditions mainly those complicated with shock, sepsis, and disseminated intravascular coagulation (DIC). Here in, we describe a parturient with peripartum cardiomyopathy (PPCM) and SPG. Clinicians should be aware of this entity as early recognition can help in reducing morbidity and mortality. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Jaryal</LastName>
<ForeName>Ajay</ForeName>
<Initials>A</Initials>
<Affiliation>Department of Medicine, Dr. Rajendra Prasad Govt. Medical College, Tanda, Kangra, Himachal Pradesh, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Raina</LastName>
<ForeName>Sujeet</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Thakur</LastName>
<ForeName>Surender</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sontakke</LastName>
<ForeName>Tushar</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752485</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Disseminated intravascular coagulation</Keyword>
<Keyword MajorTopicYN="N">peripartum cardiomyopathy</Keyword>
<Keyword MajorTopicYN="N">symmetrical peripheral gangrene</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984244</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Acute generalized exanthematous pustulosis: A rare side effect of a common over-the-counter drug, Acetylsalicylic acid.</ArticleTitle>
<Pagination>
<MedlinePgn>231-3</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115529</ELocationID>
<Abstract>
<AbstractText>Acute generalized exanthematous pustulosis is an uncommon cutaneous reaction characterized by sudden onset of generalized non-follicular aseptic pustules. It is most often secondary to drugs but causes as varied from viral infection to insect bites are reported. A case report of a 48-year-old male who developed pustular eruptions after taking acetylsalicylic acid is reported here. Clinicians need to be aware of this entity when dealing with pustular rash as this rare side effect of a very common drug is both, easy to miss and easy to manage. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bahuguna</LastName>
<ForeName>Amit</ForeName>
<Initials>A</Initials>
<Affiliation>MD, Graded specialist, Skin Department, 92 Base Hospital, India.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752486</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Acetyl salicylic acid</Keyword>
<Keyword MajorTopicYN="N">drug reaction</Keyword>
<Keyword MajorTopicYN="N">over-the-counter drugs</Keyword>
<Keyword MajorTopicYN="N">pustular eruption</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984245</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Speckled lentiginous nevus syndrome with median nerve paresis: A rare syndrome with a new association.</ArticleTitle>
<Pagination>
<MedlinePgn>234-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115530</ELocationID>
<Abstract>
<AbstractText>Speckled lentiginous nevus (SLN) represents a mosaic phenotype which consists of café au lait macule superimposed by melanocytic nevi. Recently, SLN syndrome has been characterized where ipsilateral neurological abnormalities have been reported in association with SLN with papular type of melanocytic nevi only. This case describes the presence of ipsilateral thenar muscle atrophy with median nerve paresis in nevus spilus which had melanocytic nevi of the macular type alone, thus delineating a new association in SLN syndrome, hitherto unreported. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mendiratta</LastName>
<ForeName>Vibhu</ForeName>
<Initials>V</Initials>
<Affiliation>Department of Dermatology and STD, Lady Hardinge Medical College, Shaheed Bhagat Singh Marg, New Delhi, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Jabeen</LastName>
<ForeName>Masarat</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Barara</LastName>
<ForeName>Meenu</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Varshney</LastName>
<ForeName>Manish</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752487</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Median nerve paresis</Keyword>
<Keyword MajorTopicYN="N">nevus spilus</Keyword>
<Keyword MajorTopicYN="N">syndrome</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984246</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>A rare case of malignant chondroid syringoma of scalp.</ArticleTitle>
<Pagination>
<MedlinePgn>236-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115533</ELocationID>
<Abstract>
<AbstractText>Chondroid syringoma represents the cutaneous counterpart of mixed tumor (pleomorphic adenoma) of salivary glands, therefore it is also termed "mixed tumour of the skin." It is generally accepted that there are both eccrine and apocrine variants of mixed tumors of skin. Malignant chondroid syringoma is a malignant eccrine neoplasm that is very rarely encountered in radio-pathological and clinical practice. Unlike the benign variety which occurs most often on the head and neck, malignant chondroid syringomas are most often found on the trunk and extremities. The usual presentation is that of an asymptomatic slow-growing mass in the region of head or neck. We present here a case report of histopathologically proven malignant chondroid syringoma of scalp in occipital region, with dural invasion. Malignant chondroid syringomas clinically appear as very large nodules and they metastasize at a very high rate. The treatment of these malignancies is surgical excision. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Malik</LastName>
<ForeName>Rajesh</ForeName>
<Initials>R</Initials>
<Affiliation>Department of Radiodiagnosis and Imaging, Gandhi Medical College, Bhopal, Madhya Pradesh, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Saxena</LastName>
<ForeName>Agamya</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kamath</LastName>
<ForeName>Namita</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752488</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Chondroid syringoma</Keyword>
<Keyword MajorTopicYN="N">pleomorphic adenoma</Keyword>
<Keyword MajorTopicYN="N">scalp tumors</Keyword>
<Keyword MajorTopicYN="N">skin tumors</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984247</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Erosive adenomatosis of the nipple masquerading as Paget's disease.</ArticleTitle>
<Pagination>
<MedlinePgn>239-40</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115534</ELocationID>
<Abstract>
<AbstractText>Erosive adenomatosis of the nipple (EAN) is a rare, benign neoplasm of breast lactiferous ducts. Peak incidence is in the fifth decade in women. Clinically, it is mistaken for eczema during early stages and Paget's disease at later stages. We present a young lady with EAN who was advised mastectomy. It is important for dermatologists to be familiar with this entity to avoid topical steroid abuse and unwarranted breast removal. This case is presented for awareness and importance of correct and early diagnosis. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Kumar</LastName>
<ForeName>Parimalam K</ForeName>
<Initials>PK</Initials>
<Affiliation>Department of Dermatology, Stanley Medical College, Chennai, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Thomas</LastName>
<ForeName>Jayakar</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752489</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Adenomatosis</Keyword>
<Keyword MajorTopicYN="N">erosive</Keyword>
<Keyword MajorTopicYN="N">nipple</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984248</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>A case report of focal dermal hypoplasia-Goltz syndrome.</ArticleTitle>
<Pagination>
<MedlinePgn>241-3</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115535</ELocationID>
<Abstract>
<AbstractText>Goltz syndrome is a rare multisystem disorder with cutaneous, ocular, dental and skeletal abnormalities. Other mesoectodermal abnormalities are also present. Its hallmark is thinning of the dermis resulting subcutaneous fat herniation. The present case is a 5 year old girl having linear skin atrophy with fat herniation, skeletal abnormalities in the form of polysyndactyly, facial asymmetry, squint with coloboma iris, deformed pinna, abnormal dentition, umbilical hernia along with osteopathia striata of long bones which is consistent with Goltz syndrome. We are presenting this case due to its rarity. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bharani</LastName>
<ForeName>Sheela</ForeName>
<Initials>S</Initials>
<Affiliation>Department of Pediatrics, Medical College, Vadodara, Gujarat, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Thakkar</LastName>
<ForeName>Sejal</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752490</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Focal dermal hypoplasia</Keyword>
<Keyword MajorTopicYN="N">Goltz syndrome</Keyword>
<Keyword MajorTopicYN="N">fat herniation</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984249</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Dermpath quiz.</ArticleTitle>
<Pagination>
<MedlinePgn>244-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115536</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Durda</LastName>
<ForeName>Johanna</ForeName>
<Initials>J</Initials>
<Affiliation>Department of Dermatology, Elbe Klinikum Buxtehude, Buxtehude, Germany ; Ackerman Academy of Dermatopathology, New York, USA.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Kazlouskaya</LastName>
<ForeName>Viktoryia</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Blochin</LastName>
<ForeName>Elen</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Maguire</LastName>
<ForeName>Ciara A</ForeName>
<Initials>CA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Elston</LastName>
<ForeName>Dirk</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752491</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984250</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Ingenol mebutate: A novel topical drug for actinic keratosis.</ArticleTitle>
<Pagination>
<MedlinePgn>246-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115538</ELocationID>
<Abstract>
<AbstractText>The global incidence of non-melanoma skin cancer is rising. Significant morbidity leading to unacceptable cosmetic outcomes and/or functional impairment is a major concern. Search for non-surgical, non-invasive and tissue-sparing treatment modalities has led to development of new therapeutic agents. Actinic keratoses (AK) are one part of a continuous spectrum of benign sun damage to squamous cell carcinoma (SCC). Although it is not possible to predict which AK might progress to SCC, the presence of AK is a biomarker of risk for patients and must be treated to avoid possible morbidity and mortality. Ingenol mebutate is a novel topical drug from the latex sap of a plant-Euphorbia peplus that acts by chemoablative and immunostimulatory properties. Clinical studies have proven it to be safe and efficacious, leading to FDA approval of this chemotherapeutic agent for field therapy of AK in 2012. Current topical agents for field therapy of AK must be applied for weeks, whereas ingenol needs to be applied for three days. Ingenol offers a new therapeutic option that is convenient, safe, effective, acceptable and well-tolerated. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Aditya</LastName>
<ForeName>Suruchi</ForeName>
<Initials>S</Initials>
<Affiliation>Department of Pharmacology, Dr Harvansh Singh Judge Institute of Dental Sciences, Sector 25, Chandigarh, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Gupta</LastName>
<ForeName>Sanjeev</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752492</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Actinic keratosis</Keyword>
<Keyword MajorTopicYN="N">ingenol mebutate</Keyword>
<Keyword MajorTopicYN="N">nonmelanoma skin cancer</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984251</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>A clinical study of the spectrum of vitiligo in children versus adults and its associations.</ArticleTitle>
<Pagination>
<MedlinePgn>250-1</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115539</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Prakash</LastName>
<ForeName>Preeti</ForeName>
<Initials>P</Initials>
<Affiliation>Department of Dermatology and STD, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Thappa</LastName>
<ForeName>Devinder Mohan</ForeName>
<Initials>DM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752493</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984252</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Verrucous trichoadenoma - presenting as discharging sinus on face.</ArticleTitle>
<Pagination>
<MedlinePgn>251-2</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115540</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Arora</LastName>
<ForeName>Swati</ForeName>
<Initials>S</Initials>
<Affiliation>Department of Dermatology, S.G.R.D. Medical College, Amritsar, Punjab, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Kaur</LastName>
<ForeName>Jasleen</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kaur</LastName>
<ForeName>Harjot</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752494</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984253</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Herpes zoster in infancy.</ArticleTitle>
<Pagination>
<MedlinePgn>252-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115541</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gupta</LastName>
<ForeName>Lalit Kumar</ForeName>
<Initials>LK</Initials>
<Affiliation>Department of Dermatology, Venereology and Leprosy, R.N.T. Medical College, Udaipur, Rajasthan, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Khare</LastName>
<ForeName>Ashok Kumar</ForeName>
<Initials>AK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mittal</LastName>
<ForeName>Asit</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kuldeep</LastName>
<ForeName>C M</ForeName>
<Initials>CM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752495</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984254</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Radiotherapy induced keobernisation of vitiligo.</ArticleTitle>
<Pagination>
<MedlinePgn>254-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115542</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Phiske</LastName>
<ForeName>Meghana</ForeName>
<Initials>M</Initials>
<Affiliation>Department of Dermatology, Assistant Professor, L. T. M. Medical College and General Hospital, Sion, Mumbai, Maharashtra, India.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752496</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984255</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Cutaneous angiomyolipoma.</ArticleTitle>
<Pagination>
<MedlinePgn>255-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115543</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Ammanagi</LastName>
<ForeName>A S</ForeName>
<Initials>AS</Initials>
<Affiliation>Department of Pathology, S. N. Medical College, Bagalkot, Karnataka, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Dombale</LastName>
<ForeName>V D</ForeName>
<Initials>VD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shindholimath</LastName>
<ForeName>V V</ForeName>
<Initials>VV</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752497</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984256</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>SkIndia Quiz 10 Papulonodular lesions in a Human Immunodeficiency Virus-positive patient.</ArticleTitle>
<Pagination>
<MedlinePgn>257-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.110655</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gupta</LastName>
<ForeName>Lalit Kumar</ForeName>
<Initials>LK</Initials>
<Affiliation>Department of Dermatology, Venereology and Leprosy, R.N.T. Medical College, Udaipur, Rajasthan, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Pargi</LastName>
<ForeName>Sonakshi</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Khare</LastName>
<ForeName>Ashok Kumar</ForeName>
<Initials>AK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mittal</LastName>
<ForeName>Asit</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mehta</LastName>
<ForeName>Sharad</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kuldeep</LastName>
<ForeName>C M</ForeName>
<Initials>CM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752498</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984257</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Prayer sign.</ArticleTitle>
<Pagination>
<MedlinePgn>259</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115545</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Raina</LastName>
<ForeName>Sujeet</ForeName>
<Initials>S</Initials>
<Affiliation>Department of Medicine, Dr. Rajendra Prasad Govt. Medical College, Tanda, Kangra, Himachal Pradesh, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Jaryal</LastName>
<ForeName>Ajay</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sonnatakke</LastName>
<ForeName>Tushar</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752499</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984258</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>A baby with photosensitivity and red teeth.</ArticleTitle>
<Pagination>
<MedlinePgn>260-1</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115546</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Mondal</LastName>
<ForeName>Ashim Kumar</ForeName>
<Initials>AK</Initials>
<Affiliation>Department of Dermatology, Medical College &amp; Hospital, Kolkata, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Kumar</LastName>
<ForeName>Piyush</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gharami</LastName>
<ForeName>Ramesh Chandra</ForeName>
<Initials>RC</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752500</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23984259</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">2229-5178</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>4</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Indian dermatology online journal</Title>
<ISOAbbreviation>Indian Dermatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Porokeratosis of Mibelli: Giant variant.</ArticleTitle>
<Pagination>
<MedlinePgn>262-3</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/2229-5178.115547</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Avhad</LastName>
<ForeName>Ganesh</ForeName>
<Initials>G</Initials>
<Affiliation>Department of Dermatology, L. T. M. Medical College and General Hospital, Mumbai, Maharashtra, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Jerajani</LastName>
<ForeName>Hemangi</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian Dermatol Online J</MedlineTA>
<NlmUniqueID>101586880</NlmUniqueID>
<ISSNLinking>2229-5178</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3752501</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983277</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0019-5049</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>57</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Indian journal of anaesthesia</Title>
<ISOAbbreviation>Indian J Anaesth</ISOAbbreviation>
</Journal>
<ArticleTitle>Safety first, safety at early age: The quagmire of neurotoxicity in paediatric anaesthesia.</ArticleTitle>
<Pagination>
<MedlinePgn>221-2</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/0019-5049.115572</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bhaskar</LastName>
<ForeName>S Bala</ForeName>
<Initials>SB</Initials>
<Affiliation>Department of Anaesthesiology and Critical Care, Vijayanagar Institute of Medical Sciences, Bellary, Karnataka, India E-mail: sbalabhaskar@yahoo.com.</Affiliation>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian J Anaesth</MedlineTA>
<NlmUniqueID>0013243</NlmUniqueID>
<ISSNLinking>0019-5049</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3748673</OtherID>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983278</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0019-5049</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>57</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Indian journal of anaesthesia</Title>
<ISOAbbreviation>Indian J Anaesth</ISOAbbreviation>
</Journal>
<ArticleTitle>Perioperative ischaemia-induced liver injury and protection strategies: An expanding horizon for anaesthesiologists.</ArticleTitle>
<Pagination>
<MedlinePgn>223-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/0019-5049.115576</ELocationID>
<Abstract>
<AbstractText>Liver resection is an effective modality of treatment in patients with primary liver tumour, metastases from colorectal cancers and selected benign hepatic diseases. Its aim is to resect the grossly visible tumour with clear margins and to ensure that the remnant liver mass has sufficient function which is adequate for survival. With the advent of better preoperative imaging, surgical techniques and perioperative management, there is an improvement in the outcome with decreased mortality. This decline in postoperative mortality after hepatic resection has encouraged surgeons for more radical liver resections, leaving behind smaller liver remnants in a bid to achieve curative surgeries. But despite advances in diagnostic, imaging and surgical techniques, postoperative liver dysfunction of varied severity including death due to liver failure is still a serious problem in such patients. Different surgical and non-surgical techniques like reducing perioperative blood loss and consequent decreased transfusions, vascular occlusion techniques (intermittent portal triad clamping and ischaemic preconditioning), administration of pharmacological agents (dextrose, intraoperative use of methylprednisolone, trimetazidine, ulinastatin and lignocaine) and inhaled anaesthetic agents (sevoflurane) and opioids (remifentanil) have demonstrated the potential benefit and minimised the adverse effects of surgery. In this article, the authors reviewed the surgical and non-surgical measures that could be adopted to minimise the risk of postoperative liver failure following liver surgeries with special emphasis on ischaemic and pharmacological preconditioning which can be easily adapted clinically. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pandey</LastName>
<ForeName>Chandra Kant</ForeName>
<Initials>CK</Initials>
<Affiliation>Department of Anaesthesiology and Critical Care Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Nath</LastName>
<ForeName>Soumya S</ForeName>
<Initials>SS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pandey</LastName>
<ForeName>Vijay K</ForeName>
<Initials>VK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Karna</LastName>
<ForeName>Sunaina T</ForeName>
<Initials>ST</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tandon</LastName>
<ForeName>Manish</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian J Anaesth</MedlineTA>
<NlmUniqueID>0013243</NlmUniqueID>
<ISSNLinking>0019-5049</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3748674</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Ischaemia</Keyword>
<Keyword MajorTopicYN="N">liver resection</Keyword>
<Keyword MajorTopicYN="N">perioperative</Keyword>
<Keyword MajorTopicYN="N">protection</Keyword>
</KeywordList>
</MedlineCitation>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">23983279</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted>
<Year>2013</Year>
<Month>08</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>08</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0019-5049</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>57</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Indian journal of anaesthesia</Title>
<ISOAbbreviation>Indian J Anaesth</ISOAbbreviation>
</Journal>
<ArticleTitle>A simple method for evaluation of the uptake of isoflurane and its comparison with the square root of time model.</ArticleTitle>
<Pagination>
<MedlinePgn>230-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/0019-5049.115587</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The square root of time (SqRT) model had been used to predict the uptake of volatile agents.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We studied the rate of uptake of isoflurane in 10 patients using liquid isoflurane infusion through syringe pump into the closed circuit. The infusion rates were titrated to maintain a constant end tidal concentration of isoflurane of 1.5%. The predicted uptake values were also calculated from the square root principle and compared with the derived uptake.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The observed rate of uptake was higher than predicted from the Lowe and Ernst equation (P&lt;0.001). There exists considerable inter-individual variability in uptake pharmacokinetics and it showed statistically significant correlation with ideal body weight, body weight (P&lt;0.01), body surface area, and body weight¾ from 30 min of start of isoflurane infusion (P&lt;0.05).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">SqRT model is inaccurate in predicting isoflurane uptake and underestimates it during closed circuit anaesthesia.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bangaari</LastName>
<ForeName>Ashish</ForeName>
<Initials>A</Initials>
<Affiliation>Department of Anaesthesiology and Pain Medicine, Fellow Liver Transplant Anaesthesia, Asan Medical Centre, Seoul, Korea.</Affiliation>
</Author>
<Author ValidYN="Y">
<LastName>Panda</LastName>
<ForeName>Nidhi Bidyut</ForeName>
<Initials>NB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Puri</LastName>
<ForeName>Goverdhan Dutt</ForeName>
<Initials>GD</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>India</Country>
<MedlineTA>Indian J Anaesth</MedlineTA>
<NlmUniqueID>0013243</NlmUniqueID>
<ISSNLinking>0019-5049</ISSNLinking>
</MedlineJournalInfo>
<OtherID Source="NLM">PMC3748675</OtherID>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Anaesthetics</Keyword>
<Keyword MajorTopicYN="N">equipment</Keyword>
<Keyword MajorTopicYN="N">isoflurane</Keyword>
<Keyword MajorTopicYN="N">pharmacokinetic</Keyword>
<Keyword MajorTopicYN="N">volatile</Keyword>
</KeywordList>
</MedlineCitation>
</MedlineCitationSet>